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Abstract 
The intestinal epithelium is the most rapidly renewing tissue in the body. Dynamic self-
renewal in the intestine is achieved through continuous proliferation of intestinal stem cells, 
and is under the tight regulation of numerous signalling pathways. IL-6 and PGE2 are 
pleiotropic cytokines, with well characterised roles in inflammation and intestinal 
tumorigenesis; however the roles for IL-6 and PGE2 in intestinal renewal during homeostasis 
remain unknown.  
The aim of this research was to determine the mechanisms through which autocrine and 
paracrine IL-6 and PGE2 regulate tissue renewal in the small intestine and colon, respectively, 
during homeostasis. This work also aimed to investigate a potential source of IL-6 and PGE2 
in the intestinal lamina propria, the eosinophil.  
This thesis demonstrates that in the mouse small intestine, IL-6 signalling induces pSTAT3 
activation in Paneth cells, which was shown to be the site of IL-6 receptor expression. This 
induced an increase in crypt cell proliferation and ISC expansion of small intestinal crypts, 
most likely through IL-6-classic signalling, with involvement of the WNT signalling pathway. 
The colonic epithelium expresses COX enzymes for PGE2 synthesis, and EP1-4 receptors for 
PGE2 signal transduction. Autocrine PGE2 signalling was required for colonic crypt cell 
proliferation during steady state renewal, which was mediated through the EP1/EP3 
receptors. Paracrine signalling through the IL-6 and PGE2 pathways also induced small 
intestinal and colonic crypt proliferation respectively. A potential paracrine source of IL-6 
and PGE, that resides in the intestinal lamina propria during health is the eosinophil. A novel 
spatial relationship between eosinophils and the stem cell niche (site of renewal) and crypt 
top (site of regeneration) was identified, suggesting that eosinophils play a role in modulating 
epithelial cell renewal during homeostasis.  
This work demonstrates that autocrine and paracrine IL-6 and PGE2 signalling is required for 
the maintenance of intestinal homeostasis.  
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Preface 
The intestinal epithelium forms a vital barrier between the microbial contents of the gut 
lumen, and underlying host tissues. It is formed of a one-cell thick monolayer, which 
invaginates millions of times into structures called crypts. The small intestine has finger-like 
projections termed villi, which increase the surface area of the epithelium in order to fulfil 
the main function of the small intestine, absorption of nutrients from food. The intestinal 
epithelium is the most rapidly renewing tissue in the body, with the entire epithelium 
renewing itself every 5-7 days. Dynamic renewal is achieved by way of intestinal stem cells, 
which reside at the base of crypts, thought to be a relatively safe harbour away from the 
microbial contents of the gut lumen. Stem cells proliferate, differentiate (into all the cell 
types of the intestinal epithelium: goblet cells, Paneth cells, tuft cells, enteroendocrine cells, 
enterocytes), migrate up the crypt (-villus) axis, and are shed into the gut lumen (Barker et 
al., 2007). The renewal process is tightly regulated by a number of signalling pathways, which 
can be epithelial-derived (autocrine) or derived from immune cells residing in the underlying 
lamina propria of the mucosa (paracrine). The master regulator of intestinal renewal is 
thought to be WNT signalling, aberrant signalling of which induces intestinal polyposis and 
the development of cancers (Schepers and Clevers, 2012). A number of other signalling 
pathways contribute to the maintenance of gut renewal during homeostasis, including Bone 
Morphogenetic Protein (BMP), Transforming Growth Factor β (TGFβ), Epidermal Growth 
Factor (EGF) and Noggin (Vanuytsel et al., 2013; Reynolds et al., 2014); however, during 
stressful conditions, activation of inflammatory cytokine pathways also induces crypt 
regeneration. Two inflammatory cytokines which are emerging to have roles in crypt 
regeneration are Interleukin-6 (IL-6) though the Janus Kinase/ Signal Transducer and 
Activator of Transcription (JAK/STAT) pathway and Prostaglandin-E2 (PGE2).   
IL-6 is a pleiotropic cytokine involved in a plethora of cellular and immune responses in health 
and disease (Mihara et al., 2012; Garbers et al., 2015; Hunter and Jones, 2015). Seminal work 
in Drosophila showed that the regenerative response to tissue injury or infection in the gut 
are modulated by JAK/STAT signalling in gut epithelial stem cells through the release of 
Unpaired 3 (Upd3), an IL-6-like cytokine (Jiang et al., 2009; Osman et al., 2012). In the 
mammalian gut, IL-6 and STAT3 have been shown to induce proliferation in the intestinal 
epithelium following tissue injury/inflammation (Pickert et al., 2009; Kuhn et al., 2014), and 
to promote the survival of normal epithelial cells during Inflammatory Bowel Diseases (IBD) 
and cancer (Bollrath et al., 2009; Grivennikov et al., 2009; Jin et al., 2010; Lee et al., 2012).  
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Similarly, in the colon, PGE2 is another cytokine that has been implicated in cancer and IBD, 
with an emerging role in crypt cell proliferation and regeneration during homeostasis. The 
enzymes responsible for the synthesis of PGE2 are Cyclooxygenase enzymes 1 and 2 (COX-1 
and COX-2), which are upregulated in colorectal cancer (Wang and Dubois, 2010). Therefore, 
COX enzyme inhibition represents an attractive target for the development of anti-cancer 
therapies. Indeed, the use of non-steroidal anti-inflammatory drugs (NSAIDs) to inhibit COX 
enzymes in patients with Familial Adenomatous Polyposis (FAP) was shown to reduce the 
incidence of intestinal polyps and tumour growth; however, this was associated with 
significant side effects (Bresalier et al., 2005; Solomon et al., 2005; Arber et al., 2006; Rostom 
et al., 2007). Recent studies have demonstrated that epithelial production of PGE2 through 
COX-2 activation is required for epithelial regeneration in response to injury, which is vital 
for the maintenance of intestinal homeostasis (Chen et al., 2015). These findings 
demonstrate that IL-6 and PGE2 are important for epithelial regeneration in conditions such 
as injury or cancer; however, the roles of IL-6 and PGE2 in modulating crypt renewal during 
health remain largely unknown. Furthermore, the potential sources of IL-6 and PGE2 in the 
intestines have not yet been fully investigated. Secretion of IL-6 and PGE2 by the epithelium 
(autocrine) or immune cells in the underlying lamina propria (paracrine) represent 
potentially important sources of IL-6 and PGE2 in vivo.  
Immune cells also have an emerging role in the regulation of crypt renewal during 
homeostasis (Pull et al., 2005; Seno et al., 2009; Kuhn et al., 2014; Skoczek et al., 2014). The 
intestinal lamina propria underlying the epithelium is home to a number of immune cells in 
inflammation and during health. One immune cell subtype that is abundant in the lamina 
propria during health, which is emerging to have vital roles in the maintenance of gut 
immune homeostasis, is the eosinophil (Carlens et al., 2009; Chu et al., 2014). Eosinophils 
express a number of cytokines and receptors known to be important for crypt renewal and 
regeneration, including IL-6 and PGE2 (Melo et al., 2013; Rosenberg et al., 2013). This 
suggests that eosinophils are a potential paracrine source of IL-6 and PGE2 in vivo in the gut 
mucosa.  
The sources, targets and influence of IL-6 and PGE2 on intestinal homeostasis is the focus of 
this thesis. The general introduction will discuss the autocrine and paracrine factors known 
to modulate crypt renewal during homeostasis, and what is known about IL-6, PGE2 and 
eosinophils in intestinal tissue renewal and regeneration in health and disease. 
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1 Chapter 1. General Introduction 
1.1 The Gastrointestinal Tract 
The gastrointestinal tract (GI tract) consists of a 10-meter long hollow tube that begins at the 
oral cavity, pharynx and oesophagus, continues through the stomach, small and large 
intestines to the rectum and anus (Figure 1.1). The GI tract is home to trillions of 
microorganisms and is an interface of constant challenge from microbial peptides from food. 
The main purpose of the GI tract is to digest and absorb nutrients from food. Food is ingested 
into the oral cavity and propelled along the in various organs of the GI tract by peristalsis, to 
the anus where it is expelled.  
The GI tract wall is comprised of four distinct layers. The outermost layer, the serosa, consists 
of a layer of epithelial cells termed the mesothelium, and fat.  Above the serosa is a smooth 
muscle layer called the muscularis externa, which is comprised of longitudinal and circular 
smooth muscle to aid the mechanical breakdown of food and peristalsis through the GI tract 
lumen. The next layer is the submucosa, which is comprised of connective tissue, blood 
vessels and lymphatics, which extend to the innermost layer, the mucosa. The mucosa itself 
is comprised of three layers, the epithelium, lamina propria and muscularis mucosa. The 
epithelium forms a physical barrier between the host and external environment. The lamina 
propria underlying the epithelium is comprised of a network of blood vessels, nerves, 
lymphoid tissue and glandular tissue, which is surrounded by a smooth muscle layer called 
the muscularis mucosa (Figure 1.1). The type of epithelial cells present in the mucosa varies 
dependent on the function of the region of the GI tract: for example the oral cavity is lined 
by squamous epithelial cells, designed to support any abrasion caused by passing food; 
whereas the stomach and intestines are lined by columnar epithelial cells to aid absorption 
and secretion (Tortora GJ, 2008).  
The small and large intestines constitute the largest component of the GI tract; the epithelial 
surface covering approximately 400m2 of surface area. The epithelium of both the small and 
large intestines are exquisitely organised into millions of invaginations called crypts, also 
known as the crypts of Lieberkühn (Figure 1.1). The major function of the small intestine is 
to absorb nutrients from food, and the large intestine is responsible for the resorption of 
water and formation of stools. The differences in function of the small and large intestines 
require a degree of variation in structure and cell type, as demonstrated by the presence of 
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villi in the small intestine which increases the surface area of the intestine for maximal 
nutrient absorption (Johnson, 2013). The epithelium also has a vital function as a physical 
barrier between the contents of the intestinal lumen and underlying host tissues.  
 
Figure 1.1. Anatomy of the gastrointestinal tract. 
The GIT consists of a hollow tube beginning at the oral cavity, pharynx and oesophagus, 
continues through the stomach, small and large intestines to the rectum and anus. The GIT 
wall is comprised of 4 distinct layers: (1) Mucosa (2) Submucosa (3) Circular and longitudinal 
muscle (4) Serosa. The intestinal epithelium forms millions of invaginations called crypts, 
which form a vital barrier between luminal content and underlying tissues. Figure adapted 
from Encyclopaedia Britannica, Inc 2003
Within the intestinal lumen reside trillions of microorganisms; the total microbial load of the 
intestine is approximately 1013-1014 microorganisms (Sartor, 2008). The intestinal 
microbiome is comprised of autochthonous (indigenous) and allochthonous (transient) flora. 
The indigenous flora reside in the intestines, whilst the transient flora colonizes the intestine 
following inflammation or stress (Hao and Lee, 2004). The bacteria present have a huge 
diversity of species thought to be from an estimated 15,000 to 36,000 individual species 
(Sartor, 2008). Human foetuses are born germ-free from the sterile environment in the 
uterus; however, the colonization of epithelial surfaces with bacteria begins immediately 
after birth. The majority of these bacteria are commensal, and form a beneficial relationship 
with the host. Commensal bacteria have major functions in the maintenance of normal 
gastrointestinal immune function through secretion of pro/anti-inflammatory signals, 
metabolism of non-digestible dietary components from which energy is supplied to the host, 
(4) Serosa
(3) Longitudinal 
muscle
(3) Circular muscle
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Muscularis mucosae
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and in the degradation of epithelial cells which have been shed into the gut lumen (Flint et 
al., 2012). However, despite the vast numbers of bacteria present in the intestinal lumen, 
the mucosal surface itself is maintained virtually sterile by way of protective mucus layers 
overlaying the epithelial barrier (Johansson et al., 2008). 
1.1.1 The Epithelial Barrier  
The intestinal epithelium forms a vital barrier between microbial content in the gut lumen 
and immune cells residing in the underlying lamina propria. The integrity of the barrier is 
dependent on epithelial cell integrity, epithelial paracellular permeability maintained by 
tight junctions, mucus layers overlying the epithelium and the presence of associated 
immune cells.   
The intestinal epithelium forms a physical barrier between luminal microbes and the host 
tissues. When this physical barrier is breached, the microbial content of the gut lumen 
comes into direct contact with host tissues. This process leads to inflammation, and chronic 
exposure leads to the development of the Inflammatory Bowel Diseases (IBD): Ulcerative 
Colitis and Crohn’s disease (McGuckin et al., 2009; Pastorelli et al., 2013).  
Intestinal epithelial cells (IECs) are tightly bound together by intracellular junctional protein 
complexes, which regulate paracellular permeability (Figure 1.2) (Turner, 2009). The 
junctional complexes are comprised of tight junctions, adherens junctions, gap junctions 
and desmosomes. Adherens junctions are involved in cell-cell adhesion and intracellular 
signalling (Perez-Moreno and Fuchs, 2006). Gap junctions regulate intracellular 
communication (Sosinsky and Nicholson, 2005) whilst desmosomes are involved in cell-cell 
adhesions (Garrod and Chidgey, 2008). Of particular interest are tight junctions, which 
specifically seal the paracellular space to prevent paracellular diffusion of microbes, whilst 
allowing selective absorption of nutrients across the epithelial barrier. They are highly 
dynamic structures, which are constantly remodelled in response to external stimuli, 
including both commensal and pathogenic bacteria. Commensal and probiotic bacteria 
have been shown to enhance epithelial barrier function via redistribution of zonula 
occluding proteins (Ulluwishewa et al., 2011), which connect the transmembrane domains 
of tight junctions to the perijunctional actomyosin ring (Fanning et al., 1998). When 
intracellular junctional protein complexes are incorrectly formed, increased epithelial 
permeability and susceptibility to colitis is observed (Vetrano et al., 2008).   
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Figure 1.2. The Epithelial Barrier. 
(A) IECs are bound together by intracellular junctional protein complexes comprised of tight 
junctions, adherens junctions and desmosomes, which regulate paracellular permeability. 
(B) The intestinal epithelium is coated with protective layers of mucus, the inner firmly 
adherent layer, which is devoid of bacteria, and outer loose mucus layer (colon only), where 
commensal bacteria reside. Figure adapted from (Turner, 2009; Johansson et al., 2013).
 
The intestinal epithelium is coated with a protective layer of mucus (Figure 1.2) (Johansson 
et al., 2013). The inner firmly adherent mucus layer is continuously replenished by goblet 
cells of the epithelium and is thought to be sterile to the luminal microbial content (Hansson 
and Johansson, 2010). The outer layer, present in the large intestine only, is more loosely 
associated with the epithelium and creates an environment where commensal bacteria can 
reside (Johansson et al., 2008). The mucus of the small and large intestines is primarily 
comprised of Mucin-2 (Muc-2). This belongs to a family of four gel-forming mucins, which 
are highly glycosylated glycoproteins with numerous O-glycans attached to domains rich in 
proline, threonine and serine (Gum et al., 1994). The loosely adherent characteristic of the 
outer layer of mucus is due to cleavage of Muc-2 thus enabling bacterial penetration. 
Deletion of Muc-2 in mouse studies leads to direct physical contact between bacteria and 
the intestinal epithelium. These mice developed loose stools, diarrhoea containing blood 
and fail to thrive (Johansson et al., 2008). This suggests an integral role for mucus in the 
maintenance of intestinal barrier homeostasis.  
However, it is important that in the event that bacteria penetrate the inner mucus layer and 
come into contact with the epithelium, IECs must be able to detect microbial patterns in 
Inner mucus
Outer loose 
mucus
Bacteria
A B
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order to mount an immune response. IECs therefore express receptors on their cell surface 
membrane for the detection of microbial peptides, including Toll-Like Receptors (TLRs; 
signalling discussed in detail later), Nucleotide-binding site and Leucine-rich repeat-
containing receptors (NLRs) and Retinoic acid inducible gene-I-Like Receptors (RLRs). In 
response to microbial challenge IECs are able to release anti-microbial molecules, and 
secrete cytokines and chemokines in order to link the innate and adaptive immune system 
(Rescigno, 2011). This suggests that IECs are able to initiate inflammatory pathways in 
response to microbial sensing.  
The presence of innate immune cells underlying the intestinal mucosa forms an important 
part of the intestinal barrier. These immune cells have roles in microbial clearance following 
pathogenic challenge and breach of the mucosal barrier, modulation of the adaptive immune 
response, as well as emerging roles in modulating renewal in the gastrointestinal tract.   
1.1.2 Intestinal Tissue Renewal 
The gut epithelium is the most rapidly renewing tissue in the body. The duration of the 
renewal cycle is 5-7 days, with approximately 10 billion cells shed into the gut lumen every 
day. These cells are continually replaced by Intestinal Stem Cell (ISC) progeny residing at the 
bases of intestinal crypts (Figure 1.3); ISC are vital for the self-renewal capacity of the 
intestines (Barker et al., 2007). ISC maintenance and proliferation is dependent on a number 
of factors: WNT signalling is vital for steady state crypt renewal (Korinek et al., 1998; Pinto 
et al., 2003; Kuhnert et al., 2004); the WNT agonist Rspondin-1 which causes crypt 
hyperplasia in vivo (Kim et al., 2005); Epithelial Growth Factor (EGF) signalling which is 
important for crypt growth in culture (Dignass and Sturm, 2001); and Noggin which induces 
expansion of crypt numbers in vivo (Haramis et al., 2004). Pluripotent ISCs reside at the 
crypt base, thought to be a relatively stable environment, away from the contents of the 
gut lumen. The kinetics of ISC division are best modelled by symmetric cell division (Snippert 
et al., 2010), however there is some evidence to suggest that ISCs also undergo asymmetric 
cell division (Potten et al., 2002; Quyn et al., 2010). How and when asymmetric cell division 
occurs remains to be fully elucidated. Following ISC division, one daughter cell is fated to 
remain a pluripotent ISC, the other will differentiate into a multipotent progenitor cell and 
enter the transit amplifying zone of the crypt. These cells continue to proliferate and 
differentiate into one of five lineages: enterocytes, enteroendocrine cells, goblet cells, 
Paneth cells (small intestine only) and the recently described tuft cells (Snippert et al., 2010; 
Gerbe et al., 2012). Following the differentiation process, enterocytes, enteroendocrine 
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cells, goblet cells and tuft cells all migrate towards the top of the crypt, or villus in the small 
intestine. In contrast, Paneth cells migrate to the base of the crypts in the small intestine 
and reside in the stem cell niche (Barker et al., 2007).  
When cells reach the apex of the crypt (or villus in the small intestine), they undergo 
apoptosis, detach from the epithelium via anoikis and are shed into the gut lumen where 
they are degraded by residing commensal bacteria. The loss of cells into the lumen through 
cell shedding was initially thought to cause a breach or ‘gap’ in the epithelial barrier 
(Kiesslich et al., 2007); however, it is now widely accepted that epithelial cells are lost into 
the lumen whilst maintaining the integrity of the epithelial barrier (Watson et al., 2005; 
Marchiando et al., 2011).  This is dependent on complex interplay between microtubules, 
microfilaments and redistribution of apical junction complex proteins, which form 
intercellular barriers to maintain mucosal function (Marchiando et al., 2011).  
This hierarchy of tissue renewal is thought to minimise the possibility of molecular damage 
to the continuously proliferating stem cell niche. 
 
Figure 1.3. Colonic crypt renewal. 
(A) Proliferation is initiated by intestinal stem cells residing at the base of crypts. (B) Stem 
cell progeny migrate up the crypt axis and differentiate into goblet cells, enterocytes, 
enterendocrine cells or tuft cells. (C) When cells reach the top of crypts, they detach from 
the epithelium through anoikis and are shed into the gut lumen, where they are removed by 
residing commensal microbes.  
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1.1.2.1 Epithelial Cell Types of the Small and Large Intestine 
As mentioned above, when ISC differentiate they give rise to all cell types present within the 
intestinal crypt (summarised in Figure 1.4), which have distinct functions.  
Enterocytes make up approximately 80% of all cells in the intestine (Cheng and Leblond, 
1974). The primary function of enterocytes is nutrient absorption hence their hyperpolarised 
nature. They are essential for maintaining the polarised nature of crypt cells, which is vital 
for the integrity of the epithelial barrier. Luminal antigens are taken up by enterocytes 
through fluid-phase endocytosis and processed in one of two ways; enzymatic degradation 
of the antigens by lysosomes, or released into the interstitial space where they enter the 
systemic circulation. The expression of Major Histocompatibility Complex class I and class II 
allows enterocytes to present processed antigens directly to T cells which may elicit an 
immune response (Snoeck et al., 2005).  
Enteroendocrine cells (EEC) are hormone-secreting cells comprising approximately 1% of the 
intestinal epithelial cells. They are usually located sporadically, interspersed between other 
types of epithelial cells (Buffa et al., 1978). The frequency of EECs in the intestines falls from 
the duodenum to the colon and then rises again in the rectum, where you occasionally see 
clusters of EECs (Cristina et al., 1978). A common characteristic of EECs are apical cytoplasmic 
processes with microvilli that extend towards the lumen, however basal processes extending 
towards adjacent epithelial cells have also been described in the large intestine (Sjolund et 
al., 1983). These processes act as sensors of the luminal contents. EECs are also characterised 
by the presence of secretory vesicles which are able to secrete peptide products which 
impact on colonic motility and secretion and exert effects on distant sites in the GI tract, 
including gastric emptying (Gunawardene et al., 2011). 
As described above, the functional integrity of the intestinal epithelium is largely dependent 
on the mucus layer overlying the epithelial cells (Kim and Ho, 2010). Goblet cells are 
responsible for the secretion and constant replenishment of the mucus layer, which provides 
the first line of defence against invasive microbes arising from ingested food. The main 
component of the mucus secreted by goblet cells is mucin, formed of large glycoproteins 
with a polymeric protein backbone structure linked to numerous oligosaccharide side-chains 
(Andrianifahanana et al., 2006). The intestine is the site of colonization of a wide variety of 
bacteria, both commensal and pathogenic. These bacteria get trapped in the mucus layer 
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secreted by goblet cells and are eliminated by peristalsis before they reach the epithelial 
surface (Lievin-Le Moal and Servin, 2006; Dharmani et al., 2009).  
Paneth cells are an important part of the innate immune system in the small intestine, and 
secrete anti-microbial peptides including lysozyme and defensins (Bevins and Salzman, 
2011). Defensins are antimicrobial cationic peptides which can disrupt bacterial 
membranes, leading to microbial death. In the small intestine, following interactions 
between Pathogen-Associated Molecular Patterns (PAMPs) and the intestinal epithelium, 
α-defensins are produced by Paneth cells residing in the stem cell niche (Ayabe et al., 2000). 
As they are produced by Paneth cells, there are no α-defensins in the large intestine. 
However, β-defensins are produced endogenously throughout the GI tract (Vora et al., 
2004).   
The migration of Paneth cells to the stem cell niche following maturation suggests a role for 
Paneth cells in the maintenance of the stem cell niche. Paneth cells were first described as 
slow-cycling or quiescent stem cells. Following injury, Paneth cells switch to a proliferative 
phenotype, gaining gene expression features characteristic of stem cells, and losing their 
Paneth cell identity. This process is thought to potentially underlie the regenerative response 
of the crypt (Roth et al., 2012). During homeostasis, Paneth cells express EGF, TGFα, WNT3 
and the Notch-ligand Delta-like ligand 4 (DLL4), all of which are essential for proliferation of 
stem cells in culture. This was confirmed by in vivo genetic deletion of Paneth cells, which 
resulted in a loss of intestinal stem cells. Although Paneth cells are not present in the large 
intestine, in the colonic crypt stem cell niche resides a pool of CD24+ secretory type cells, 
distinct from mature goblet cells; these cells are thought to be the colonic Paneth cell 
equivalent (Sato et al., 2011).   
Although intestinal tuft cells were previously acknowledged on many occasions, a lack of 
molecular markers meant that the functional characteristics of tuft cells were not defined 
until relatively recently (Gerbe et al., 2012). A number of genetically modified mouse lines, 
as well as genetic modification of cell lines have allowed further information regarding the 
function of tuft cells within the intestine to be elucidated. Tuft cells were identified to be the 
main source of endogenous intestinal opioids and a unique source of COX enzymes 
(discussed later) in the intestinal epithelium (Gerbe et al., 2011). 
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Figure 1.4. Characterisation of intestinal epithelial cell lineages in crypts and villi. 
(A) In the small intestine, Lgr5+ stem cells reside at the base of crypts. Lgr5+ stem cells, 
proliferate and give rise to rapidly proliferating transit-amplifying (TA) cells, which 
differentiate into the following cell lineages: Paneth cells, which migrate to the base of 
crypts; slow cycling +4 stem cells, which reside at the +4 position; goblet cells, enterocytes, 
enteroendocrine cells and tuft cells which all migrate up the crypt villus axis. When cells 
reach the villus tip, they are shed into the gut lumen by anoikis. (B) The colonic epithelium 
are comprised of Lgr5+ stem cells, which proliferate, give rise to rapidly proliferating TA cells, 
and differentiate into goblet cells, enterocytes, enteroendocrine cells and tuft cells. Cells 
migrate up the crypt-axis and are shed into the gut lumen by anoikis. Figure from (Barker 
2014) 
A Small intestine
B Colon
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1.1.2.2 Characterisation of Intestinal Stem Cells 
As mentioned previously, ISC are vital for the self-renewing capacity of the intestinal 
epithelium. However, until the important publications by Clevers’ group in 2007 (Barker and 
Clevers, 2007; Barker et al., 2007), no stem cells had been identified in the colon. Previously, 
long-term DNA label retention studies had suggested cycling +4 position crypt cells were the 
stem cells of the small intestine (Potten et al., 2002). However, the functional identity of 
small intestinal stem cells remained unknown until relatively recently due to a lack of specific 
markers and stem-cell assays. 
A number of intestinal stem cell markers have since been characterised. Seminal work from 
the Clevers laboratory identified the stem cell marker Lgr5 (leucine-rich-repeat-containing 
G-protein-coupled receptor 5). The WNT signalling pathway was known to be crucial for the 
regulation of crypt stem cells in the intestines (Reya and Clevers, 2005). It is for this reason 
that a panel of WNT target genes were hypothesised to be specifically expressed in intestinal 
stem cells. A unique expression pattern of Lgr5 in murine small intestinal crypts but not in 
the villi was observed. Lgr5+ cells were also present at all crypt bases, and appeared to mark 
the cycling crypt base columnar cells between Paneth cells in the small intestine. 
Development of an inducible Cre knock-in allele and the Rosa26-LacZ reporter strain (Figure 
1.5), allowed lineage-tracing experiments of Lgr5+ cells to be undertaken. In this system, Cre 
DNA recombinase is fused to a mutant estrogen ligand-binding domain; which, upon binding 
of tamoxifen, is able to enter the nucleus. This complex excises an upstream stopper 
cassette, which allows expression of β-galactosidase or fluorescent protein (Snippert and 
Clevers, 2011).  Once activated, expression is observed in stem cells, and all daughter cells. 
Lineage-tracing of a single Lgr5+ cell revealed that within 5 days, Lgr5+ cells were able to 
differentiate into all the cell types of the colonic epithelium suggesting that Lgr5+ cells are 
the true stem cells of the intestines (Barker et al., 2007). Lgr5-EGFP-ires-CreERT2 mice were 
utilised in this thesis to enable the visualisation of Lgr5 stem cells in the intestine through 
fluorescence microscopy (Figure 1.5).  
Evidence has since revealed the presence of two subtypes of stem cells, defined by their 
location and cycling dynamics. Lgr5+ stem cells are fast-cycling, and are interspersed 
between Paneth cells at the base of crypts, which support them by secreting factors including 
WNT and DLL4 (Barker et al., 2007; Sato et al., 2011). Slower-cycling cells represent a rarer 
population of stem cells, reside at the +4 positive above Paneth cells in the crypt, and are 
marked by expression of BMI1 (B lymphoma Moloney-murine leukaemia virus insertion 
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region 1 homolog) (Sangiorgi and Capecchi, 2008). Following genetic ablation of Lgr5 cells, it 
was shown that BMI1 slow-cycling stem cells are able to repopulate crypts and give rise to 
all the cell types of the epithelium, including Lgr5+ stem cells (Tian et al., 2011). More recent 
studies have determined that quiescent crypt cells are secretory precursors which express 
Lgr5 and are committed to mature into Paneth and enteroendocrine cells; however following 
intestinal injury, these cells are capable of extensive proliferation and give rise to all epithelial 
cell types (Buczacki et al., 2013).  
The ability of other cells within the crypt to act as reserve stem cells has also been tested 
(reviewed in (Philpott and Winton, 2014; Beumer and Clevers, 2016)). Delta-like ligand 1 
(DLL1) is a Notch ligand expressed by secretory progenitors of the crypt. When Lgr5+ stem 
cells were ablated by irradiation, DLL1 cells were shown to de-differentiate to a stem cell 
state, where they are able to replenish all cells within the crypt (van Es et al., 2012). The DLL1 
secretory progenitors form only a small proportion of cells within the crypt, therefore it was 
hypothesised that should the cells of the highest abundance within crypts have the ability to 
retain stemness, this would increase the pool of ‘reserve stem cells’ significantly. Similarly to 
secretory cells, alkaline phosphate intestinal (ALPi)-expressing enterocytes were also shown 
to replenish all cells within the crypt following Lgr5 stem cell ablation (Tetteh et al., 2016).  
A number of laboratories are now taking advantage of the ability of the fast-cycling, self-
renewal properties of intestinal stem cells in order to grow stem cells in in vitro culture (Sato 
et al., 2009; Jung et al., 2011; Sato et al., 2011; Skoczek et al., 2014; Parris and Williams, 
2015). Tissue samples from the mouse and human intestine are broken down into individual 
stem cells or whole crypts are isolated, which grow in culture as organoids or crypts in a 
culture media containing WNT, R-spondin1, EGF and Noggin in a laminin-rich matrigel. 
Mouse intestinal organoids grow as budding cysts, containing crypt (and villus)-like domains. 
These organoids grow and expand in culture for several months or even years, maintaining 
all cell types of the epithelium observed in vivo and retaining genomic stability (Barker et al., 
2008; Sato et al., 2011). Human whole crypt culture, as developed by the Williams laboratory, 
recapitulates the topological hierarchy of the intestinal epithelium to permit the study of 
native polarised epithelial cells (Reynolds et al., 2014; Parris and Williams, 2015).  
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Figure 1.5. Generation of mice expressing EGFP and creERT2 through Lgr5 gene knock-in. 
In order to visualise Lgr5, an EGFP-IRES-creERT2 cassette was inserted into the Lgr5 gene 
locus. A fluorescent protein or LacZ is inserted in the locus of the ubiquitously expressed 
Rosa26 gene. Expression is prevented by an upstream STOP cassette. The EGFP-IRES-creERT2 
allele was crossed with the Cre-inducible Rosa26-lacZ reporter. The addition of tamoxifen 
allows Cre recombinase fused to a mutant estrogen ligand-binding domain to enter the 
nucleus. The STOP cassette is excised, and the LacZ reporter is expressed irreversibly in Lgr5+ 
cells, allowing for lineage tracing of Lgr5 stem cells. UTR, untranslated region; FP, fluorescent 
protein; IRES, internal ribosome entry site; CreERT2, Cre recombinase fused to mutant 
estrogen ligand-binding domain; polyA, polyadenylation sequence; SA, splice acceptor. 
Adapted from (Barker, van Es et al. 2007) 
 
 
1.1.3 Autocrine and Paracrine Regulation of Epithelial Renewal 
As described above, through the secretion of WNT, EGF, TGFα and DLL4, CD24+ cells 
maintain the intestinal stem cell niche in a crypt autonomous manner (Sato et al., 2011). In 
addition to secretion by Paneth cells, EGF and the EGFR are expressed endogenously 
throughout the epithelium, suggesting that cells are able to respond to EGF in an autocrine 
fashion. EGF is a potent activator of crypt cell proliferation and also has roles in intestinal 
healing and cancer (Dignass and Sturm, 2001; Normanno et al., 2006). 
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The WNT signalling pathway has been described as the master regulator of intestinal tissue 
renewal (Schepers and Clevers, 2012). Paneth cells are the major source of WNTs in the 
intestine. Co-culturing of Paneth cells with sorted Lgr5+ stem cells induced a marked 
improvement in organoid forming efficiency, which was also induced by addition of 
exogenous WNT to culture media in the absence of Paneth cells (Sato et al., 2011; Farin et 
al., 2016). The importance of WNT signalling in epithelial renewal was investigated through 
depletion of the gene for Tcf-4 (a major transcription factor activated by WNT signalling), 
which leads to the development of an epithelium which is comprised solely of differentiated, 
non-dividing cells. The lack of a proliferative compartment in intestinal crypts suggests that 
Tcf-4 maintains the crypt stem cells of the intestine (Korinek et al., 1998). WNT signalling was 
confirmed to be important in the maintenance of adult intestinal stem cells by transgenic 
expression of the WNT inhibitor Dickkopf-related protein 1 (DKK1) in adult mice, which 
induces the complete loss of crypts (Reya and Clevers, 2005). Constitutive activation of WNT 
signalling using Rspondin-1, a potent WNT signal enhancer induces massive proliferation in 
crypts (Kim et al., 2005). R-spondin-1 binds Lgr5 with high affinity and was shown to be vital 
for WNT-mediated self-renewal of intestinal stem cells (Yan et al., 2017).  
All WNT proteins have a covalent lipid modification which tether them to the cell membrane. 
Porcupine is the enzyme responsible for the WNT protein lipid modification (Kadowaki et al., 
1996); inhibition of porcupine by Inhibitor of Wnt Production-2 (IWP2) is widely used as an 
in vitro WNT signalling inhibitor (Chen et al., 2009; Koo et al., 2012). The transmembrane 
protein Wingless (WL) binds lipidated WNTs and conveys them to the plasma membrane for 
secretion (Najdi et al., 2012). Secreted WNT may then be incorporated into secretory 
vesicles, where they remain bound to WL, until they are presented to Frizzled receptors 
(Gross et al., 2012). Binding of WNT3 to Frizzled receptors on Paneth cells at the base of 
intestinal crypts tethers WNT3 to the basal membrane of crypts. Tethered WNT3 is 
transferred to neighbouring Lgr5+ stem cells, which then distribute the WNT ligand to 
daughter cells through cell division (Farin et al., 2016). The WNT3 signal is therefore diluted 
along the crypt-axis, inducing a WNT signalling gradient from the base to the top of crypts, 
which has previously been described (Davies et al., 2008; Reynolds et al., 2014). 
Upon WNT receptor activation, three different signalling transduction pathways are known 
to be activated: the canonical WNT signalling cascade, and two non-canonical WNT 
pathways, the planar cell polarity pathway and the WNT/calcium pathway (reviewed in 
Nusse (2012)). In the canonical WNT pathway, in the absence of WNT ligand, a destruction 
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complex of Axin, adenomatous polyposis coli (APC) and glycogen synthase kinase-3 (GSK3) 
phosphorylates β-catenin, which continually targets it for degradation by the proteasome 
(Rubinfeld et al., 1993; Siegfried et al., 1994; Ikeda et al., 1998). In the presence of WNT, 
WNT ligand binds Frizzled, or the transmembrane co-receptor Lrp5/6 (inducing a complex 
formation with Frizzled), which instils a conformational change in the receptor to enable 
phosphorylation. This inhibits GSK3 and binds Axin, preventing interaction with APC, which 
inhibits the formation of a destruction complex with β-catenin. Translocation and 
subsequent accumulation of β-catenin in the nucleus occurs, where it induces transcription 
factors Tcf/Lef (Figure 1.6) (reviewed in Nusse (2012)). The APC gene is known to be mutated 
in the hereditary cancer syndrome familial adenomatous polyposis (FAP) whereby 
innumerate pre-cancerous intestinal polyps are formed in the intestine, which eventually 
leads to the formation of malignant adenocarcinoma (Nishisho et al., 1991).  Loss of both 
APC alleles also occurs in the majority of sporadic colon cancers (Kinzler and Vogelstein, 
1996). Mutated APC induces stabilisation and accumulation of β-catenin in the nucleus, 
leading to inappropriate transcription of Tcf reporter constructs, which in turn activates a 
genetic program to maintain cell proliferation in crypt stem and progenitor cells (Korinek et 
al., 1997). Confirmation of this paradigm was provided by Barker et al., (2009), where the 
APC gene was deleted in Lgr5+ stem cells, which induced formation of a rapidly growing (but 
not differentiating) microadenoma in the proliferative compartment of the crypts. In these 
crypts, constitutive activation of WNT signalling lead to conservation of the proliferative 
nature of stem cells and prevention of differentiation (Barker et al., 2009).  
Non-canonical WNT signalling is independent of β-catenin and instead requires the 
recruitment of Dishevelled (Dsh). There are two defined non-canonical WNT signalling 
pathways, the planar cell polarity (PCP) pathway, and the WNT/Calcium pathway (Figure 
1.7).  In the PCP pathway, WNT binds to Frizzled and either Neurotrophin receptor homolog 
1 (NRH1), Ryk (related to receptor tyrosine kinase), Pseudo Tyrosine Kinase 7 (PTK7) or 
Receptor tyrosine kinase like Orphan Receptor 2 (ROR2) as a co-receptor. The receptor 
complex then recruits Dsh and forms a complex with Dishevelled-associated activator of 
morphogenesis 1 (DAAM1). DAAM1 activates Rho, which activates Rho-associated kinase 
(ROCK). Dsh also forms a complex with Ras-related C3 botulinum toxin substrate 1 (Rac1), 
which activates c-Jun N-terminal kinases (JNK). DAAM1 also activates the actin-binding 
protein Profilin. Signalling from Profilin, ROCK and JNK lead to actin polymerization and other 
cytoskeletal changes required to regulate cell polarity and gastrulation (Figure 1.7A) (Komiya 
and Habas, 2008). Aberrant non-canonical WNT signalling through the PCP pathway is also 
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known to induce malignant phenotypes of cancer through abnormal tissue polarity, cell 
invasion and metastasis. 
The WNT/Calcium signalling pathway depends on the interaction of G proteins with Dsh to 
activate phospholipase C (PLC). This then leads to accumulation of inositol triphosphate (IP3) 
and diacyclglyceride (DAG) which induces intracellular calcium release. Elevated intracellular 
calcium activates Ca2+/calmodulin-dependent protein kinase II (CamKII) and calcineurin 
(Krausova and Korinek, 2014). CamKII activates TGF–β Activated Kinase-1 (TAK1), which 
inhibits the function of β-catenin/TCF. Calcineurin activates nuclear factor of activated T cells 
(NFAT) to regulate ventral cell fates. DAG also activates protein kinase C (PKC), which 
activates CDC42 for mediation of tissue separation during gastrulation (Figure 1.7B) (van 
Amerongen, 2012). 
 
Figure 1.6. The canonical WNT signalling transduction pathway. 
(A) In the absence of WNT, a destruction complex of Axin, APC and GSK3 phosphorylates β-
catenin, which targets it for degradation by the proteasome. (B) In the presence of Wnt and 
R-spondin, Wnt ligand binds Frizzled and Lrp5/6 which induces phosphorylation. This inhibits 
GSK3 and binds actin, which inhibits formation of a destruction complex with β-catenin. This 
leads to an accumulation of β-catenin in the nucleus where it induces transcription factors 
Tcf/Lef, which have a number of roles in intestinal tissue renewal and embryogenesis. 
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Figure 1.7. The non-canonical WNT signalling transduction pathways. 
(A) The planar cell polarity pathway. WNT binds to Fr and a Co-receptor (gold) and recruits 
Dsh. Dsh forms a complex with Daam1, Daam1 activates Rho, which activates ROCK. Dsh also 
forms a complex with Rac1 which activates JNK. Profilin activation by Daam1, ROCK and JNK 
lead to actin polymerization. (B) The WNT/calcium pathway. WNT binds Fr and recruits Dsh 
to activate PLC. This leads to accumulation of IP3 and DAG which induces intracellular 
calcium release and PKC. Ca2+ activates calcineurin and CamK11 which activate NFAT and 
inhibit β-catenin/TCF.  
 
Recent studies suggest that WNT signals are modulated by cross talk with other signalling 
pathways including BMPs and TGFβ. Reduced WNT signalling impeded cell proliferation, but 
migration and shedding remained unaffected, resulting in diminished crypts, suggesting that 
WNT signalling alone is insufficient to maintain renewal of the epithelium. The combination 
of canonical WNT activation, with suppressed TGFβ/BMP signalling maintained steady state 
renewal of the human colonic epithelium (Reynolds et al., 2014). BMP signalling is a negative 
regulator of intestinal stem cell renewal through the suppression of WNT signalling (He et 
al., 2004). Activation of BMP signalling induces phosphorylation of SMAD proteins, which 
translocate to the nucleus and induce transcription of BMP target genes (Haramis et al., 
2004). In contrast to the expression of WNT by the intestinal epithelium, BMP signals are 
increased towards the top regions of crypts (Reynolds et al., 2014), where they have a role 
in crypt cell positioning, differentiation and apoptosis. BMP signalling is crucial for the 
maintenance of intestinal crypt homeostasis by preventing excessive proliferation of 
intestinal stem cells and therefore reducing the risk of carcinogenesis (Vanuytsel et al., 2013). 
Noggin is a potent antagonist of BMP signalling, which is expressed by intestinal 
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myofibroblasts at the base of crypts and is required for organoid growth in culture (Haramis 
et al., 2004; Sato et al., 2009). This suggests that in vivo, BMP signalling inhibition is mediated 
by paracrine secretion of noggin by myofibroblasts. 
WNT signalling is augmented by Prostaglandin-E2 (PGE2) (Goessling et al., 2009), a growth 
factor known to induce progression of colorectal cancer (Wang and Dubois, 2010). Tuft cells 
of the intestinal epithelium are an endogenous source of opioids including COX enzymes 
which synthesise PGE2 (Gerbe et al., 2012). The roles for PGE2 in the progression of colorectal 
cancer have been well characterised; however, PGE2 is also known to induce crypt cell 
proliferation during homeostasis (Wang and Dubois, 2010). The expression of COX enzymes 
is also observed in myofibroblasts and immune cells residing in the underlying lamina propria 
of the gastrointestinal mucosa (Roulis et al., 2014). This suggests that the intestinal 
epithelium synthesises and responds to PGE2 in an autocrine and paracrine manner 
(described in detail in Section 1.4).  
Roles are emerging for immune cells residing in the underlying lamina propria of the 
intestinal mucosa in the modulation of crypt renewal (Pull et al., 2005; Seno et al., 2009; 
Kuhn et al., 2014; Skoczek et al., 2014). Skoczek et al., (2014) showed that luminal microbial 
addition to the air apical interface of colonic explants induces migration of monocytes and 
eosinophils towards to the stem cell niche. This immune cell migration was associated with 
an increase in proliferation and stem cell number in colonic crypts. The physical interaction 
and microbial sensing of the luminal content through Myeloid Differentiation primary 
response 88 (MyD88) signalling was shown to be required for monocyte-induced crypt cell 
proliferation and stem cell expansion (Skoczek et al., 2014). This suggests that immune cells 
are able to induce stem cell driven tissue renewal in a paracrine manner, although the 
mechanism through which monocytes are able to induce crypt renewal remains to be seen. 
The role of eosinophils in modulating human colonic crypt cell proliferation will be addressed 
in this thesis.  
The residing immune cells in the intestinal lamina propria are known to secrete a variety of 
factors, including cytokines, which have a number of downstream functions in health and 
disease (Rosenberg et al., 2013; Hunter and Jones, 2015; Villarino et al., 2015). Epithelial cells 
also secrete a variety of cytokines and chemokines and express receptors for cytokines 
(reviewed by Peterson and Artis (2014)). Roles are emerging for paracrine and autocrine 
cytokine secretion in the regulation of intestinal tissue renewal from infiltrating 
inflammatory cells and from epithelial cells themselves. Of particular interest is Interleukin-
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6 (described in detail in Section 1.3), which signals through the JAK/STAT signalling pathway 
and has been associated with crypt regeneration following tissue injury or damage in both 
the Drosophila and mammalian gut (Jiang et al., 2009; Kuhn et al., 2014).  
In summary, the complex interplay between growth factors and signalling pathways is 
required for the finely tuned regulation of epithelial renewal (summarised in Figure 1.8) 
(reviewed in Vanuytsel et al. (2013)). Aberrant signalling through the pathways responsible 
for epithelial renewal, specifically WNT signalling, leads to the development of 
adenocarcinomas in the intestinal epithelium (Schepers and Clevers, 2012; Nusse and 
Clevers, 2017). Epithelial cells produce and respond to cytokines and growth factors in an 
autocrine manner, and immune cells residing in the lamina propria underlying the epithelium 
deliver signals to maintain epithelial renewal through paracrine signalling (Figure 1.8). This 
thesis aims to address the roles of IL-6, PGE2 and eosinophils in epithelial renewal during 
homeostasis.  
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Figure 1.8. Paracrine and autocrine regulation of intestinal tissue renewal. 
WNT signalling by Paneth cells (small intestine only) and CD24+ cells (colon) at the base of 
crypts induces ISC proliferation. BMP signalling is a negative regulator of epithelial renewal; 
however, secretion of Noggin by myofibroblasts antagonises BMP. Epithelial cells express 
and respond to EGF signalling in an autocrine manner to enhance cell proliferation. Tuft cells 
express the enzymes responsible for Prostaglandin (PG) secretion. Immune cells in the 
underlying lamina propria and epithelial cells secrete cytokines, which have pleiotropic roles 
in epithelial renewal. Monocytes enhance ISC expansion and proliferation through physical 
interactions with ISC. Adapted from (Vanuytsel et al., 2013).
 
1.2 The Intestinal Immune System 
The largest number of immune cells of anywhere in the body are contained within the 
intestine, of which 20-40% are eosinophils (Carlens et al., 2009). The intestinal epithelium is 
continually exposed to dietary antigens and commensal microbiota and forms a vital barrier 
between the contents of the gut lumen and underlying immune cells. A plethora of immune 
cells reside in the lamina propria, which are able to mount an immune response in order to 
clear pathogens in the event of a breach of the epithelial barrier (Mowat and Agace, 2014). 
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Following bacterial penetration of the barrier, innate immune cells, including monocytes, 
macrophages, dendritic cells, neutrophils and eosinophils form the first line of defence, and 
directly or indirectly destroy invading pathogens. Cells of the innate immune system also 
secrete cytokines which leads to the recruitment of adaptive components (including T cells 
and IgA+ B cells), which are able to specifically recognize and remember bacterial antigens 
to enable a more efficient response in the event of repeat exposure to pathogens (Figure 
1.9) (Mowat and Agace, 2014). 
 
Figure 1.9. The intestinal immune system. 
The small intestinal (LEFT) and colonic (RIGHT) epithelium form a vital barrier between 
microbial content of the gut lumen and immune cells in the underlying lamina propria. 
Protective mucus layers prevent commensal microbes from coming into contact with the 
epithelium. In the event of a breach of the epithelial barriers, immune cells in the underlying 
LP mount an immune response to destroy invading pathogens. Adapted from (Mowat and 
Agace, 2014). 
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1.2.1 Innate Immunity 
The innate immune system is the first line of defence against microbial pathogens. The 
human innate immune system is comprised of immune cells, epithelial cells and mucosal 
barriers, which are able to produce an immediate initial response against invading 
pathogens (Mowat and Agace, 2014).  
The cellular components of innate immunity are vital in the cross-activation of the adaptive 
immune system. The majority of these cells are of myeloid origin: monocytes, macrophages, 
mast cells, dendritic cells and granulocytes (neutrophils, eosinophils and basophils). 
However, some lymphoid cells such as natural killer cells, innate lymphoid cells and other 
lymphocytes are also involved in innate immunity.  
Innate immune cells are derived from hematopoietic stem cell (HSC) which firstly 
differentiate into a common myeloid progenitor (CMP). CMPs then differentiate into either 
megakaryocyte and erythroid progenitor (MEP) or granulocyte and macrophage progenitor 
(GMP). MEPs terminally differentiate into erythrocytes or platelets. GMPs then differentiate 
further into a monocyte progenitor which gives rise to monocytes (can be further derived 
into dendritic cells or macrophages), or a granulocyte progenitor which gives rise to the 
granulocytes: neutrophils, eosinophils and basophils. Collectively, the process of 
differentiation of HSCs to all lineages of blood cells is called haematopoiesis (Figure 1.10) 
(Laiosa et al., 2006).  
The major role for cell-mediated immunity is the phagocytosis of invading pathogens, which 
are then presented on the cell surface inducing inflammation and triggering the adaptive 
immune system.  Following activation by microbial sensing, monocytes differentiate into 
macrophages or dendritic cells. Macrophages directly phagocytose pathogens; both 
macrophages and dendritic cells are then able to become Antigen Presenting Cells (APCs) 
through uptake of bacterial antigens and migrating to the lymph nodes in order to present 
surface antigen to naïve T and B cells, in order to mount an adaptive immune response. 
Neutrophils and eosinophils are potent effector cells; neutrophils engulf the pathogen and 
destroy it through the release of antimicrobial toxins, whereas eosinophils release 
cytoplasmic granule content upon activation, which is cytotoxic to pathogens.
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Figure 1.10. Haematopoiesis. 
A multipotent stem cell gradually differentiates into mature blood cells: first into a common 
myeloid progenitor (CMP) or a common lymphoid progenitor (CLP); CLPs differentiate into 
the cells of the adaptive immune system; CMPs differentiate into either erythrocytes, 
platelets of myeloblasts. Myeloblasts then differentiate further into granulocytes, basophils, 
neutrophils or eosinophils – or monocytes, which further differentiate into dendritic cells or 
macrophages (adapted from OpenStax, Anatomy & Physiology)
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In addition to the vital role of immune cells in pathogen clearance, evidence is beginning to 
emerge for a role of immune cells in the regulation of intestinal tissue renewal (Pull et al., 
2005; Seno et al., 2009; Kuhn et al., 2014; Skoczek et al., 2014). Indeed, immune cells express 
a number of factors known to be important for epithelial renewal and the abundance of 
immune cells present in the lamina propria in the absence of pathogenic challenge suggests 
that they may play a role in epithelial renewal during homeostasis (Lee et al., 2010; 
Rosenberg et al., 2013).  Of particular interest to this thesis are eosinophils, which have a 
number of functions not only in host defence against pathogens, but also in immune cell 
regulation and the maintenance of homeostasis, discussed in detail in Section 1.5.
1.2.2 Adaptive Immunity 
The adaptive immune response is activated by APCs of the innate immune system, and 
characterised by its ability to recognize and remember specific pathogens and is constituted 
of two main cell types: T-lymphocytes and B-lymphocytes.  
Once activated, T-lymphocytes undergo clonal expansion and differentiate into a number of 
subsets of T cells, which convey different functions. Helper T cells (TH cells) release cytokines 
to activate macrophages and induce differentiation of cytotoxic T cells and B cells (Garay and 
McAllister, 2010). TH cells can be further sub-divided into TH1, TH2 or TH17 cells; TH1 cells are 
important for clearance of intracellular pathogens, whereas TH2 cells enhance the clearance 
of extracellular microorganisms (Diehl and Rincon, 2002). The more recently defined TH17 
cells have been implicated in the induction of autoimmune diseases through the secretion 
of IL-17 (Bettelli et al., 2006); however, they also play a role in bridging the innate and 
adaptive immune system through the activation of neutrophils through granulocyte-colony 
stimulating factor secretion (Stockinger and Veldhoen, 2007). Cytotoxic T cells (TC cells) form 
a synapse with infected cells to induce direct lysis (Marshall and Swain, 2011). The generation 
of memory T cells, which are preserved following resolution of inflammation, enables the 
immune system to mount a rapid, specific response when exposed to the same pathogenic 
antigen again (Mahnke et al., 2013). Regulatory T cells (Treg cells) are important to suppress 
inappropriate T cell responses and prevent autoimmune responses (Kleinewietfeld and 
Hafler, 2014).  
Following activation, B-lymphocytes differentiate into plasma cells, which secrete antibodies 
specific to the invading antigen. The antibodies bind to target antigens to form immune 
complexes which are able to activate complement or target them for phagocytosis by 
macrophages. B cell activation is thought to be mainly induced by TH cells, however a role is 
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emerging for eosinophil-mediated generation of plasma cells in the bone marrow and 
intestinal lamina propria (Chu et al., 2011; Chu et al., 2014).  
1.2.3 Induction of Cytokine Secretion 
In order for an immune response to be elicited, it must be possible for mammalian cells to 
recognise pathogens at the mucosal surfaces. Pattern recognition receptors (PRRs) on the 
surface of immune cells allow mammalian cells to distinguish between harmless antigens 
and potentially pathogenic microbial components (Medzhitov and Janeway, 2000). These 
receptors are present on a variety of innate immune cells including macrophages, 
eosinophils, neutrophils and dendritic cells. An example of PRRs are TLRs, which enable 
mammalian cells to recognise PAMPs such as lipopolysaccharides which are present on the 
membrane of gram-negative bacteria, which are the dominant bacteria present in the colon 
(Raetz and Whitfield, 2002). TLRs can also induce an immune response by binding to a toll 
Interleukin-1 receptor domain. Activation of this domain stimulates an association with 
MyD88 which induces downstream activation of the Nuclear Factor κ-light-chain-enhancer 
of activated B cells (NFκB) signalling pathway (Baumgart and Carding, 2007), which plays a 
major role in the regulation of cytokine secretion.   
In response to antigen challenge, cytokines are produced by immune cells and epithelial 
cells. Cytokines have immunomodulatory functions and chemoattractant properties: 
activation of cytokines induces recruitment of immune cells of the innate and adaptive 
immune system (Jung et al., 1995; Maaser and Kagnoff, 2002; Abreu et al., 2003).  Two 
cytokines which are known to induce inflammation in the intestinal epithelium are IL-6 and 
PGE2. In the next sections, IL-6 and PGE2 signalling transduction pathways and emerging 
roles for IL-6 and PGE2 in intestinal homeostasis will be discussed. 
1.3 Interleukin-6 
Interleukin-6 is a pleiotropic cytokine involved in a plethora of cellular and immune 
responses in health and disease (Mihara et al., 2012; Garbers et al., 2015; Hunter and Jones, 
2015). As well as playing a pivotal role in the activation of immune cells, IL-6 is known to play 
a role in the regulation of metabolism, the maintenance of bone homeostasis and in 
pathological pain responses (Scheller et al., 2011). Furthermore, recent studies have 
implicated IL-6 in epithelial regenerative responses following injury. Seminal work in the 
Drosophila midgut demonstrated that following acute stress such as enteric infection, 
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enterocytes are stimulated to produce Upd3, an IL-6-like cytokine, which activates JAK/STAT 
signalling in intestinal stem cells to promote cell division and therefore regeneration (Jiang 
et al., 2009; Osman et al., 2012). In the mammalian gut, STAT3 and IL-6 are known to play a 
role in regeneration of the intestinal epithelium following colonic tissue injury (Pickert et al., 
2009; Kuhn et al., 2014) and to promote the survival of epithelial cells (Grivennikov et al., 
2009; Jin et al., 2010) during inflammation and IBD (Bollrath et al., 2009; Lee et al., 2012).  
Whilst a role for IL-6 in health is beginning to emerge, little is known about the influence of 
IL-6 in the maintenance of intestinal homeostasis.  
1.3.1 IL-6 and Homeostasis 
A role for IL-6 in the survival of normal epithelial cells has recently been described. IL-6 
secreted by lamina propria myeloid cells was shown to promote the survival of pre-malignant 
colonic epithelial cells. This was shown to be mediated by STAT3 activation (Grivennikov et 
al., 2009). Following addition of IL-6, pSTAT3 activation was observed in enterocytes of villi 
but not in crypts. An increase in the induction of anti-apoptotic factors and decreased 
caspase activity was observed, resulting in a prolonged life span of enterocytes. When these 
mice were subsequently challenged with ischemic reperfusion, IL-6 treated mice exhibited 
increased barrier function and reduced small intestinal injury (Jin et al., 2010). These data 
suggest that IL-6 is able to promote the survival of normal tissue during homeostasis and in 
small intestinal and colonic tissue injury.  
IL-6 also has important roles in the regulation of the immune system, which is required to 
maintain intestinal homeostasis; a pivotal role for IL-6 in the switch from innate to adaptive 
immunity has been described (Scheller et al., 2011). Acute inflammation is characterised by 
a rapid infiltration of neutrophils, which are replaced by monocytes and T cells in order to 
prevent tissue damage from secreted products of neutrophils. Secretion of chemokines 
(including IL-6) leads to the recruitment of neutrophils, proteolytic cleavage of the IL-6 
receptor then drives IL-6 trans-signalling in resident tissue cells which induces switching from 
neutrophil recruitment to monocyte recruitment (Kaplanski et al., 2003). Monocytes 
differentiate into either macrophages or dendritic cells, upregulation of Macrophage-Colony 
Stimulating Factor (M-CSF) expression by IL-6 trans-signalling has been shown to skew 
differentiation of monocytes towards the macrophage lineage (Chomarat et al., 2000). The 
resolution of inflammation following pathogenic challenge in the intestine is vital for the 
maintenance of the epithelial barrier. The apoptosis of neutrophils following infiltration is 
key for the resolution of inflammation, and this has been shown to be driven by IL-6 
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(Kaplanski et al., 2003). IL-6 also has a critical role in the differentiation of B cells, which are 
integral for intestinal immunity. In fact, IL-6 was first characterised for its role in enhancing 
antibody production of a B cell line (Hirano et al., 1985). The promotion of antibody 
production by B cells was shown to be dependent on IL-6-induced IL-21 production of T cells 
(Dienz et al., 2009; Eddahri et al., 2009). Recent studies have defined a role for eosinophil-
mediated IL-6 secretion in the maintenance of plasma cells in the bone marrow and lamina 
propria, which is crucial for the maintenance of long term immunity (Chu et al., 2011; Chu et 
al., 2014). However, the role of IL-6 in epithelial cell renewal during homeostasis remains 
largely unknown.  
IL-6 can signal through classic or trans signalling, the two signalling events having divergent 
functions (Scheller et al., 2011). The roles for IL-6 in homeostasis are thought to be associated 
with IL-6 classic signalling, whilst IL-6 trans signalling is thought to promote inflammation and 
cancer growth (summarised in Figure 1.11). The next section will discuss the IL-6 classic and 
trans signalling transduction pathways.  
 
Figure 1.11. The roles of IL-6 signalling in health and disease. 
IL-6 signalling is mediated by classic or trans signalling, which have divergent functions in 
health and disease. Classic IL-6 signalling is associated with epithelial proliferation and 
survival and the maintenance of bone and metabolic homeostasis. IL-6 trans signalling has a 
number of roles in inflammation, including recruitment of immune cells to inflammatory 
sites, where IL-6 promotes survival and differentiation of T cells. IL-6 trans-signalling has also 
been associated with tumorigenesis. Adapted from (Scheller et al., 2011). 
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1.3.2 The IL-6 Signalling Transduction Pathway 
The signal transduction of IL-6 is induced through binding of IL-6, complexed to the IL-6 
receptor (IL-6R), to the β-receptor Glycoprotein 130 (gp130) which is expressed ubiquitously 
on all cells throughout the human body (Garbers et al., 2015). Classical IL-6 signalling is 
traditionally associated with homeostasis (Scheller et al., 2011) and occurs through binding 
of IL-6 to the membrane-bound IL-6R, which then complexes to the ubiquitously expressed 
gp130 receptor. This results in activation of a number of downstream signalling cascades 
including the JAK/STAT pathway. Jak1 phosphorylates tyrosine residues of the gp130 
receptor, which leads to recruitment and phosphorylation of STAT3 (Garbers et al., 2015) 
(Figure 1.12). Several mouse models have identified a role for IL-6 classic signalling in the 
activation of anti-inflammatory pathways on target cells, including apoptosis of neutrophils 
for the resolution of inflammation (Kaplanski et al., 2003). Furthermore, IL-6 classic signalling 
has been shown to be essential for the regeneration of intestinal epithelial cells following 
Dextran Sodium Sulfate (DSS)-induced tissue injury (Kuhn et al., 2014). 
The pro-inflammatory effects of IL-6 signalling are thought to be mediated through IL-6 trans-
signalling (Rose-John, 2012). In IL-6 trans-signalling, metalloproteinases termed A Disintegrin 
and metalloproteinase domain-containing protein (ADAM) 10 (Matthews et al., 2003) and/or 
ADAM17 (Chalaris et al., 2010) cleaves the IL-6R from the membrane, resulting in soluble IL-
6R (sIL-6R) which is able to bind directly to IL-6. The IL-6/sIL-6R complex can then activate IL-
6 signalling in any cell expressing the gp130 protein, which is constitutively expressed by the 
intestinal epithelium (Figure 1.12). The trans-signalling pathway has been associated with 
inflammatory disorders including Crohn’s disease and rheumatoid arthritis, and cancer 
(Jones et al., 2005; Scheller et al., 2011). Genetic overexpression of the soluble form of the 
gp130 protein (sgp130Fc), which binds IL-6/sIL-6R complex and therefore inhibits IL-6 trans-
signalling has been shown to prevent inflammation (Rabe et al., 2008), without blocking IL-6 
classical signalling through the membrane bound IL-6R (Jostock et al., 2001).  
Conflicting roles for IL-6 in the regulation of metabolic homeostasis have been described; IL-
6 is secreted by muscle cells in the post-exercise period when insulin action is enhanced 
(Pedersen and Febbraio, 2008), but IL-6 has been associated with obesity and reduced insulin 
action (Skurk et al., 2007). However, although one study demonstrated induction of obesity 
in IL-6 Knockout (KO) mice (Wallenius et al., 2002), this has not been reproduced by other 
studies (Di Gregorio et al., 2004). Detailed analysis of wild type and IL-6KO mice has since 
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shown that a lack of IL-6 leads to insulin resistance and glucose intolerance as well as liver 
inflammation (Matthews et al., 2010). Interestingly, mice with a hepatocyte IL-6R deletion 
alone exhibited increased glucose tolerance and sensitivity to insulin with no marked effects 
on liver inflammation (Wunderlich et al., 2010). Activation of IL-6 trans-signalling in mice 
overexpressing IL-6/sIL6R lead to a significant reduction in body mass and body fat, 
accompanied by an induction of proliferation and differentiation of inflammatory cells in the 
liver (Peters et al., 1997). These studies suggest that IL-6 classical-signalling plays a role in 
the control of glucose tolerance, and IL-6 trans-signalling is involved in hepatic inflammatory 
responses. 
 
Figure 1.12. Classical and trans IL-6 signalling. 
Cells that express gp130 and the IL-6R can respond to IL-6 (classic signalling). Cells which 
express gp130 can still respond to IL-6 by trans-signalling; sIL-6R binds to IL-6 and activates 
signalling in any cell expressing gp130. Figure adapted from (Scheller et al., 2011, Garbers et 
al., 2015). 
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1.3.3 IL-6 in Inflammation and Cancer  
IL-6 signalling plays a major role in the regulation of inflammation. Classical IL-6 signalling, 
through activation of the IL-6R on naïve T cells has been shown to enhance the differentiation 
of naïve T cells into TH17 cells, whilst also inhibiting the formation of Treg cells, which protect 
tissues from autoimmune injury (Bettelli et al., 2006). Interestingly, the IL-6R is 
proteolytically cleaved from the membrane of TH17 cells upon activation, suggesting that IL-6 
trans-signalling promotes the maintenance of TH17 cells, which induces downstream tissue 
injury (Figure 1.13) (Jones et al., 2010). Cleavage of the IL-6R from other IL-6R expressing 
immune cells such as neutrophils and eosinophils may also promote IL-6 trans signalling. 
Neutrophil infiltration is a key process in inflammation, and the resolution of inflammation 
is dependent on neutrophil apoptosis. Induction of apoptotic pathways in neutrophils was 
previously shown to induce IL-6R cleavage from the membrane of neutrophils, which drives 
IL-6 trans signalling in neighbouring cells, and promotes the recruitment of phagocytic 
mononuclear cells which are involved in the removal of apoptotic neutrophils. In this study, 
early apoptosis of pre B cells (transfected with gp130 and the IL-6R) also induced cleavage of 
the IL-6R from the membrane (Chalaris et al., 2007). This suggests that apoptosis is a natural 
inducer of IL-6R cleavage from other immune cells which subsequently may promote IL-6 
trans signalling in inflammation.  
Following bowel injury induced by biopsy or bacterial triggered colitis, inhibition of IL-6 
decreased epithelial proliferation and resulted in impaired wound healing in mice (Kuhn et 
al., 2014). Use of an IL-6-/- mouse demonstrated that whilst there was no change in the basal 
rate of proliferation in the intestine of IL-6KO mice, a significant decrease in proliferation was 
observed following DSS exposure compared to wild type, suggesting that IL-6 is required for 
proliferation following induction of inflammation. IL-6 was also shown to promote tumour 
growth by enhancing proliferation of tumour initiating cells (Grivennikov et al., 2009; Jin et 
al., 2010). 
The roles of IL-6 in tumorigenesis is widely accepted in a number of cancers including lung, 
melanoma, breast and colorectal (reviewed in Wang and Sun (2014)). IL-6 expression by 
tumour cells and in serum is indicative of increased tumour stage, size, metastasis and 
reduced overall survival of patients with colorectal cancer (Knupfer and Preiss, 2010; Hara et 
al., 2017). These effects were observed in patients with inflammatory conditions such as IBD, 
who are significantly predisposed to develop colorectal cancer, and also in sporadic 
colorectal cancer mediated through IL-6 trans-signalling (Yamamoto and Rose-John, 2012).    
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Figure 1.13. The roles of IL-6 in T cell differentiation. 
IL-6 inhibits TH1 and Treg cell differentiation (red arrows). Classical IL-6 signalling promotes IL-
4-induced TH2 cell differentiation to enhance clearance of extracellular organisms. TH17 cell 
differentiation is promoted by IL-6 classical signalling, membrane bound IL-6R is cleaved from 
TH17 cells and trans-IL-6 signalling promotes maintenance of TH17 cells and downstream 
tissue damage. 
 
1.3.4 STAT3 Signalling in Health and Disease 
The STAT pathway was originally described in the context of downstream IL-6 signalling. 
Activation of the gp130 by the IL-6/IL-6R signalling complex induces activation of a number 
of downstream signalling cascades including the JAK/STAT pathway. However, it has since 
emerged that STAT signalling can be activated by a number of cytokines as well as G Protein-
coupled receptors (GPCRs), TLRs and miRNAs; tight regulation of which is crucial for many 
cancers. STAT3 signalling, and downstream gene expression is known to modulate tumour 
cell proliferation, survival, invasion and inflammation (reviewed in Yu et al. (2014)). STAT3 is 
able to directly activate transcription factors such as c-Myc, CyclinD1, CyclinB1 and Cell 
division cycle protein 2 homolog (Cdc2), which promote cell proliferation (Bromberg et al., 
1999; Bowman et al., 2001; Masuda et al., 2002). Alongside activation of proliferative genes, 
STAT3 also regulates transcription of anti-apoptotic genes Bcl-XL, Bcl-2, Bcl-w and Mcl-1 and 
activates the cell survival marker Survivin (Zushi et al., 1998; Bromberg et al., 1999; 
Stephanou et al., 2000). In addition, the induction of vascular endothelial growth factor 
(VEGF) expression by STAT3 induces angiogenesis, and invasion of tumour cells is mediated 
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by expression of tissue-degrading metalloproteinases MMP-2 and MMP-9 (Jarnicki et al., 
2010).  
A number of cytokines are able to activate the STAT3 pathway, including IL-6, IL-10/IL-22 and 
IL-17/IL-23 families (Ernst et al., 2014). As described in the previous sections, IL-6 activates 
downstream STAT3 to induce a number of functions in health and disease. Another member 
of the IL-6 family, IL-11 has been shown to be more potent than IL-6 in the context of 
promoting gastric and colon cancer progression. Pharmacological inhibition of IL-11 reduced 
STAT3 activation and suppressed tumour growth (Putoczki et al., 2013). STAT3 activation is 
observed following DSS-induced experimental colitis in mice, and this was shown to be 
dependent on IL-22, rather than IL-6 (Pickert et al., 2009). In addition, IL-22 induced pSTAT3 
activation in intestinal stem cells, which was required for organoid formation and epithelial 
regeneration (Lindemans et al., 2015).   
STAT3 activation induced by IL-6 also has defined roles as a regulator of TH17 cell 
differentiation and function, which was dependent on IL-17. IL-17 is the major cytokine 
produced by TH17 cells, and they are most abundant in the small intestinal lamina propria 
(Ivanov et al., 2006), where they respond to pathogen invasion (Ivanov et al., 2009). Complex 
interplay between IL-17 and IL-6 contributes to the development of arthritis and 
autoimmune disease. IL-6-induced STAT3 activation drives T cell development to TH17 
lymphocytes. TH17 cells secrete IL-17, which stimulates stromal cells to produce IL-6 and 
induce further inflammation (reviewed in Camporeale and Poli (2012)). Furthermore, STAT3 
is also known to regulate other T cell subtypes, including Natural Killer T (NKT) cells and 
mucosal-associated invariant T cells, which are important for pathogen clearance through 
activation of the IL-23R and IL-21R (Wilson et al., 2015).  
In the intestinal epithelium, STAT3 is required to maintain mucosal barrier integrity. The 
secretion of antimicrobial proteins RegIII-β, RegIII-γ and β-defensins by Paneth cells is 
stimulated by STAT3 (Wolk et al., 2004). Mucus is a major component of the epithelial barrier 
and prevents luminal microbes from coming into direct contact with the epithelium, 
therefore preventing inappropriate immune responses (Hansson and Johansson, 2010). 
STAT3 has been shown to directly induce expression of the mucin genes including Muc-1, 
which is expressed by intestinal epithelial cells (Li et al., 2009). The roles of epithelial STAT3 
during steady state epithelial renewal remain to be elucidated.  
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Another inducer of JAK/STAT signalling during cancer is PGE2, which indirectly activates the 
JAK/STAT pathway through cross-activation of the EGF signalling pathway (Oshima et al., 
2011). Berberine, an alkaloid used in traditional Chinese medicine, has been shown to have 
anti-tumour efficacy in the treatment of a number of cancers including colorectal cancer. The 
mechanism of action for Berberine was shown to be through inhibition of COX-2/PGE2 
signalling, and downstream JAK2/STAT3 activation (Liu et al., 2015).  
The convergence of a number of cytokines on the STAT3 signalling pathway (IL-11, IL-22, IL-
17) highlights the need for investigation into the effects of IL-6-mediated STAT3 activation in 
intestinal tissue renewal. A number of unanswered questions remain in relation to the roles 
of IL-6/STAT3 signalling in intestinal homeostasis: the epithelial and non-epithelial sources 
of IL-6, characterisation of IL-6 receptor expression on epithelial cell types, cellular 
localisation of pSTAT3 activation in response to IL-6 signalling, and the downstream effects 
in intestinal renewal and stem cell expansion. This thesis aims to address these questions.  
1.4 Prostaglandin-E2  
The focus of this thesis is the regulation of epithelial renewal by autocrine and paracrine 
signalling. Another cytokine that is known to induce epithelial renewal during inflammation 
and cancer is Prostaglandin-E2, however PGE2 also has emerging roles in induction of 
proliferation during health (Wang and Dubois, 2010). Recent studies have shown that 
epithelial production of PGE2 through COX-2 activation is required for epithelial regeneration 
in response to injury, which is vital for the maintenance of intestinal homeostasis (Chen et 
al., 2015). High levels of PGE2 have been associated with exacerbation of the inflammatory 
response, promotion of tumour growth via stimulation of angiogenesis, cell invasion, cell 
growth and inhibition of apoptosis (Wang and Dubois 2006). 
COX-1 and COX-2 enzymes are responsible for the synthesis of endogenous PGE2, which are 
upregulated in colorectal cancer and associated with unfavourable survival (Wang and 
Dubois 2010). Constitutive activation of COX-1 is observed throughout the epithelium in tuft 
cells (Gerbe et al., 2011), but COX-2 has been shown to be activated when the tissue is under 
stress conditions such as in DNA damage (Wang and Dubois 2010). Inhibition of COX enzymes 
utilising NSAIDs has previously been targeted for the prevention of colorectal cancer 
initiation and development. Regular use of NSAIDs for 10-15 years has been shown to reduce 
the risk of developing colorectal cancer by 40-50% (Flossmann et al., 2007; Rostom et al., 
2007; Chan et al., 2008), particularly when tumours express high levels of COX-2 (Chan et al., 
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2007). In addition, the use of NSAIDs in patients with colorectal at stage I, II and III improves 
overall survival (Chan et al., 2009). These findings prompted initial clinical trials for the 
prevention of adenoma formation in patients with FAP where treatment with NSAIDs lead 
to regression of pre-existing adenomas (Rostom et al., 2007), and the prevention of 
recurrence of adenoma formation (Bresalier et al., 2005; Solomon et al., 2005; Arber et al., 
2006). However, this was associated with a significant increase in the risk of cardiovascular 
thromboembolic events. It is possible that side effects following NSAID use could be due to 
inhibition of PGE2 signalling required for normal tissue renewal and stem cell maintenance, 
therefore targeting of specific downstream PGE2 signalling components could potentially 
lead to the development of anti-cancer therapies with reduced side effects.  
The identification of a novel cell type within the epithelium which expresses COX enzymes 
(Gerbe et al., 2011), and previous studies demonstrating the presence of PGE2 receptors E-
Prostanoid (EP) receptors 1-4 mRNA in the intestinal epithelium (Shoji et al., 2004; Sugimoto 
and Narumiya, 2007), suggests that the epithelium may be able to produce and respond to 
PGE2 signalling in an autocrine manner.  The importance of autocrine PGE2 signalling in stem 
cell maintenance has previously been described in other systems. Self-renewal of 
mesenchymal stem cells (MSCs) derived from cord blood or adipose tissue was shown to be 
dependent on autocrine PGE2 signalling through activation of the EP2 receptor on the cell 
membrane of MSCs (Lee et al., 2016). In non-small cell lung cancer, autocrine (and paracrine) 
PGE2 signalling through the EP4 receptor was shown to mediate MMP-2/CD44-dependent 
invasion (Dohadwala et al., 2002). This suggests that the PGE2 signalling-axis forms an 
autocrine loop and activates differential EP receptor subtypes in order to induce different 
functions in homeostasis and disease. Whilst the roles of differential EP receptor 
activation/inhibition in tumorigenesis is becoming better defined, (described in detail below) 
the role of EP receptor activation/inhibition in normal tissue renewal remains largely 
unknown.  
1.4.1 Prostaglandin-E2 Synthesis  
PGE2 is synthesised via the arachidonic acid pathway (Figure 1.14). Arachidonic acid is 
released from cellular membranes through Phospholipase A2. The enzymes COX-1 and COX-
2 oxidize arachidonic acid to prostaglandin-G2, which is rapidly converted to prostaglandin-
H2 (PGH2). PGH2 is then converted to PGE2 through the action of Prostaglandin E Synthase 
(PGES) (Smith et al., 2000). PGE2 can then be degraded by 15-hydroxyprostaglandin 
dehydrogenase (15-PGDH) which oxidises the 15-hydroxyl group on prostanoids to a ketone, 
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and therefore abrogating binding of ligands to the prostaglandin receptors (Tai et al., 2002; 
Myung et al., 2006). The healthy colonic mucosa expresses high levels of 15-PGDH, however 
15-PGDH is lost in colorectal cancers and FAP. Recent studies suggest that inhibition of 15-
PGDH accelerates hematopoietic recovery in mice following bone marrow transplant, and 
promotes tissue regeneration in mouse models of colitis and liver injury (Zhang et al., 2015). 
 
 
Figure 1.14. Synthesis of PGE2. 
Following release from cell membrane through phospholipase A2, arachidonic acid is 
converted to PGG2 and rapidly PGH2 through the action of Cyclooxygenase enzymes Cox-1 
and Cox-2. PGH2 is then converted to PGE2, which is degraded by 15-PGDH. PGE2 signals 
through four GPCRs, EP1, EP2, EP3 and EP4. 
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PGE2 mediates actions by binding to one of four G protein-coupled receptors EP1-4. The 
distinct signalling transduction pathways of the EP receptor subtypes allows for the diverse 
functionality of PGE2 activation (Figure 1.15). The EP1 receptor is coupled to Gαq proteins, 
which mediate signalling through activation of PLC. This leads to the accumulation of 
intermediates including IP3 and DAG, which induce an increase in intracellular Ca2+, 
activating PKC. This induces the expression of NFAT, NFκB and Mitogen-Activated Protein 
Kinase (MAPK) (Sugimoto and Narumiya, 2007). Intracellular calcium signals are known to 
regulate a number of cellular processes, including proliferation and apoptosis in all 
mammalian cell types (Roderick and Cook, 2008). EP2 and EP4 receptors are coupled to 
adenylate cyclase stimulation via Gs. This increases intracellular cyclic AMP and activates 
Protein Kinase A (PKA). EP2 and EP4 can also activate Phosphoinositide 3-kinase (PI3K) 
through the β-arrestin pathway, and EP2 activates the GSK3/β-catenin pathway, which 
increases expression of many cancer- associated genes (Fujino et al., 2002). The EP3 receptor 
is coupled to Gi and Gαs; activation of Gi leads to adenylate cyclase inhibition, whereas binding 
of Gs activates adenylate cyclase signalling and cyclic AMP production (Namba et al., 1993).  
The generation of mouse models deficient in each EP receptor subtype, and the development 
of EP receptor selective agonists and antagonists has allowed for the physiological role of 
each EP receptor subtype to begin to be investigated.  
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Figure 1.15. The distinct signalling transduction pathways of EP receptor subtypes. 
(A) EP1 receptor is coupled to Gαq proteins, and activate PLC. This leads to accumulation of 
IP3 and DAG to increase intracellular calcium, activating PKC and inducing expression of 
NFAT, NFκB and MAPK. (B) EP2 is coupled to Gαs protein, and induces adenylate cyclase 
activation to increase intracellular cAMP, which in turn activates PKA and CREB. EP2 can also 
activate PI3K, and the GS3K/β-catenin pathway. (C) EP4 is coupled to Gαs and adenylate 
cyclase activation, and also activates the PI3K pathway to induce AKT and NFκB expression. 
(D) The EP3 receptor can bind either Gi or Gαs proteins. Gi inhibits adenylate cyclase and 
activates Raf/MAPK and calcium signalling. Binding of Gαs activates adenylate cyclase, to 
induce cAMP and PKA expression. Adapted from (O'Callaghan and Houston 2015).
 
1.4.1.1 EP1 Receptor 
EP1 receptor (mRNA) expression has previously been shown to be restricted to the lung, 
stomach and kidney (Watabe et al., 1993), where activation of EP1 receptor has a role in 
mediating stress responses (Matsuoka et al., 2003; Matsuoka et al., 2005) and promoting 
chemical carcinogenesis (Mutoh et al., 2002). However, more recent studies observed EP1 
receptor expression at the mRNA level in the colonic mucosa (Shoji et al., 2004; Olsen Hult 
et al., 2011). Selective pharmacological inhibition of the EP1 receptor in APC1309 mice (mice 
deficient in APC) reduced polyp formation (Kitamura et al., 2003). Furthermore, a systemic 
genetic deletion of the EP1 receptor in mice inhibits colon tumour growth induced by 
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treatment with azoxymethane and induces apoptosis of tumour cells (Kawamori et al., 2005). 
EP1 receptor signalling is also thought to promote carcinogenesis through activation of 
signalling pathways which mediate migration and invasion, which is key for tumour 
metastasis (Yang et al., 2010; Kim et al., 2011; Zhang et al., 2014). EP1-mediated PGE2 
signalling induces focal adhesion kinase (FAK) expression in cancer cells, which activates 
pathways key for regulation of cell migration and proliferation, namely PKC/c-Src and EGFR 
(Bai et al., 2013). Signalling through the EP1 receptor is also thought to play a role in the 
suppression of the immune system, which is associated with tumour progression. PGE2 is 
secreted by tumour cells in response to Fas binding to Fas ligand, constitutive expression of 
which is key for optimal tumour growth. This is associated with the infiltration of tumours by 
potent immunosuppressive immune cells, Myeloid-Derived Suppressor Cells (MDSCs) which 
help tumours to overcome the immune response of the host (Zhang et al., 2009). 
Furthermore, EP1-receptor mediated PGE2 signalling has also been associated with 
decreased barrier function of Caco-2 cells, which is a key characteristic of IBD (Rodriguez-
Lagunas et al., 2010). 
1.4.1.2 EP2 Receptor 
The EP2 receptor subtype is the least abundant EP receptor mRNA detected in mouse tissue 
(Katsuyama et al., 1995), but expression is highly inducible following stimulation with 
lipopolysaccharide (LPS) (Ikegami et al., 2001). EP2 is most highly expressed in the uterus of 
mice, where it plays a role in ovulation and fertilisation (Hizaki et al., 1999). However, EP2 
has also been shown to be expressed by the colonic epithelium (Shoji et al., 2004; Olsen Hult 
et al., 2011), and mediate PGE2 signalling in APC (Delta716) mice, where an upregulation of 
COX-2 enzyme induces intestinal polyposis (Sonoshita et al., 2001). The EP2 receptor is also 
highly expressed by tumour cells in colon cancer (Gustafsson et al., 2007). The role of EP2-
mediated PGE2 signalling in cancer is thought to be associated with tumour angiogenesis; 
EP2 receptor activation induces expression of the pro-angiogenic factor VEGF (Sales et al., 
2004; Chang et al., 2005), as well as regulating endothelial cell motility and survival 
(Kamiyama et al., 2006). The increase in cyclic AMP associated with EP2 (and EP4) receptor 
activation has also been shown to play a major role in inhibition of the anti-tumour immune 
response (Kalinski, 2012), by inhibition of T helper cells (Harris et al., 2002) and promoting 
development of T regulatory cells which suppress the immune response (Sharma et al., 
2005). 
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1.4.1.3 EP3 Receptor 
Expression of the EP3 receptor is widely distributed, and was detectable in almost all tissues 
examined including kidney, uterus, stomach and ileum (Sugimoto et al., 1992). Three splice 
variants have been identified for the EP3 receptor subtype, which exhibit identical binding 
properties but differ in their functions. EP3α and β are exclusively coupled to adenylate 
cyclase inhibition through Gi, whereas the EP3γ variant is coupled to both Gi and Gs, leading 
to adenylate cyclase inhibition at low PGE2 concentrations, and stimulation at high PGE2 
concentrations (Namba et al., 1993). EP3-mediated PGE2 signalling has been described in the 
mediation of fever (Ushikubi et al., 1998), pain responses (Minami et al., 2003; Takasaki et 
al., 2005) and more recently, in inflammatory vascular permeability by activation on mast 
cells (Morimoto et al., 2014). The roles of EP3 receptor activation in tumorigenesis remain 
unclear. Deletion of the EP3 receptor in APC (Delta716) mice had no effects on polyp 
formation (Sonoshita et al., 2001). However, in a study using azoxymethane-treated mice 
and rats, EP3 receptor activation was shown to play a role in suppression of growth and 
deletion of EP3 enhanced colon carcinogenesis suggesting an anti-tumorigenic role for the 
EP3 receptor in this model. Furthermore, expression of the EP3 receptor was shown to be 
downregulated in tumour cells compared to epithelial cells from the normal mucosa (Shoji 
et al., 2004). In addition, Macias-Perez et al. (2008) demonstrated a decrease in 
tumorigenesis in vivo following EP3 receptor activation, and a reduction in tumour cell 
proliferation (Macias-Perez et al., 2008). In contrast, other studies have eluded to a role for 
EP3 in angiogenesis associated with tumour growth by enhancing expression of VEGF 
(Amano et al., 2003) and MMP9 (Amano et al., 2009; Ogawa et al., 2009).  
1.4.1.4 EP4 Receptor 
The EP4 receptor is expressed abundantly in a diverse range of tissues, with high expression 
levels observed in the ileum, thymus and uterus (Ikegami et al., 2001). The EP4 receptor has 
also been well characterised for its role in tumorigenesis. Ablation of EP4 receptor on 
myeloid cells of APCMin/+ mice showed marked inhibition of adenoma size and number 
(Chang et al., 2015). Activation of the EP4 receptor has been associated with transactivation 
of the EGFR signalling pathway (Buchanan et al., 2006; Oshima et al., 2011), which leads to 
downstream activation of a number of pathways including MAPK, PI3K/AKT, STAT and PLC 
which have been defined for their roles in proliferation, differentiation, migration and cell 
survival (Normanno et al., 2006). In HT-29 colorectal cancer cells, enhanced EP4-mediated 
PGE2 signalling was associated with resistance to apoptosis and increase in anchorage-
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independent growth (Hawcroft et al., 2007); of note, in this system the EP4-mediated 
signalling did not trans-activate EGFR signalling. 
Signalling through the EP4 receptor subtype has also been associated with a number of pro-
tumorigenic immune responses, inducing the development of T regulatory cells (Sharma et 
al., 2005), and immune-suppressing MDSCs (Sinha et al., 2007; Obermajer and Kalinski, 
2012). However, EP4 receptor signalling has also been associated with wound healing 
following mucosal injury. Using a biopsy injury system to generate wounds in the mouse 
colon, it has been shown that mice deficient in the EP4 receptor exhibit multiple deficiencies 
in tissue repair including incomplete wound covering with wound associated epithelial cells 
(WAE) (Manieri et al., 2012; Manieri et al., 2015). In this system, the authors identified an 
induction of EP4 receptor expression in mesenchymal cells in the underlying lamina propria 
(Manieri et al., 2012). More recently, Miyoshi et al (2017) showed that EP4 receptor 
signalling induced the differentiation of WAE through direct inhibition of GSK3β and 
therefore nuclear β-catenin activation, independent of canonical WNT signalling (Miyoshi et 
al., 2017).  
In agreement with a role for EP4 in epithelial repair following injury, EP4 receptor signalling 
has also been shown to ameliorate severe colitis and mucosal damage in mice treated with 
DSS by downregulating the immune response (Kabashima et al., 2002). However, using a 
different model of inducible colitis in mice, where naïve T cells are transferred into mice 
deficient in recombinase-activation gene 2, transfer of EP4+/- or EP4-/- T cells was shown to 
induce a weaker inflammatory response compared to transfer of T cells from wild type 
controls (Yao et al., 2013). 
1.4.2 Paracrine Signalling 
Previous studies have suggested that paracrine PGE2 signalling is important for promoting 
intestinal tissue repair and regeneration following tissue injury, which is vital for the 
maintenance of epithelial homeostasis. The use of COX-2 conditional knockout mice to 
analyse the role of COX-2 expression in distinct cell types revealed that deletion of COX-2 in 
myeloid cells including macrophages and granulocytes (eosinophils and neutrophils) 
exacerbated DSS-induced murine colitis. Deletion of COX-2 in epithelial cells had no effects 
on DSS-induced colitis compared to littermate controls. (Ishikawa et al., 2011). Furthermore, 
paracrine PGE2 signalling by myofibroblasts in the intestinal lamina propria play a major role 
in the response to innate/inflammatory signals initiated following epithelial injury (Roulis et 
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al., 2014). Myofibroblasts sense inflammatory signals which induces the expression of Tumor 
progression locus-2 (Tpl2), which has previously been described to be activated in response 
to signalling pathways with contrasting roles in homeostasis and inflammation (Fukata et al., 
2005; Roulis et al., 2011). The expression of Tpl2 by myofibroblasts induces COX-2 synthesis 
of PGE2, which was shown to mediate the epithelial homeostatic proliferation response to 
injury (Roulis et al., 2014).  
Eosinophils are myeloid cells present in the lamina propria of the colonic and small intestinal 
mucosa, which are emerging as an immune cell type with differential functions in health and 
disease (Melo et al., 2013; Rosenberg et al., 2013). Phenotypic differences have been 
described between circulating eosinophils in the blood, and activated eosinophils which are 
recruited into tissues where they gain/induce expression of additional receptors (Carlens et 
al., 2009; Wallon et al., 2011), and have an increased survival (Wu et al., 2011). Eosinophils 
are known to express a number of the components required for PGE2 signalling. Eosinophils 
secrete PGE2 in lipid bodies present in the cytoplasm, and EP2 and EP4 receptor expression 
is observed on the cell surface of eosinophils (Rosenberg et al., 2013), suggesting that 
eosinophils may be a good candidate for the source of paracrine PGE2 signalling in the colonic 
epithelium, whilst also secreting and responding to PGE2 in an autocrine manner.  The 
differential activation of EP receptors have been shown to have various functions in health 
and disease (Sugimoto and Narumiya, 2007). Activation of the EP2 receptor has been shown 
to induce epithelial cell proliferation and tumour invasion through VEGF (Kamiyama et al., 
2006; Lee et al., 2016), and EP4 receptor activation has a number of roles in tumorigenesis 
but also in amelioration of inflammation in mouse models of colitis (Kabashima et al., 2002; 
Chang et al., 2015). This suggests that autocrine PGE2 signalling in eosinophils may have 
varying roles in inflammation and cancer. The relationship between paracrine PGE2 secretion 
by eosinophils and epithelial renewal and regeneration has not yet been described.  
Eosinophils also express IL-6, and the IL-6R (Melo et al., 2013), suggesting that they are able 
to induce autocrine IL-6 signalling. Evidence has also previously been presented for a role of 
paracrine IL-6 signalling by eosinophils on the maintenance of plasma cells in the bone 
marrow (Chu et al., 2011), and in the generation and maintenance of IgA expressing B cells 
in the small intestinal lamina propria (Chu et al., 2014). The next section explores the 
emerging roles of eosinophils in the maintenance of homeostasis and immune cell 
regulation.  
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1.5 The Eosinophil 
Eosinophils are potent effector cells, which are recruited to sites of inflammation, however 
they also constitute an abundant population under homeostatic conditions in tissues such as 
the GI tract. Eosinophils are most commonly associated with helminth infection, allergic 
asthma and IBD; however, the large numbers of eosinophils present along the GI tract from 
birth and in quiescent IBD have prompted initial experiments into the roles of eosinophils in 
homeostasis (reviewed in Rosenberg et al. (2013)). As such, eosinophils are emerging as 
regulators of tissue remodelling, inflammation and the maintenance of epithelial barrier 
function.  
1.5.1 Structure and Function 
Eosinophils are specialised granulocytes which were first described by Paul Ehrlich in 1979 
for their affinity to acidophilic dyes. They are present from birth and develop from 
pluripotent progenitors in the bone marrow. Eosinophils enter the peripheral circulation in 
a mature state, where they can circulate for up to 18h (Steinbach et al., 1979) before they 
are activated and recruited into tissues in response to stimuli such as eotaxin (the major 
chemokine for eosinophils) or Interleukin-5 where they have a prolonged survival (Hogan et 
al., 2008; Blanchard and Rothenberg, 2009). During homeostasis, eosinophils reside in the 
thymus and along the GI tract (Lamouse-Smith and Furuta, 2006).  
The eosinophil is formed of a bilobed nucleus surrounded by a characteristic cytoplasmic 
accumulation of specific granules (Figure 1.16). Each granule is comprised of a dense 
crystalline core surrounded by a less-dense matrix, enclosed by a trilaminar matrix. The 
major granule components are as follows: cationic proteins such as major basic protein 
(MBP) and eosinophil peroxidase (EPO); and eosinophil-associated RNases (EARs) such as 
eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) (reviewed in 
Rosenberg et al. (2013)). These proteins are toxic to microbial pathogens, as well as host 
tissues. Therefore, the uncontrolled degranulation of eosinophils could lead to epithelial 
damage. A novel mechanism has been described which minimises the risk of damage to 
surrounding tissues. Eosinophils are now known to expel a matrix of mitochondrial DNA, 
known as an eosinophil extracellular trap (EET), which captures the cytotoxic granule 
proteins and invading bacteria. This process has not yet been described in the GI tract but 
has been characterised in the asthmatic airway and in atopic dermatitis (Yousefi et al., 2008; 
Yousefi et al., 2012). Other non-cytotoxic components of the specific granules include a 
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number of cytokines, chemokines and growth factors. One of the growth factors secreted 
with eosinophilic granules is EGF, which is vital for intestinal crypt cell proliferation. Another 
prominent feature of eosinophils is the presence of lipid bodies, where prostaglandins and 
leukotrienes are synthesised (reviewed by Rosenberg et al. (2013)).   
 
 
Figure 1.16. Eosinophils express a number of receptors and factors for health and disease. 
Schematic diagram of an eosinophil showing a characteristic bi-lobed nucleus and expression 
of receptors with a number of different functions. Eosinophils degranulate when activated 
and release granule contents including MBP, ECP, EDN, GM-CSF, VEGF, EGF and APRIL. 
Eosinophils secrete PGE2 in their lipid bodies and express EP2 and EP4 receptors on their 
surface. Expression of chemoattractant, cytokine and growth factor receptors as well as 
pattern recognition receptors is observed on the cell surface of eosinophils. 
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On their cell surface membrane, eosinophils express a variety of receptors for ligands specific 
for degranulation, growth, chemotaxis, adhesion and cell-cell interactions (summarised in 
Figure 1.16). Of note, eosinophils express CC-chemokine receptor 3 (CCR3), which mediates 
eosinophil chemotaxis in response to binding of eotaxins, Interleukin-5 receptor subunit-α 
(IL-5Rα) and the sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8). Of particular 
importance is IL-5Rα, which responds to IL-5. IL-5 is important for all aspects of eosinophil 
development, activation and survival. IL-5 is produced by TH2 cells, mast cells, natural killer 
(NK) cells, NKT cells and by eosinophils themselves. Activation of IL-5Rα induces eosinophil 
development from progenitors, activation of eosinophils and prolonged eosinophil survival 
in the periphery and tissues (reviewed in Rosenberg et al. (2013)).  
Eosinophils also express a number of PRRs, as discussed earlier, including TLR7 and TLR5. This 
suggests that eosinophils are able to mount an immune response following the recognition 
of PAMPs.   
1.5.2 Roles of Eosinophil in Homeostasis 
Eosinophils are able to respond to signals from other leukocytes, namely secreted IL-5, as 
well as playing a major role in modulating the function of other leukocytes to regulate 
inflammation. The expression of components on the eosinophil cell surface specific to 
antigen presentation, such as Major Histocompatibility Complex class II molecules, allows 
eosinophils to process antigens and stimulate T cell proliferation and cytokine release in 
response to specific antigens (Wang et al., 2007). Eosinophils are able to promote 
recruitment of TH2 cells in response to production of chemoattractants such as C-C motif 
chemokine ligand 17 (CCL17) and CCL22 (Jacobsen et al., 2008). Eosinophils also interact with 
other innate immune cells. Dendritic cell maturation is induced by eosinophils activated by 
the pathogen-derived molecular pattern CpG DNA (Lotfi and Lotze, 2008), and the eosinophil 
granule protein EDN also promotes dendritic cell maturation (Yang et al., 2003; Yang et al., 
2008). The eosinophil granule protein MBP also acts on neutrophils, inducing an oxidative 
burst, IL-8 secretion and increasing expression of the integrin complement receptor 3 on the 
neutrophil cell surface (Haskell et al., 1995).   
Eosinophils have also been shown to prime B cells for the production of IgM, and support 
the survival of plasmablasts in the bone marrow via secretion of IL-6 and A Proliferation 
Inducing Ligand (APRIL) (Chu et al., 2011). Plasma cells are crucial for long-term immune 
protection through their secretion of antigen-specific antibodies. Mature long-lived 
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plasmablasts migrate to the bone marrow following B cell differentiation, where their 
survival is prolonged via secretion of cytokines and chemokines (Dilosa et al., 1991; Blink et 
al., 2005; Radbruch et al., 2006). Expression of the chemokine C-X-C motif chemokine 12 
(CXCL12) by stromal cells induces bone marrow migration of plasmablasts as well as 
supporting long-term survival (Hargreaves et al., 2001; Hauser et al., 2002; Nie et al., 2004). 
In vitro studies have identified a role for APRIL, IL-6, Tumor Necrosis Factor, IL-10, IL-4 and 
IL-5 in plasma cell survival (Cassese et al., 2003). Further to these experiments, APRIL was 
shown to be crucial for the long-term survival of plasmablasts in the bone marrow (Belnoue 
et al., 2008). Eosinophils were shown to be the major source of APRIL and depletion of 
eosinophils considerably reduced the numbers of plasma cells in the bone marrow (Chu et 
al., 2011). Recent studies have also revealed a role for eosinophils in the generation and 
maintenance of IgA expressing plasma cells in the intestinal lamina propria. Use of 
eosinophil-deficient mouse models showed that a loss of eosinophils induced a reduction in 
the number of IgA+ plasma cells and secreted IgA in the small intestinal lamina propria, and 
defects in the epithelial barrier (Chu et al., 2014). This data demonstrates a crucial role for 
eosinophils in the modulation of the intestinal immune system.  
Eosinophils also play an important role in mammary gland formation. Initially, a mouse 
model depleted of leukocytes and restored with a bone marrow transplant identified a role 
for recruitment of eosinophils and macrophages to the growing terminal end buds (TEB) of 
the mammary gland during postnatal development. Using mouse models homozygous for a 
null mutation in the gene for eotaxin, eosinophil recruitment around the TEB was depleted. 
This led to reduced mammary gland branch and TEB formation. Furthermore, macrophage 
depletion with a Colony-Stimulating Factor-1 null mutation also lead to reduced mammary 
gland formation (Gouon-Evans et al., 2000). This data highlights an important role for 
eosinophils and macrophages in development.   
In addition, alternatively activated macrophages play a major role in recruitment of 
eosinophils to tissues via release of a chitinase-like selective eosinophil chemoattractant, 
YM1. In parallel, eosinophil are able to recruit alternatively activated macrophages through 
release of IL-4 and IL-13 and prolong their viability in adipose tissues (Wu et al., 2011). It has 
also been suggested that eosinophils may aid macrophages in apoptotic cell clearance in the 
thymus (Kim et al., 2010). Mast cells and eosinophils reside in close proximity under 
homeostatic conditions in the GI tract, as well as in inflammation in the allergic lung and 
diseased gut in patients with Crohn’s disease. The eosinophil granule proteins, MBP, ECP and 
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EPO induce histamine release by mast cells and prolong mast cell survival (Munitz and Levi-
Schaffer, 2004).  
Although, as yet, the roles for eosinophils in epithelial homeostasis remain largely unknown, 
these data have demonstrated a crucial role for eosinophils in homeostasis, through 
regulation of the immune system and in development. The abundance of eosinophils 
amongst other immune cells in the intestinal lamina propria highlights the possibility of a 
role for eosinophils in the maintenance of intestinal homeostasis, either by regulation of 
other immune cells, or as a direct influence on the intestinal epithelium. 
1.5.3 Roles of Eosinophils in Disease 
Both beneficial and pathological roles of eosinophils have been described in the IBDs, Crohn’s 
disease and Ulcerative Colitis. IBD is characterised by an infiltration of leukocytes, including 
eosinophils, neutrophils, monocytes and lymphocytes, into the intestinal mucosa. Although 
eosinophils only represent a small proportion of the infiltrating leukocytes (Walsh and 
Gaginella, 1991), the level of eosinophils in the colonic mucosa has been shown to correlate 
with disease severity and a poorer prognosis (Desreumaux et al., 1999). High levels of 
eosinophil degranulation products, i.e. MBP, ECP, EDN and EPO, have been associated with 
adult IBD, and these levels correlated with disease severity (Raab et al., 1998; Carlson et al., 
1999). Levels of eotaxin-1, were also shown to be elevated in the serum of adult IBD patients 
(Chen et al., 2001; Mir et al., 2002).  Studies using DSS-induced mouse models of colitis 
demonstrated a crucial role for eotaxin-1 for the recruitment of eosinophils to the colonic 
mucosa, and deletion of eotaxin-1 led to a decrease in the number of eosinophils in the 
colonic mucosa, and attenuation of symptomatic colitis in mouse models (Ahrens et al., 
2008). A mechanism for this response was later described in 2011. Paediatric genome-wide 
studies implicated the 17q12 loci, encoding eotaxin-1, in early-onset IBD. In mouse models, 
recruitment of inflammatory monocytes to the colon was observed following DSS treatment. 
These monocytes were shown to express eotaxin-1, which lead to the recruitment of 
eosinophils to the colon. Furthermore, depletion of inflammatory macrophages using a 
CCR2/- mouse showed decreased eotaxin-1 expression and decreased eosinophilic 
inflammation in the colon (Waddell et al., 2011).   
Eosinophil accumulation in IBD is also associated with an altered epithelial barrier function. 
In a recent study, colonic samples from patients with Ulcerative Colitis showed increased 
permeability to antigens compared with control. This was shown to be associated with an 
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increase in corticotrophin-releasing factor (CRF), which alongside mast cells, regulates 
intestinal barrier permeability. In this study, colonic eosinophils were shown to express the 
muscarinic receptors M2 and M3 on their cell surface. This is in contrast to peripheral 
eosinophils, which did not express M2 or M3 receptors. Furthermore, from co-culture 
studies it was shown that eosinophil activation with carbachol induced CRF production, 
which lead to increased T84 cell permeability (Wallon et al., 2011).   
The eosinophil granule protein MBP was shown to have similar effects on epithelial barrier 
function. Using a co-culture of human eosinophils or AML14.3D10 eosinophil myelocytes 
with T84 epithelial cells it was shown that accumulation of eosinophils led to decreased 
transepithelial resistance and increased transepithelial flux. Cell-free co-culture supernatant 
experiments revealed that this was dependent on MBP (Furuta et al., 2005).   
Eosinophils are also commonly associated with allergic exacerbation in the asthmatic airway. 
During the inflammatory response, eosinophils are recruited to the lungs by TH2-secreted 
cytokines, such as IL-5, and chemokines including eotaxins. Eosinophilic accumulation and 
degranulation causes epithelial damage due to the release of toxic granule proteins such as 
MBP which leads to airway hypersensitivity (Walsh, 2001). The use of mouse models of 
allergic airway disease, whereby mice are sensitized usually with ovalbumin or Aspergillus, 
has allowed for the detailed study of the allergic asthmatic exacerbation response. In these 
mice, allergic antigen sensitization induces an accumulation of eosinophils in the airway, 
increased numbers of TH2 cells, excess mucus secretion and airway hypersensitivity.   
Findings have also suggested a role for eosinophil-epithelial cell interactions in the resolution 
of epithelial inflammation following an asthma exacerbation. Apoptosis of inflammatory cells 
is a key factor in the resolution of inflammation. Studies investigating induced sputum of 
patients following asthma exacerbations have shown that treatment with steroids induced 
eosinophil apoptosis which are recognised and phagocytosed by macrophages (Woolley et 
al., 1996). Eosinophils have also been shown to migrate into the airway lumen where they 
are subsequently cleared (Uller et al., 2001). Furthermore, it has been shown that epithelial 
cells have the ability to phagocytose apoptotic eosinophils (Walsh et al., 1999). The 
phagocytic capacity of epithelial cells was shown to be dependent on integrin, lectin and 
phosphatidylserine membrane receptors and enhanced by the corticosteroid 
dexamethasone (Sexton et al., 2001).   
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1.5.4 Eosinophil-Epithelial Cell Interactions 
Interactions between epithelial cells and eosinophils have been extensively reviewed (Sexton 
and Walsh, 2002).  Epithelial cells have the potential to secrete and respond to a variety of 
inflammatory mediators including cytokines, chemokines and lipid and peptide products 
(Peterson and Artis, 2014). The expression of the major chemokine for eosinophils, eotaxin, 
on airway epithelial cells has been described (Conroy and Williams, 2001). Eotaxin expression 
in the airway is regulated by inflammatory cytokines including IL-13, IL-4, Tumor Necrosis 
Factor-α and IL-1 (Lamkhioued et al., 1997; Lilly et al., 1997; Fujisawa et al., 2000; 
Jedrzkiewicz et al., 2000). Epithelial cells in the airway also express functional CCR3, which is 
the receptor for eotaxin (Stellato et al., 2001). Preliminary results from the Sobolewski 
laboratory have also shown expression of CCR3 by the colonic epithelium (El Hadi, personal 
communication). The expression of CCR3 may be a mechanism of regulating chemokine 
production, whereby secreted eotaxin can be sequestered by the epithelium and presented 
to infiltrating eosinophils to enhance their activation. Epithelial cells have also been shown 
to support eosinophil survival and activation through secretion of eosinophil activation 
factors including IL-5 and GM-CSF (Motojima et al., 1996; Salvi et al., 1999).   
Other cytokines have also been implicated in eosinophil-epithelial interactions in 
inflammation. Addition of IL-9 to HBE4-E6/E7 human epithelial cells in culture led to release 
of the T cell chemoattractants IL-16 and Regulated on Activation, Normal T cell Expressed 
and Secreted (RANTES) (Little et al., 2001), which induced increased expression of eosinophil 
IL-5R, leading to enhanced activation and prolonged survival (Gounni et al., 2000). The use 
of a polarized in vitro epithelial model of inverted BEAS-2B human bronchial epithelial cells 
demonstrated the importance of the polarity of epithelial cells for their ability to influence 
eosinophil behaviour. Purified eosinophils were added into co-culture, and eosinophil 
transmigration was only observed from the basal to the apical side of the monolayer; this 
was shown to be modulated by eotaxin, RANTES and the presence of functional CCR3 on the 
eosinophil surface membrane. Transmigration was only partially inhibited by removing 
eotaxin and RANTES and blocking CCR3, suggesting that epithelial secretion of cytokines and/ 
or chemokines are also involved in eosinophil transmigration. When BEAS-2B epithelial cells 
were co-cultured with activated human eosinophils, an increased biosynthesis of cysteinal 
leukotrienes was observed (Jawien et al., 2002). Cysteinal leukotrienes play a major role in 
the pathogenesis of asthma, including bronchoconstriction, mucus hypersecretion, airway 
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remodelling, accumulation of eosinophils and epithelial and endothelial damage.  These data 
suggest epithelial cells are able to actively promote eosinophil attraction and activation.    
The components of eosinophil granules are cytotoxic to microbial cells. The eosinophil 
granule protein MBP has also been shown to induce tissue damage of intestinal epithelial 
cells (Gleich et al., 1979) and bronchial epithelial cells (Kato et al., 2012) in vitro. The exertion 
of EETs by eosinophils in vivo in response to microbial pathogens is thought to minimise the 
cytotoxic effects of eosinophil granule proteins on surrounding tissues (Yousefi et al., 2012). 
However, degranulation of eosinophils in the colon is thought to be associated with epithelial 
damage in patients with colitis, although the mechanism remains unknown (Levy et al., 
2001).   
The presence of a number of innate immune cell subtypes, including macrophages, 
monocytes and neutrophils, in the colonic lamina propria suggest that a complex interplay 
between different innate immune cells contributes to regeneration and renewal of the 
colonic epithelium. Immune cells have been shown to relocalize in response to epithelial 
injury and induce epithelial regeneration (Pull et al., 2005; Brown et al., 2007; Seno et al., 
2009). WNT signalling is vital for intestinal crypt proliferation (Pinto et al., 2003) and 
macrophages have been shown to promote WNT/β-catenin activity through secretion of 
Tumor Necrosis Factor α (Oguma et al., 2008). Macrophages activated by microbial challenge 
have been shown to be necessary for the colonic crypt regenerative response to injury (Pull 
et al., 2005). Furthermore, Triggering Receptor Expressed On Myeloid Cells 2 (Trem2) 
signalling by macrophages induced expression of IL-4 and IL-13 in colonic mucosal injury, 
which was required for increased epithelial proliferation and wound repair (Seno et al., 
2009). Previous work by Skoczek et al. (2014) showed using an explant culture system, that 
addition of luminal microbes to the apical surface of explants induces migration of 
monocytes to the stem cell niche. Physical interactions between monocytes and intestinal 
stem cells were shown to induce crypt cell proliferation and increase stem cell number. 
Furthermore, in this system, following luminal microbial input, CCR3+ eosinophils were also 
shown to move closer to the stem cell niche, suggesting that eosinophils may play a similar 
role in modulation of crypt renewal during homeostasis (Skoczek et al., 2014).  
In the study by Skoczek et al. (2014), a novel protocol for the co-culture of monocytes and 
isolated colonic crypts was also developed. However, the use of an eosinophil-crypt co-
culture model in the human has not yet been described. Previous studies into the functional 
effects of eosinophils have relied on the promyelocytic cell line HL-60 Clone 15 cells (which 
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differentiate into a stable eosinophil phenotype following addition of Butyric acid), 
AML14.3d10 eosinophil myelocytes, or eosinophils isolated from blood (Fischkoff, 1988; 
Sedgwick et al., 1996; Jawien et al., 2002; Farahi et al., 2007; Bates et al., 2010; Akuthota et 
al., 2012). Investigations into the role of eosinophils in epithelial cell permeability have 
utilised the T84 epithelial cell line, where eosinophils were shown to reduce barrier function 
through secretion of MBP (Furuta et al., 2005). Whilst eosinophils isolated from the blood 
represent a good system for investigation of eosinophils, differences in function between 
peripheral and tissue resident eosinophils have been described (Hogan et al., 2008; 
Blanchard and Rothenberg, 2009). Therefore, the ideal model system for investigation of 
tissue resident eosinophil function would be eosinophils isolated from the intestinal mucosa. 
1.6 Rationale 
In the laboratory, we are interested in the regulation of epithelial renewal by autocrine 
epithelial-derived factors and by immune cell-derived paracrine factors. Under stressful 
conditions, i.e. tissue injury or cancer, regeneration of the colonic epithelium is modulated 
by cytokines including IL-6 and PGE2 (Wang and Dubois, 2006; Wang and Dubois, 2010; Kuhn 
et al., 2014). There is also a large body of evidence to show that activation of cytokine 
signalling pathways modulates epithelial renewal during homeostasis (reviewed in Vanuytsel 
et al. (2013)). However, no studies have fully investigated the roles of IL-6 and PGE2 in 
epithelial renewal during health through autocrine and/or paracrine signalling. Therefore the 
research questions of this thesis asks what are the autocrine sources of IL-6 in health in the 
intestinal epithelium, what are the cellular locations of the IL-6 receptor and what are the 
effects of IL-6R activation on small intestinal renewal during health. Whilst the epithelium is 
known to be a source of PGE2, this thesis asks whether an autocrine role for PGE2 exists in 
the colonic epithelium, and whether differential EP receptor activation induces crypt renewal 
during health (Figure 1.17). The regulation of intestinal renewal by IL-6 and PGE2 constitute 
the main focus and findings of this thesis.  
Another, less well defined, focus of the thesis is the potential paracrine sources of crypt 
regenerative factors in the intestinal mucosa. Previous work in the Sobolewski laboratory 
has shown that in vitro eosinophils regulate crypt renewal in a paracrine manner in the 
mouse colonic epithelium (unpublished, AS, DS); initial experiments suggests that a similar 
paradigm exists in the human colonic mucosa (unpublished, Sobolewski lab). Eosinophils are 
a paracrine source of PGE2 and IL-6, and the eosinophil is resident in abundance in the human 
gut mucosa during health, where eosinophils are known to modulate gut immune 
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homeostasis (Figure 1.17) (Rosenberg et al., 2013; Chu et al., 2014). This begs the question 
of the role of human eosinophils in the maintenance of crypt homeostasis. For these reasons, 
the development of an eosinophil-crypt co-culture model was also attempted and is 
described in the latter part of the thesis.  
 
Figure 1.17. Graphical representation of rationale. 
(A) IL-6 has been shown to be important for small intestinal crypt regeneration following 
injury. In colorectal cancers and tissue injury, autocrine and paracrine PGE2 signalling has 
been shown to induce proliferation and carcinogenesis. Initial experiments suggest that 
eosinophils induce mouse colonic crypt cell proliferation. (B) This thesis aims to determine 
the roles of autocrine and paracrine IL-6 and PGE2 in steady-state renewal of the small 
intestine and colon respectively, and to examine the spatial relationship between eosinophils 
and colonic crypts in the human.  
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1.7 Hypothesis 
Intestinal tissue renewal is modulated by autocrine and paracrine Interleukin-6 and 
Prostaglandin-E2 signalling during homeostasis. 
1.8 Aims 
1. Determine the role of IL-6 signalling in crypt renewal during homeostasis 
2. Examine the role of PGE2 in colonic crypt renewal, and determine the contribution 
of differential EP receptor activation in modulating crypt cell proliferation 
3. Evaluate the spatial characteristics of eosinophil distribution along the colonic crypt 
axis, and develop and characterise an eosinophil-crypt co-culture system to 
investigate the effects of eosinophils on colonic crypt homeostasis. 
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2 Chapter 2. Materials and Methods 
2.1 Reagents and buffers 
2.1.1 Chemicals and reagents 
Table 2.1. List of Chemicals and Reagents 
Chemical or Reagent Supplier 
Advanced DMEM Invitrogen 
Ammonium Chloride (NH4Cl2) Fisher Scientific 
Bovine Serum Albumin Sigma 
Calcium Chloride (CaCl2) VWR International 
Collagenase A Roche 
Click-IT reaction kit Fisher Scientific 
D-Glucose Fisher Scientific 
Dimethyl Sulfoxide (DMSO) Sigma 
DNaseI Sigma 
Donkey Serum Sigma 
EDTA Sigma 
Ethanol Sigma 
Fetal Bovine Serum (FBS) Sigma 
FITC-conjugated Ulex europaeusLectin (UEA-1 FITC)  Sigma 
Goat Serum Abcam 
Growth factor reduced matrigel VWR international 
HEPES Fisher Scientific 
Hoescht Life Technologies 
IMDM  Invitrogen 
Iso-pentane Fisher Scientific 
Low Melting Point Agarose (LMA) Sigma 
Magnesium Chloride (MgCl2) Fluka (Sigma) 
Mouse IL-6 Peprotech 
Murine recombinant epidermal growth factor Peprotech 
Murine recombinant noggin Peprotech 
Murine recombinant R-spondin1 R&D systems 
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O.C.T Compound Tissue-Tek 
Paraformaldehyde Sigma 
Percoll Sigma 
Phosphate buffered saline OXOID 
Potassium Chloride (KCl) Fisher Scientific 
Quik-Diff staining kit Reagena 
RPMI Invitrogen 
Sodium Bicarbonate (Na2HPO4) Fisher Scientific 
Sodium Chloride (NaCl) Fisher Scientific 
Sodium Dodecyl Sulfate (SDS) Melford 
Triton-X-100 Roche 
Vectashield Vector laboratories 
Xylene Sigma 
2.1.2 Buffers 
Table 2.2. List of buffers used
Buffer Formula 
Citrate Buffer (pH 6.0) Tri-sodium Citrate 2.94g in 1L of H2O (10mM) 
HEPES Buffered Saline (HBS) (pH 7.4) 
NaCl (140mM), KCl (5mM), Hepes (10mM), d-
glucose (5.5mM), Na2HPO4 (1mM), MgCl2 
(0.5mM), CaCl2 (1mM) 
2.1.3 Primary and Secondary Antibodies 
Table 2.3. List of primary and secondary antibodies used in the study 
Antibody  
Species 
Origin 
Clonality 
Working 
concentration 
Supplier 
anti-BrdU Rat Monoclonal 1:100 Abcam 
anti-CCR3 Rabbit Monoclonal 1:50 Abcam 
Anti-CD14 Rabbit Polyclonal 1:100 LSBio 
anti-Chromagranin-A Mouse Monoclonal 1:100 Abcam 
anti-Cleaved caspase 3 Rabbit Polyclonal 1:100 Cell signaling 
anti-COX-1 Goat Polyclonal 1:50 Santa Cruz 
anti-COX-2 Goat Polyclonal 1:50 Santa Cruz 
anti-COX-2 Mouse Monoclonal 1:50 Santa Cruz 
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anti-E-cadherin Goat Polyclonal 1:100 R&D Systems 
anti-E-cadherin Mouse Monoclonal 1:100 Abcam 
anti-EP1 Rabbit Polyclonal 1:50 Cayman 
anti-EP2 Rabbit Polyclonal 1:50 Cayman 
anti-EP3 Rabbit Polyclonal 1:50 Cayman 
anti-EP4 Rabbit Polyclonal 1:50 Cayman 
anti-IL-6 neutralising Rat Monoclonal 
58 µg/g in vivo, 
100µM in vitro 
BioXcell 
anti-IL-6R blocking Rat Monoclonal 
58 µg/g in vivo, 
100µM in vitro 
BioXcell 
anti-Ki67 Rabbit Polyclonal 1:100 Abcam 
anti-Lgr5(212) Mouse Monoclonal 1:100 Origene 
anti-Lgr5(2A2) Mouse Monoclonal 1:100 Origene 
anti-Lysozyme Rabbit Polyclonal 1:100 Abcam 
anti-Lysozyme Mouse Monoclonal 1:100 Abcam 
anti-MBP Mouse Monoclonal 1:50 Biorbyt 
anti-Mucin-2 Rabbit Polyclonal 1:100 Santa-cruz 
anti-Mucin-2 Mouse Polyclonal 1:100 Abcam 
anti-OLFM4 Rabbit Polyclonal 1:100 Abcam 
anti-PGE2 blocking Mouse Monoclonal 50µM Creative Biolabs 
anti-pSTAT3 Tyr705 Rabbit Polyclonal 1:50 Cell signaling 
anti-Siglec-8 Rabbit Polyclonal 1:50 Novus 
          
Antibody  
Species 
Origin 
 Working 
concentration 
Supplier 
anti-rabbit Alexa Fluor 488 Donkey   1:100/1:200 Invitrogen 
anti-rabbit Alexa Fluor 568 Donkey   1:100/1:200 Invitrogen 
anti-rabbit Alexa Fluor 647 Donkey   1:100/1:200 Invitrogen 
anti-mouse Alexa Fluor 488 Donkey   1:100/1:200 Invitrogen 
anti-mouse Alexa Fluor 568 Donkey   1:100/1:200 Invitrogen 
anti-mouse Alexa Fluor 647 Donkey   1:100/1:200 Invitrogen 
anti-goat Alexa Fluor 488 Donkey   1:100/1:200 Invitrogen 
anti-goat Alexa Fluor 568 Donkey   1:100/1:200 Invitrogen 
anti-goat Alexa Fluor 647 Donkey   1:100/1:200 Invitrogen 
anti-rat Alexa Fluor 488 Goat   1:200 Invitrogen 
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anti-Rabbit IgG (H+L) Alexa 
Fluor 647 AffiniPure Fab 
Fragment 
Donkey   1:100 
Jackson 
Immunoresearch 
2.2 Experimental Approach 
Before the identification of the intestinal stem cell marker Lgr5 by Clevers laboratory, 
previous studies on epithelial cells relied on cell culture of a monolayer of epithelial cells. The 
recent development and characterisation of small intestinal organoid and colonic crypt 
culture models provide a 3D model culture system, which contains all the cell types of the 
epithelium, and maintains the topological hierarchy of crypts observed in vivo (Sato et al., 
2009; Jung et al., 2011; Sato et al., 2011; Skoczek et al., 2014; Parris and Williams, 2015). This 
forms an ideal platform through which the roles of paracrine and autocrine signalling on 
epithelial renewal can be investigated.  
In this thesis, organoid culture experiments were undertaken alongside in vivo antibody 
studies using Lgr5EGFP mice to enable visualisation of stem cells within the epithelium. 
Immunofluorescent labelling was utilised in combination with RT-PCR to characterise 
expression of IL-6 and PGE2 signalling pathway components at the protein and molecular 
level. A pharmacological approach was undertaken to determine downstream signalling 
events induced by PGE2. Immunofluorescent labelling was also utilised to characterise the 
distribution of immune cells in the intestinal lamina propria. Furthermore, a reductionist co-
culture system of eosinophils and human colonic crypts was developed in order to 
investigate the roles of eosinophils in human colonic crypt renewal.  
2.3 Mouse experiments 
2.3.1 Mice and in vivo mouse experiments 
LGR5-EGFP-Ires-CreERT2 (Jackson Labs) or C57BL/6, aged 8-12 weeks were used. Generation 
and genotyping of the LGR5-EGFP-Ires-CreERT2 allele has been described previously (Barker 
et al., 2007). All animal experiments were conducted in accordance with the Home Office 
Animals Scientific procedures Act of 1986 with approval of the University of East Anglia 
Ethical review Committee, Norwich, United Kingdom and under Home Office project licence 
number 80/2545 (AG/AS). Blocking antibodies for IL-6 and IL-6 receptor or IgG controls 
(BioXcell) were administered to mice 3 times on alternate days by intraperitoneal injection 
at a concentration of 58 µg/g. Previous studies have utilised intraperitoneal injection of IL-6 
neutralising or IL-6 receptor blocking antibodies at concentrations between 20µg-1mg/g for 
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3-6 doses (Debock et al., 2012; Berger et al., 2013; Kugler et al., 2013; Barber et al., 2014; 
Khmaladze et al., 2014; Benevides et al., 2015; Tsukamoto et al., 2015). Consideration of the 
antibody efficacies previously described led us to arrive at a concentration of 58µg/g of IL-6 
neutralising or IL-6 receptor blocking antibody for use in this study. Animals were euthanized 
by Schedule One approved methods on day 6, and intestinal tissue processed immediately.  
In addition, small intestinal tissue from IL-6 knockout mice (Jackson Labs B6.129S2-
Il6tmlKopf/J, a kind gift from Marcello Chieppa) was used to count the number of lysozyme 
positive cells per small intestinal crypt. Tissue samples were either utilised for isolation of 
organoids/crypts, or immediately fixed in 4% paraformaldehyde for 2h at 4˚C. 
2.3.2 Mouse fixed tissue sections 
Following fixation in 4% paraformaldehyde, tissue samples were washed in PBS and left 
overnight before embedding in OCT, and freezing in Isopentane on liquid nitrogen. Sections 
(8-20μm thick) were cut on a Cryostat and stored at -20˚C until required. Sections were 
rehydrated in PBS before processing for immunofluorescent labelling (see section 2.3.5). 
2.3.3 Isolation and culture of mouse small intestinal organoids 
Small intestinal crypts were isolated from the proximal small intestine of LGR5EGFP mice as 
previously described (AS) (Barker et al., 2008). Briefly, the mouse small intestine was opened 
longitudinally, washed with phosphate buffered saline (PBS), cut into 2-4 mm pieces and 
incubated with 1mM EDTA in PBS (pH7.4) for 30mins at 4°C.  Crypts were liberated by serial 
rounds of pipetting in ice cold PBS and removal of the crypt enriched supernatant; the 
solution was then filtered through a 70µm cell strainer followed by centrifugation. Crypts 
(50-100 per coverslip) were embedded in a 200 µl droplet of growth factor reduced-Matrigel 
and seeded on No. 0 coverslips contained within a 12 well plate. After polymerisation at 37°C 
for 5-10 mins, crypts were flooded with 0.5 ml of mouse small intestinal culture medium 
(MSICM): advanced F12/DMEM containing B27, N2, n-acetylcysteine (1mM), HEPES (10mM), 
penicillin/ streptomycin (100 U/ml), Glutamax (2mM), epidermal growth factor (50 ng/ml), 
noggin (100 ng/ml) and R-spondin 1 (1 µg/ml). Small intestinal crypts grow in culture as 
budding organoids containing crypt-like and villus-like domains (Figure 2.1).  
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Figure 2.1. Small intestinal crypts grow as budding organoids with crypt and pseudo-villus 
domains. 
Representative white light DIC image of a small intestinal organoid in culture, showing a 
crypt-like domain (CD) and pseudo-villus domains (VD).
 
2.3.4 IL-6 and STAT3 culture conditions 
In IL-6 neutralising or IL-6 receptor blocking antibody experiments crypts were incubated for 
the entire 48 hour period in MSICM and appropriate antibody (100µg/ml) before addition of 
BrdU (1µM) for 17 hours. 
Following 48 hours culture with MSICM crypts were stimulated with IL-6 at concentrations 
of 10ng/ml to 1µg/ml for 15 mins to 17 hours for pSTAT3 experiments; for proliferation 
experiments crypts were placed into 10% MSICM for 5 hours, after which BrdU (1µM) was 
added for 17 hours. For STAT3 inhibition studies, crypts were pre-incubated with STATTIC 
(20µM, as previously utilised for STAT3 inhibition in intestinal organoids by Lindemans et al. 
(2015)) or IWP2 (5µM, as previously described by Chen et al. (2009)) for 1 hour prior to 
addition of IL-6 (100ng/ml) for 17 hours. 
For pSTAT3 activation studies, the IL-6 neutralising antibody was pre-incubated with IL-6 
(100ng/ml) for 1h before addition to organoid culture for 1h. For receptor antibody studies, 
organoids were pre-incubated for 1h with the IL-6 receptor blocking antibody before 
addition of IL-6 (100ng/ml) for 1h. The same protocol was used for proliferation experiments, 
prior to the addition of IL-6 and BrdU (1µM) for 17h. 
CD
VD
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For chronic stimulation, crypts were incubated for 2-5 days with MSICM containing 100ng/ml 
IL-6 or STATTIC (20μM) before addition of BrdU (1µM) for 17h; media was changed every 2 
days.  
2.3.5 Immunofluorescent labelling 
Following 2-5 days in culture, organoids were fixed in 4% paraformaldehyde for 1h at 4˚C. 
Following washing in PBS (or rehydrating for sections), samples were permeabilised with 
13min NH4CL2, 5min 1% SDS, 30min 1% Triton X-100 and non-specific binding blocked with 
10% donkey serum. Samples were incubated with primary antibody overnight before 
addition of appropriate fluorescently tagged secondary antibodies for 2h. A list of primary 
and secondary antibodies utilised in these studies are outlined in Table 2.3. For antibodies 
not previously characterised in the laboratory, negative controls were undertaken using IgG, 
secondary antibody incubation alone (i.e. no primary antibody added) and/or blocking 
peptide to primary antibody. No fluorescent labelling was observed in negative controls, 
confirming specify of antibodies utilised in the study. Example confocal images of negative 
staining are shown in Figure 2.2. After washing, samples were mounted with Vectashield 
containing Hoescht, Sytox blue or DAPI for visualisation of nuclei before imaging using 
epifluorescent (Nikon Ti) or confocal microscopy (Zeiss LSM META).  
2.3.6 Isolation and culture of mouse colonic crypts 
Using methodology previously described, mouse colonic crypts were isolated from the colon 
of LGR5EGFP mice (AS). Colonic tissue samples were collected in ice cold PBS, transported to 
the laboratory and incubated in Hepes-buffered saline (HBS), which was devoid of Ca2+ and 
Mg2+, and supplemented with EDTA (1mM) for 1h at room temperature. Crypts were 
liberated by vigorous shaking, crypt sedimentation and collection. Crypt were embedded in 
GF-reduced matrigel and 50-100 crypts seeded per coverslip on a 12WP. After 
polymerisation at 37°C for 5-10 mins, crypts were flooded with 0.5 ml of mouse colonic crypt 
culture medium (MCCCM): advanced F12/DMEM containing B27, N2, n-acetylcysteine 
(1mM), HEPES (10mM), penicillin/ streptomycin (100 U/ml), Glutamax (2mM), epidermal 
growth factor (50 ng/ml), noggin (100 ng/ml), R-spondin 1 (2 µg/ml) and Wnt3 (200ng/ml).
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Figure 2.2. Controls of immunofluorescent labelling specificity 
Representative confocal images of (A) lysozyme primary antibody (green) (B) IgG control 
(green) (C) pSTAT3 primary antibody (green) (D) Blocking peptide control, pSTAT3 antibody 
labelling in green (E) pSTAT3 primary antibody (green) (F) Secondary antibody only, no 
primary antibody added (green). Nuclei are marked with DAPI, red. Scale bars 10µm. 
 
2.3.7 PGE2 and EP Receptor activation and inhibition 
PGE2 or selective EP receptor agonists: EP1, EP2, EP3, EP4; or selective EP receptor 
antagonists: EP1, EP2, EP3, EP4, were dissolved in DMSO/methyl acetate/ethanol to give a 
10mM concentration, and added at a final concentration of 1-20μM to the culture conditions 
(Table 2.4) on day 0-1 of isolation as described below. Appropriate controls (DMSO, methyl 
acetate or EtOH) were added to control crypts in the culture media. Colonic crypts were 
Blocking 
peptide
pSTAT3
20 Ab onlypSTAT3
IgGLysozymeA B
C D
E F
Chapter 2. Materials and Methods 
 
60 
 
incubated with selective EP antagonists, COX enzyme inhibitors or PGE2 blocking antibody 
2B2 (Mnich et al., 1995), for the entire culture period before addition of EdU (10μM) for 17h 
on day 1. For investigation into EP receptor activation and PGE2-induced proliferation, 
following 24h of culture, colonic crypts were placed into growth factor free media for 5h, 
before incubation with selective EP agonists or PGE2 and EdU for 17h. In order to determine 
the role of EP receptors in PGE2-induced proliferation, following 24h in culture, colonic crypts 
were placed into growth factor free media for 5h, before pre-incubation with EP receptor 
antagonists for 2h, and subsequent addition of PGE2 and EdU for 17h. Fixation with 4% 
paraformaldehyde occurred on day 2 after isolation.  
Table 2.4. List of chemical agonists and antagonists used to treat isolated organoids and 
crypts. 
Pharmacological agents were utilised to selectively inhibit and activate EP receptor subtypes, 
concentrations were optimised in order to minimise potential cross-reactivity (Funk et al., 
1993; Kiriyama et al., 1997; Abramovitz et al., 2000; Juteau et al., 2001; Kabashima et al., 
2002; Billot et al., 2003; Gil et al., 2008; Dey et al., 2009; af Forselles et al., 2011; Birrell et al., 
2013). 
Name Function 
Working 
Concentration 
Supplier 
Potential  
Cross-reactivity 
Iloprost EP1 agonist 10μM Tocris EP3R 
Butaprost EP2 agonist 12μM Cayman None expected 
Sulprostone EP1/3 agonist 10μM Tocris EP1R 
TCS 2510 EP4 agonist 13μM Tocris None up to 14μM 
SC 19220 EP1 antagonist 20μM Tocris None expected 
PF04418948 EP2 antagonist 10μM Tocris None expected 
L-798106 EP3 antagonist 1µM/20μM Tocris None expected 
ONO-AE3-208 EP4 antagonist 10μM Tocris None expected 
Aspirin COX-1/2 inhibitor 10μM Sigma  
Valeryl 
Salicylate 
COX-1 inhibitor 10μM Sigma 
 
NS-398 COX-2 inhibitor 20μM Sigma  
STATTIC STAT3 inhibitor 20μM Tocris   
IWP2 WNT inhibitor 5μM Tocris   
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2.3.8 Immunofluorescent labelling using monovalent fab fragment antibody 
labelling 
In order to immunolabel cryosections and isolated colonic crypts with two primary 
antibodies raised in the same species, a monovalent fab fragment secondary antibody 
protocol was developed. Monovalent fab fragments bind to a single antigen site on the 
primary antibody, and as such following incubation with an excess of monovalent antibody, 
the surface of immunoglobulins are covered and therefore no longer bind to any additional 
appropriate secondary antibody; i.e. a rabbit primary antibody bound to a monovalent fab 
fragment secondary would no longer bind an anti-rabbit secondary antibody (Figure 2.3). 
This was required for EP receptor labelling in conjunction with Mucin-2 labelling in 
cryosections and isolated crypts, as both antibodies are raised in rabbit.  
Figure 2.3. Monovalent fab fragment antibody labelling 
(A) Samples are incubated with the first primary antibody overnight– rabbit anti-antigen X, 
and washed. (B) An excess of monovalent fab fragment bound to a donkey anti-rabbit IgG 
conjugated with Alexa Fluor 647 is added for 3h before washing. (C) Samples are incubated 
with the second primary antibody – rabbit anti-antigen Y and washed. (D) A goat anti-rabbit 
IgG secondary antibody conjugated to Alexa Fluor 568 is added, before washing and 
visualisation.
In order to permeabilise samples, a similar protocol to that utilised for Immunofluorescent 
labelling of samples was used (section 2.3.5). Briefly, samples were incubated with 1% SDS 
and 0.5% Triton-X, blocked with 10% donkey serum and 1% bovine serum albumin for 2h and 
incubated with rabbit anti-Muc-2 or rabbit anti-EP1/2/3/4 primary antibodies diluted (1:100 
or 1:50) in PBS overnight at 4°C. Samples were stained with donkey anti-rabbit monovalent 
fab fragment secondary antibody for 3h at 4°C, washed in PBS and blocked for a further 2h 
with 10% donkey serum and 1% BSA. Samples were incubated with rabbit anti-Muc-2 or 
rabbit anti-EP1/2/3/4 and goat anti-e-cadherin primary antibodies diluted in PBS overnight 
A B
C D
Rabbit anti-antigen X
Rabbit anti-antigen Y
Goat anti-rabbit 
Alexa Fluor 568
Donkey anti-Rabbit IgG 
Alexa Fluor 647 
AffiniPure Fab Fragment
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at 4°C followed by the corresponding fluorescent-conjugated secondary antibodies for 2h. 
Antibody specificity was determined using primary and secondary antibody negative controls 
(Figure 2.4). Sections were mounted with Vectashield containing DAPI and imaged using a 
confocal microscope (Zeiss 510 META) and an X40 1.3 NA oil-immersion objective or an X63 
1.4 0.75-mm WD oil-immersion objective. 
 
Figure 2.4. Controls for fab fragment antibody labelling. 
(1) Rabbit anti-EP1 primary antibody with appropriate secondary antibody (red). (2) Rabbit 
anti-Muc-2 antibody with appropriate secondary antibody (green). (3) Combined labelling of 
two rabbit raised primary antibodies using the fab fragment labelling system. Left: rabbit 
anti-EP1 (red), mid: rabbit anti-muc-2 (green), right: rabbit anti-EP1 and rabbit anti-muc-2 
merged image.
 
2.4 Human studies 
2.4.1 Human Colorectal Tissue Samples 
This study has been approved by the East of England National Research Ethics Committee 
(2013/2014 – 62 HT (ongoing approval)). Colorectal tissue samples were obtained with 
informed consent from patients undergoing sigmoid endoscopy, right-hemicolectomy or 
anterior resection procedures at the Norfolk and Norwich University Hospital. Histologically 
EP1/Muc-2
MERGE
Muc-2 alone 
No EP1
EP1 alone, 
no Muc-2
(1) (2)
(3) EP1 Muc-2
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normal mucosa samples were obtained from at least 10cm away from the tumour sites, and 
only used if there was no apparent intestinal pathology. 
2.4.2 Human Fixed Tissue Sections 
Human colonic mucosal biopsies were immediately fixed in 4% paraformaldehyde for 2h at 
4˚C. Following fixation, tissue was washed in PBS and left overnight. Tissue was either: 
embedded in OCT and frozen on liquid nitrogen in Isopentane before cutting 8μm thick 
sections on a cryostat; or dehydrated with xylene and ethanol before paraffin embedding 
and sectioning (5μm thick) on a microtome. 
2.4.3 Isolation and culture of human colonic crypts 
Human colonic crypts were isolated by members of the Williams Laboratory using 
methodology previously described (Reynolds et al., 2007; Reynolds et al., 2014; Parris and 
Williams, 2015). Briefly, fresh intestinal tissue samples were collected in ice cold PBS, 
transported to the laboratory and incubated in HBS, which was devoid of Ca2+ and Mg2+, and 
supplemented with EDTA (1mM) for 1h at room temperature. Crypts were liberated by 
vigorous shaking, crypt sedimentation and collection. Crypts were embedded in growth-
factor reduced matrigel and a 20µl droplet was seeded on no.0 glass coverslips contained 
within a 12 well plate. After polymerisation at 37˚C for 5-10min, crypts were flooded with 
human colonic crypt culture medium (hCCCM): advanced F12/DMEM containing B27, N2, n-
acetylcysteine (1mM), hepes (10mM), pen/strep (100U/ml) L-Glutamine (2mM), Wnt-3A 
(100ng/ml), IGF-1 (50ng/ml), Noggin (100ng/ml) or Gremlin-1 (200ng/ml), RSPO-1 
(500ng/ml), and the ALK 4/5/7 inhibitor A83-01-01 (0.5µM). Isolated crypts were cultured 
for 0-4 days in hCCCM, which was modified further to the stated experimental conditions.  
2.4.4 Immunohistochemistry of human colonic crypts 
Human colonic crypts were fixed in 4% paraformaldehyde for 1h at 4˚C. Crypts were 
permeabilised with 13min NH4Cl2, 5min 1% SDS and 30min 1% Triton X-100. Non-specific 
binding was blocked using 10% donkey serum, 1% BSA for 2h, before addition of primary 
antibodies overnight at 4˚C (Table 2.3). Crypts were incubated for 2h with appropriate Alexa 
fluor-conjugated secondary antibodies before mounting with Vectashield-Hoescht. 
Immunolabelling was visualised using laser confocal microscopy (Zeiss LSM), or 
epifluorescent microscopy (Nikon). Antibody specificity was determined using primary 
antibody negative controls. 
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2.5 EdU labelling of isolated crypts 
Crypts were fixed in 4% paraformaldehyde for 1h (human) or 35min (mouse) at room 
temperature. Crypts were permeabilised with 13min NH4Cl2, 5min 1% SDS and 30min 1% 
Triton X-100. The Click-IT reaction was prepared according to the manufacturers instructions. 
Crypts were incubated with the Click-IT reaction cocktail for 35min in dark. The reaction was 
stopped with 3% BSA, and non-specific binding blocked using 10% donkey serum, 1% BSA for 
2h. Samples were incubated with primary antibodies overnight at 4˚C. Crypts were incubated 
for 2h with appropriate Alexa fluor-conjugated secondary antibodies (Invitrogen): before 
mounting with Vectashield-Hoescht. Antibodies used in these studies are listed in (Table 2.3). 
Fluorescent labelling was visualised using epifluorescent (Nikon Ti) or laser confocal 
microscopy (Zeiss LSM).  
2.6 Immune cell-crypt co-culture models 
A monocyte-crypt co-culture model has previously been developed by Skoczek et al. (2014) 
for the study of the effects of monocytes on colonic crypt proliferation. Monocytes derived 
from the bone marrow, or THP-1 cells were added into co-culture with isolated mouse or 
human colonic crypts (Skoczek et al., 2014). In this thesis, this technique was adapted to add 
HL-60-eosinophils or human tissue resident eosinophils isolated from the colonic mucosa 
into co-culture with isolated human colonic crypts.  
The promyelocytic leukemic cell line HL-60 Clone 15 cells have proved a useful tool for 
eosinophil research. Stimulation of HL-60 cells with butyric acid induces differentiation 
towards a stable eosinophil phenotype (Fischkoff, 1988). Butyric acid differentiated 
eosinophils (HL-60-eosinophils) have since been utilised for the study of eosinophil 
chemotaxis, where similar results have been obtained using HL-60-eosinophils and primary 
eosinophils isolated from the blood of healthy donors (Fu et al., 2016). HL-60-eosinophils 
were utilised in co-culture studies with isolated human colonic crypts in these studies.  
2.6.1 HL-60-eosinophil-crypt co-culture 
HL-60 cells were cultured in RPMI 1640 media supplemented with 10% heat-inactivated FBS, 
100U/ml penicillin and 100U/ml streptomycin in a humidified incubator with 5% CO2 at 37˚C. 
Cells were differentiated towards an eosinophil phenotype as described previously (Fischkoff 
et al., 1986) by suspending 5x106 cells/ml in RPMI 1640 media containing 10% FBS, 100U/ml 
penicillin/streptomycin and 0.5mM butyric acid. The media was changed every 2 days, cells 
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were used for experiments on D5 following addition of butyric acid. Eosinophil phenotype 
was confirmed using H&E staining to confirm the presence of a bi-lobed nucleus and 
cytoplasmic acidic granule content, and the expression of eosinophil-specific markers Siglec-
8, CCR3 and MBP (Figure 2.5). HL-60 cells differentiated towards an eosinophil phenotype 
are referred to as HL-60/eos in this thesis.  
For HL-60-eosinophil-crypt co-culture studies, following 5 days of culture, HL-60-eosinophils 
were resuspended at different concentrations (5-15x104) in growth factor reduced matrigel 
containing isolated human colonic crypts (20-50 crypts per well) and cultured for 2 days in 
human colonic crypt culture medium (hCCCM), as described in Section 2.4.3. For 
proliferation studies, following 2 days in culture, EdU (10µM) or BrdU (1µM) was added to 
hCCCM for 4h before fixation in 4% paraformaldehyde. EdU labelling was visualised as 
described in Section 2.5. For visualisation of BrdU labelling, the protocol for 
Immunofluorescent labelling (as described in Section 2.3.5) was undertaken, using a primary 
antibody for BrdU.  
 
Figure 2.5. HL-60 cells differentiate towards an eosinophil phenotype. 
(A) H&E staining of Butyric acid treated HL-60 clone 15 cells. Butyric acid was added to HL-
60 cells (Day 0). Following 5 days in culture, cells are characterised by a bi-lobed nucleus and 
presence of acidic granules. (B) Immunofluorescent labelling of day 5 HL-60-eosinophils 
showing expression of markers characteristic of eosinophils; Siglec-8 (pink), MBP (red), CCR3 
(green). 
D5D0 +BA D4D3D2D1
Siglec-8 MBP CCR3
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2.6.2 Human tissue eosinophil isolation and purification 
Eosinophils isolated from the blood of healthy donors have previously been used in co-
culture studies with T84 epithelial cells (Jawien et al., 2002; Furuta et al., 2005). Cell density 
separation using Ficoll-Paque or a Percoll gradient, followed by Magnetic-Activated Cell 
Sorting (MACS) using anti-CD16 beads to remove neutrophils are the purification methods 
of choice (Sedgwick et al., 1996; Jawien et al., 2002; Farahi et al., 2007; Bates et al., 2010; 
Akuthota et al., 2012). Immune cells have previously been isolated from the small intestine 
of mice for the study of the effects of eosinophils on plasma cells in vitro. Chu et al. (2014) 
used an EDTA-mediated removal of the epithelium, before a collagenase digestion to 
disassociate immune cells within the lamina propria followed by flow cytometric cell sorting 
using antibodies specific for markers for eosinophils (B220/CD3, CD45, CD11b, Fr-1 and 
Siglec-F), B cells and T cells (Chu et al., 2011). These techniques were adapted in this thesis 
in order to develop a novel protocol for the isolation and purification of eosinophils from the 
lamina propria of human colonic tissue.  
Human tissue resident immune cells were isolated from the lamina propria or human 
colorectal tissue samples obtained from patients undergoing either a right hemicolectomy 
or anterior resection at the NNUH. Where the diagnosis was cancer, histologically normal 
mucosa samples were obtained from at least 10cm away from the tumour sites, and only 
used if there was no apparent intestinal pathology. Tissue was also obtained from patients 
undergoing resection due to IBD (Crohn’s disease or UC) or Diverticular disease. Intestinal 
tissue samples were collected in ice cold PBS and transported to the laboratory.  
2.6.2.1 Removal of epithelium 
Full thickness fresh intestinal tissue samples were stripped of underlying smooth muscle and 
submucosal layers to leave only the mucosa and cut into approximately 3mm2 pieces (Figure 
2.6). Approximately 1-1.5g of tissue samples were placed into a 50ml falcon tube containing 
10ml Hepes-buffered saline (HBS): NaCl (140mM), KCl (5mM), Hepes (10mM), d-glucose 
(5.5mM), Na2HPO4 (1mM); which was devoid of Ca2+ and Mg2+, supplemented with EDTA 
(1mM) for 15 minutes at 37˚C. The falcon tube was inverted, and samples transferred to a 
new 50ml falcon tube containing HBS devoid of Ca2+ and Mg2+, supplemented with EDTA for 
15mins. This was repeated for a total of 6 x 15 minute incubations, which was sufficient to 
remove the majority of crypts from the mucosa. Tissue was then washed 3x with HBS devoid 
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of Ca2+ and Mg2+ to ensure maximal removal of crypts. Sufficient removal of the epithelium 
was confirmed by light microscopy.  
 
 
 Figure 2.6. Preparation of colonic tissue for enzymatic isolation of mucosal immune cells. 
(A) Full thickness human colon sample is obtained, M=mucosa, subM=submucosa, 
SM=smooth muscle. (B) The mucosal layer containing the epithelium and immune cells is 
held with forceps, (C) The underlying submucosa and smooth muscle is removed by cutting 
with scissors, (D) the mucosa is removed with forceps. (E) Submucosa and smooth muscle 
are removed – LEFT, mucosal sample is washed in HBS –RIGHT. (F) Mucosal sample is cut into 
approximately 2mm2 pieces prior to EDTA treatment to remove epithelium. (G) Following 
EDTA treatment, tissue samples are washed in HBS to ensure maximal removal of crypts, 
before addition to a falcon tube containing enzymatic digestion buffer. 
 
2.6.2.2 Digestion of lamina propria 
Samples consisting of lamina propria were placed into RPMI media supplemented with 10% 
FBS, containing 2.5mg/ml Collagenase A, and 0.5mg/ml DNase I for 2h on a shaker at 37˚C. 
Tissue samples were filtered through a 20μm filter and washed 3x in ice cold PBS. The 
average yield was 9.06 cells/mg, of which approximately 33% were eosinophils before 
purification was attempted. These numbers are however only an estimate as the 
donor/preparation variation was high; the cell yield was 1.8-22.76, of which 15.2-64.5% were 
eosinophils. Cells were resuspended in 2ml RPMI media containing 10% FBS before 
separation using Percoll gradient separation.  
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2.6.2.3 Percoll gradient separation  
Cells suspended in RPMI media were underlain with 45% Percoll, and subsequent 70% Percoll 
layers, and centrifuged at 280g for 13 minutes with no brake (Figure 2.7). Cells were obtained 
from the 45%/ 70% Percoll interface using a sterile Pasteur pipette and washed 3x with ice 
cold PBS before resuspending in MACS buffer: PBS containing 1mM EDTA. Protocol for 
Percoll gradient separation was adapted from protocol used for separation of granulocytes 
in blood (Farahi et al., 2007). 
 
Figure 2.7. Protocol for Percoll gradient separation of cells. 
(A) Mixed immune cell population is resuspended in 2ml of RPMI media. (B) A glass pipette 
containing 45% Percoll is carefully placed into the bottom of the falcon tube. (C) Release 45% 
Percoll to underlay the cell suspension. (D) Repeat stage (B) this time containing 70% Percoll 
and carefully release under the 45% Percoll. (E) Following centrifugation at 280g for 13min, 
a pure population of eosinophils and neutrophils is present at the interface between 45% 
and 70% Percoll.
 
2.6.2.4 MACS separation 
Negative selection of eosinophils using a Quadromacs cell separator (Miltenyi Biotec, SF lab) 
and a commercially available kit for eosinophil purification (Miltenyi Biotec) was undertaken 
in order to purify the eosinophil population further following Percoll separation. The kit was 
previously optimised for the purification of eosinophils from blood and contains beads for 
markers of neutrophils, macrophages, dendritic cells, B cells, NK cells and red blood cells (see 
Table 2.5). All these cell types have been described to be resident in the human colonic 
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lamina propria.  However, the relative level of contamination of these cell types in the lamina 
propria is less well defined, and additional CD14 beads were required in order to obtain a 
population of eosinophils with a higher purity. The kit was used in accordance with the 
manufacturer’s instructions, with an additional 10µl of anti-CD14 beads added.  
Positive selection utilising anti-CD15 beads conjugated to biotin was also attempted, 
however high levels of neutrophil contamination were observed and therefore negative 
selection was deemed superior for eosinophil purification in the case of human tissue 
resident eosinophil purification.  
Table 2.5. MACS negative selection for purification of human eosinophils 
Marker Cell Type 
CD2 T cells 
CD14 Macrophages, neutrophils, dendritic cells 
CD16 NK cells, macrophages, neutrophils 
CD19 B cells 
CD56 NK cells, neurons 
CD123 (IL-3R) B cells 
CD235a 
(Glycophorin A) 
Red blood cells 
 
2.6.2.5 Macrophage adhesion 
Due to macrophages being the dominant contaminating cell type following MACS separation, 
and the inherent adhesive property of macrophages, a macrophage adhesion step was 
introduced in order to try to improve the purity of eosinophil population. This step was 
attempted either before or after MACS separation. Cells were placed into a T25 flask and left 
in a 37˚C/ 5%CO2 humidified incubator for 4 hours. Following this step, cells in suspension 
were removed and eosinophil purity determined using H+E staining, however no increase in 
the purity of eosinophils was observed following the macrophage adhesion step (N=3).  
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2.6.2.6 Eosinophil Characterisation 
Purity of eosinophils was assessed at each stage of isolation and purification utilising 
Hematoxylin & Eosin (H&E) staining (Figure 2.8A and B). Eosinophils are characterised by a 
bi-lobed nucleus and the presence of acidic granules which stain pink following H&E staining 
(Figure 2.8C). 
 
Figure 2.8. Characterisation of immune cells using H&E staining 
(A) H&E staining of mixed immune cell population containing 35% eosinophils (Eo). 
Contaminating cells include neutrophils (N), macrophages (M), monocytes (mo) and 
lymphocytes (L). (B) H&E staining of purified eosinophil population following Percoll gradient 
separation and negative selection using MACS, population is 85% eosinophils (Eo), 
contaminating cells include monocytes (Mo). (C) H&E image of eosinophil showing 
characteristic bilobed nucleus and pink granules. 
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2.7 PCR 
RNA from freshly isolated colonic or small intestinal crypts, tissue biopsy, or isolated immune 
cells was isolated using the Isolate II RNA mini kit (Bioline) according to manufacturers 
instructions. Total RNA yield was determined using a NanoDrop ND-1000 spectrophotometer 
(Thermo Fischer Scientific) and purity assessed by the ratio of absorbance at 260 and 280nm. 
cDNA was generated from 0.5µg of RNA using the RT2 First Strand cDNA synthesis kit 
(Qiagen).  
End-point PCR reactions were performed in a final volume of 25 µl, comprising 200 nm 
forward and reverse primers, 200 µM dNTP, 0.5 U Taq polymerase, PCR buffer (Roche), 2.5 
mM MgCl2 and 0.5 µl cDNA using a Tprofessional TRIO thermal cycler (Biometra) with the 
following thermal profile: 1 cycle at 94°C for 3 mins, 30 cycles at 94°C for 25 s, 58°C for 30 s, 
and  72°C for 50 s and  1 cycle at 72°C for 5 mins. The Primer sequences used are listed in 
Table 2.6. The following primers were kindly provided by SF lab: CCR1, CCR3, CCR7, CCR9, 
CCR10, CCRL2, CCL2, CCL5.  
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Table 2.6. Conventional PCR primers utilised in the study. 
Gene Accession Primer Sequence (F) Primer Sequence (R) 
Product 
size (bp) 
IL-6 NM_031168 
GCTACCAAACTGGATA
TAATCAGGA 
CCAGGTAGCTATGGT
ACTCCAGAA 
86 
WNT3a NM_033131.3 
CTGCTCAGCTGCGCCC
CCTTCTTT 
TTCAGCGGCCTCCCC
ATTCATTCC 
404 
COX 1 NM_008969 
CCTCTTTCCAGGAGCTC
ACA 
TCGATGTCACCGTAC
AGCTC 
96 
COX 2 NM_011198 
GCCGTACACATCATTTG
AAGAA 
TGTCACTGTAGAGGG
CTTTCAA 
70 
EP1 R NM_013641 
CCTCGTCTGCCTCATCC
ATC 
CCACCAACACCAGCA
GGG 
165 
EP2 R NM_008964 
GCCATTATGACCATCAC
CTTCG 
 CTTTAGGGAAGAGG
TTTCATCCAT 
402 
EP3 R NM_011196  
 ATCATGTGTGTGCTGT
CCGT    
 GCAGCAGATAAACC
CAGGGA 
438 
EP4 R NM_001136079  
 CTCATCTGCTCCATTCC
GCT   
 GGATGGGGTTCACA
GAAGCA 
351 
EP3α D10204.1  
 ATGGGGATCATGTGT
GTGCTG 
 ACCTGGTAGTCTGAA
GTCTGGA 
261 
EP3β NM 011196.2  
 TGGGGATCATGTGTGT
GCTG   
 TCAGGTTGTTCATCA
TCTGGCA 
349 
EP3γ D17406.1  
 ATGGGGATCATGTGT
GTGCTG 
 GGCCCTGGCTGTACT
ACTTC 
311 
15-
PGDH 
NM_000860.5 
TTGGAAGACTGGACAT
TTTGG 
CCTTCACCTCCATTTT
GCTT 
145 
CCR1 NM_001295.2  
GCCTACGAGAGTGGAA
GCTG  
TTCCGGAACCTCTCAC
CAAC  
358 
CCR3 NM_001837.3  
TTGTCCATGCTGTGTTT
GCC 
AAAAATGAGCCGGAT
GGCCT 
323 
CCR7 NM_001838.3  
CAAGTCCTGGGTCTTC
GGTG 
CCAGGACCACCCCAT
TGTAG 
497 
CCR9 NM_006641.3  
GGCAATTGCTGACCTC
CTCT 
CGAAGGGAAGGAAG
AACCCC  
413 
CCR10 NM_016602.2  
TTGCTACAAGGCCGAT
GTCC  
TGGAAGGAGGCCGA
GTAGAG 
285 
CCRL2 NM_003965.4  
TCTTCCTTCTGATGTGG
GCG 
TTCCCTCGATGTGCCT
TGTG 
272 
CCL2 NM_002982.3  
GATGCAATCAATGCCC
CAGTC 
CTTCGGAGTTTGGGT
TTGCT 
219 
CCL5 NM_002985.2  
GCATCTGCCTCCCCATA
TTCC  
AGAGTTGATGTACTC
CCGAACC  
201 
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2.8 Microscopy 
Following Immunohistochemistry, labelling was visualised using fluorescence microscopy 
which allows for detection of proteins labelled with fluorescent dyes. Proteins of interest are 
illuminated utilising light of specific wavelengths. When light hits the specimen, the 
fluorescent protein of interest is excited and emits fluorescence of a longer wavelength, 
which is detected and visualised. In this study, immunolabelling was visualised using either a 
laser scanning confocal (Zeiss 510 META) or epifluorescence (Nikon Ti) microscope.  
Epifluorescence microscopy uses a high-intensity light source, which emits broad spectrum 
light which is limited to a narrow range of wavelengths using excitation filters. Emission 
filters allow specific fluorescence to be detected by the detectors. Epifluorescence 
microscopy is a relatively fast imaging technique which is useful when high resolution images 
are not required. In this thesis, a Nikon Ti epifluorescent microscopy was utilised to image 
cells labelled with fluorescently tagged EdU or BrdU in isolated intestinal crypts and 
organoids. A x40 1.1 NA oil objective was utilised to capture images.  
In order to obtain high resolution images of Immunofluorescent labelling, laser scanning 
confocal microscopy was utilised to capture images. Confocal microscopy uses the addition 
of a confocal pinhole in order to eliminate out of focus light and point illumination, whereby 
only one point of the sample is illuminated by a laser at any one time. For confocal 
microscopy, a X40 1.3 NA oil objective of X63 1.4NS 0.75mm WD oil immersion objective was 
used to capture images. Image stacks were taken at 1-3µm intervals which allowed for 
selection of previse focal planes. In this study, laser scanning confocal microscopy was 
utilised to characterise the expression of proteins within specific cell types, including EP 
receptor labelling of colonic crypts and sections, and pSTAT3 expression of the small 
intestine.  
2.8.1 Image Analysis 
For all experiments, a minimum of between 20 and 100 crypts were counted per condition 
and each experiment was performed at least three separate times.  
For proliferation experiment analysis, ImageJ software was used to count the total number 
of DAPI labelled cell nuclei in the crypt equatorial plane, and the number of cells that were 
positive for BrdU was then expressed as a percentage of the total nuclei number. For analysis 
of EdU positive nuclei in human colonic crypts, the crypts were split into four regions along 
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the crypt-axis, each containing an equal number of nuclei and designated base, supra-base, 
mid and top. In some cases, the base and supra-base regions were combined to give three 
functional regions, base, mid and top (Figure 2.9). 
 
Figure 2.9. Analysis of human colonic crypt growth experiments. 
Human colonic crypts were split into 3 functional regions along the crypt axis, base, supra-
base, mid and top. The number of nuclei (red) incorporating EdU/BrdU (green) were 
quantified in each functional region, proliferating cells are shown in yellow. In some cases, 
crypts were split into 3 regions, base, mid and top.  
Quantification of organoid survival was determined utilising epifluorescent microscopy. On 
day 1 of culture, before the addition of experimental groups, organoids were imaged using a 
timelapse system at 37˚C with 5% humidified carbon dioxide. Regions of interest were saved 
in order to enable the imaging of the same organoids after incubation with experimental 
groups but before fixation with paraformaldehyde. Survival was determined through analysis 
of organoid morphology. 
In order to quantify the intensity of Immunofluorescent labelling of proteins, ImageJ 
software was utilised to draw appropriate regions of interest and measure the average 
fluorescence intensity within the region. For semi-quantitative analysis of pSTAT3 activation, 
regions of interest were drawn around the nuclei of Paneth cells (as determined by 
expression of UEA-1 and/or lysozyme immunofluorescence), and the average fluorescence 
intensity of pSTAT3 labelling within the region calculated (Figure 2.10A-C). Data were 
normalised to unstimulated control organoids and background corrected. For the analysis of 
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WNT3 protein expression in small intestinal organoids stimulated with IL-6 or untreated 
controls, organoids were split into three hierarchical regions, base, mid and top, containing 
an equal number of nuclei. Regions of interest were drawn below the nuclei and containing 
the surrounding basal membrane. The average intensity per unit area was background 
corrected and calculated in control organoids, and IL-6-treated organoids (Figure 2.10D).  
For analysis of stem cells and Paneth cell number in vivo, Lgr5EGFP stem cells, lysozyme or 
UEA-1 positive Paneth cells were counted by taking a z-stack across the equatorial plane of 
the crypt and counting the number of nuclei in the stack that were positive for each marker. 
To determine the crypt length and villus height, at least 25 well orientated crypts and villi 
were measured using the segmented line tool (Fiji 1.50e) from three animals in each 
treatment group.  
 
Figure 2.10. Intensity analysis of Immunofluorescent labelling. 
(A) Representative image of small intestinal organoid stimulated with IL-6; nuclei (DAPI-red), 
UEA-1 (pink), pSTAT3 (green), E-cadherin (white). (B) Regions of interest (white dashed) were 
drawn around the nuclei (DAPI-red) of UEA-1 (pink) positive cells. (C) Fluorescence intensity 
of pSTAT3 (green) was measured in ROI (white dashed). Fluorescence intensity was 
normalised to average fluorescence observed in ROI drawn in nuclei of UEA-1 positive nuclei 
of unstimulated organoids. (D) Representative image of small intestinal organoid 
immunolabelled for WNT3 (red). Organoids were split into hierarchical regions, base, mid 
and top, and regions of interest (white) drawn below the nuclei (blue) and including the basal 
membrane. Intensity was background corrected. 
A B C
pSTAT3DAPI UEA-1E-cadherin
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In order to determine the spatial characteristics of immune cell distribution in vivo, colonic 
crypts were divided into three equal regions, base, mid and top, and the number of immune 
cells positive for markers of immune cells e.g. Siglec-8, CCR3, MBP, F4/80 or CD14 present in 
the surrounding lamina propria of crypts were quantified (Figure 2.11A).  Following 24h in 
co-culture with isolated human colonic crypts, the spatial distribution of immune cells along 
the crypt-axis was quantified in vitro. Isolated human colonic crypts were divided into three 
equal regions, base, mid and top, and the number of immune cells present in a 2-cell thick 
radius surrounding crypts was quantified (Figure 2.11B). 
 
Figure 2.11. Image analysis for spatial distribution of immune cells along the crypt-axis. 
(A) Fixed colonic crypt sections were divided into three equal regions, base mid and top 
(white dashed lines). The number of immunofluorescently labelled immune cells in the 
lamina propria surrounding crypts in each region was quantified (pink, B=base, M=mid, 
T=top) in vivo. (B) The spatial distribution of immune cells in vitro was quantified using white 
light microscopy. Isolated human colonic crypts were divided into three equal regions, base, 
mid and top (white). Following 24h in co-culture, the number of immune cells present within 
a 2-cell thick radius surrounding the crypt (red dashed line) was quantified (red, B=base, 
M=mid, T=top). 
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2.9 Statistics 
Experiments were performed at least three separate times. Data are expressed as mean +/- 
SEM; N= total number of subjects (i.e. mice/patients), n= number of crypts/organoids 
derived from those ‘N’ subjects. Differences between two groups were determined by a 
paired or unpaired students’ t-test; comparisons between two or more groups were 
determined one-way analysis of variance (ANOVA) with post-hoc Tukey analysis. For each 
test, a P value of less than 0.05 was considered significant.  
For gradient analysis of EP receptor fluorescence intensity, multilevel modelling was carried 
out on the data to avoid any pseudo-replication i.e. avoid inflating the number of 
independent samples in the data (Peugh, 2010). The R statistics package was used for the 
analysis (with the ‘’lme’’ package). Where multilevel modelling indicated that there was a 
significant (P<0.05) difference in the ‘’crypt area’’ variable (levels: base, supra-base, mid and 
top), pairwise comparison of each level was carried out to assess where the significant 
difference arose (JD).  
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3 Chapter 3: Autocrine Interleukin-6 Drives Small Intestinal 
Epithelial Homeostasis 
3.1 Introduction 
The intestinal epithelium is one of the most rapidly renewing tissues in the body. Dynamic 
renewal in the small intestinal epithelium is achieved by way of Lgr5+ stem cells residing at 
the base of intestinal crypts (Barker et al., 2007). Stem cells are maintained in the stem cell 
niche by Paneth cells, which secrete factors including WNT and DLL4 (Sato et al., 2011). Other 
growth factors and cytokines as well as immune cells have previously been shown to 
modulate epithelial stem cell driven tissue renewal during homeostasis (Reynolds et al., 
2014; Skoczek et al., 2014). The mechanism by which these pathways are regulated in the 
intestinal epithelium through autocrine signalling is not yet fully understood.  
Seminal work in the Drosophila midgut demonstrated that following acute stress such as 
enteric infection, enterocytes are stimulated to produce Upd3, an IL-6-like cytokine, which 
activates JAK/STAT signalling in intestinal stem cells to promote cell division and therefore 
regeneration (Jiang et al., 2009; Osman et al., 2012). In the mammalian gut, STAT3 and IL-6 
are known to play a role in regeneration of the intestinal epithelium following injury (Pickert 
et al., 2009; Kuhn et al., 2014) and to promote the survival of epithelial cells (Grivennikov et 
al., 2009; Jin et al., 2010) during inflammation and IBDs (Bollrath et al., 2009; Lee et al., 2012). 
Mice with an IEC-specific depletion of STAT3 were highly susceptible to the induction of 
experimental colitis, and showed a significant defect in colonic epithelial regeneration 
(Pickert et al., 2009). In addition, following bowel injury induced by biopsy or bacterial 
triggered colitis, inhibition of IL-6 decreased epithelial proliferation and resulted in impaired 
wound healing (Kuhn et al., 2014). Use of an IL-6-/- mouse demonstrated that whilst there 
was no changes in the basal rate of proliferation in the colon of IL-6KO mice, a significant 
decrease in proliferation was observed following DSS exposure compared to wild type 
suggesting that IL-6 is required for proliferation following induction of inflammation. IL-6 was 
shown to promote tumour growth by enhancing proliferation of tumour initiating cells, 
however a role for IL-6 in the survival of normal intestinal tissue was also identified 
(Grivennikov et al., 2009). Furthermore, Jin et al. (2010) observed that IL-6 reduced 
enterocyte apoptosis in the small intestine by activation of anti-apoptotic proteins (Jin, 
Zimmers et al. 2010).  
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Interleukin-6 is a pleiotropic cytokine involved in a plethora of cellular and immune 
responses in health and disease (Mihara et al., 2012; Garbers et al., 2015; Hunter and Jones, 
2015). IL-6 has traditionally been associated with pro-inflammatory responses including B 
cell activation and immune cell recruitment in response to pathogenic challenge, however 
IL-6 is also emerging as an important cytokine in the regulation of immune cells during 
homeostasis. In the intestinal mucosa, secretion of IL-6 by eosinophils has also been shown 
to be vital for the maintenance of plasma cells in the lamina propria, which in turn is crucial 
for the maintenance of long-term immunity (Chu et al., 2014). 
Classical IL-6 signalling is traditionally associated with homeostasis (Scheller et al., 2011) and 
occurs through binding of IL-6 to the membrane-bound IL-6R, which then complexes to the 
ubiquitously expressed gp130 receptor. This results in activation of downstream signalling 
components including JAK and STAT3 (Garbers et al., 2015). Several mouse models have 
identified a role for IL-6 classic signalling in the activation of anti-inflammatory pathways on 
target cells, including apoptosis of neutrophils which is key to the resolution of inflammation 
(Kaplanski et al., 2003). Furthermore, IL-6 classic signalling has been shown to be essential 
for the regeneration of intestinal epithelial cells following DSS-induced tissue injury (Kuhn et 
al., 2014). 
Cells which do not express the IL-6R are still able to respond to IL-6 via trans-signalling. 
Soluble IL-6R (sIL-6R) is shed from the cell membrane through proteolytic cleavage, and binds 
to IL-6. The IL-6/sIL-6R complex can then activate IL-6 signalling in any cell expressing the 
gp130 protein, which is constitutively expressed by the intestinal epithelium (Scheller et al., 
2011). The trans-signalling pathway has been associated with inflammatory disorders 
including Crohn’s disease and rheumatoid arthritis, and cancer (Jones et al., 2005; Scheller 
et al., 2011). IL-6 trans-signalling has a pivotal role in the switch from innate to adaptive 
immunity; following acute neutrophil infiltration, proteolytic cleavage of the IL-6 receptor 
drives trans-signalling in resident tissue cells, which then leads to switching from neutrophil 
to monocyte recruitment to the inflamed area. IL-6 is also required for the recruitment of T 
cells, and trans-signalling on T-cells leads to inhibition of Treg cell differentiation, and 
promotion of differentiation into TH17 cells, which have been implicated in autoimmune 
tissue injury. 
Autocrine IL-6 signalling has been implicated in pro-inflammatory responses in a number of 
systems. In lung cancers with an associated EGFR mutation, constitutive activation of STAT3 
was shown to be required for tumour cell growth through autocrine IL-6 signalling (Gao et 
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al., 2007). HER2 overexpressing breast adenocarcinomas express high levels of IL-6 which 
contribute to the induction of proliferation and HER2-mediated oncogenesis through 
activation of STAT3 (Hartman et al., 2011). Furthermore, in experimental inflammatory 
conditions, mouse biliary epithelial cells secrete and respond to IL-6 through upregulation 
and activation of IL6R/STAT3 signalling in an autocrine manner (Yokomuro et al., 2000). 
However, the roles of IL-6 autocrine signalling in homeostasis remain unclear.  
The aim of this programme of work was to determine the roles of classical IL-6 signalling in 
the modulation of small intestinal crypt homeostasis and renewal. This work demonstrates 
a previously undefined role for autocrine IL-6 signalling in the maintenance of the crypt stem 
cell niche, via differential expression of the IL-6 receptor and pSTAT3 activation in Paneth 
cells, with involvement of the WNT signalling pathway. 
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3.2 Results 
In order to investigate the role of IL-6 signalling during homeostasis, a variety of approaches 
including mouse in vitro organoid culture and in vivo experiments were undertaken. The 
effects of IL-6 and inhibition of the STAT3 signalling pathway on proliferation, stem cell 
number and budding were determined using in vitro organoid culture. The status of STAT3 
signalling within the small intestine was characterised in in vitro organoid culture, as well as 
in vivo utilising tissue from control and IL-6 knockout mice. Furthermore, the effects of 
perturbation of the IL-6 signalling pathway in vivo using antibodies to neutralise IL-6 or block 
the IL-6 receptor, on stem cell number, Paneth cell number and tissue morphology were 
investigated. 
3.2.1 IL-6 stimulates proliferation of small intestinal organoids via a STAT3-
mediated signalling pathway 
In order to determine the effects of exogenous IL-6 on the proliferation of small intestinal 
organoids, IL-6 (10-1000ng/ml) and BrdU (1µM) was added to mouse small intestinal 
organoids on Day 1 following isolation, for 17 hours as described in Section 2.3.4, and the 
percentage of nuclei incorporating BrdU was visualised using fluorescence microscopy 
(Section 2.3.5). Representative fluorescence images of BrdU incorporation of mouse small 
intestinal organoids following IL-6 stimulation are shown in Figure 3.1A. A significant 
increase in incorporation of BrdU was observed following addition of 10 and 100ng/ml IL-6. 
A bell-shaped response curve was exhibited at higher concentrations (1000ng/ml), with no 
increase in BrdU incorporation compared to control (Figure 3.1B). Further experiments 
utilised 100ng/ml IL-6 for stimulation due to the consistent significant increase in organoid 
proliferation. STATTIC is a small molecule which has been shown to selectively inhibit STAT3 
activation, dimerization and nuclear translocation of STAT3 (Schust et al., 2006). Previous 
studies have utilised 20µM STATTIC for the inhibition of STAT3 in intestinal organoids 
(Lindemans et al., 2015). Incubation of organoids with STATTIC (20µM) and IL-6 (100ng/ml) 
showed a significant reduction in BrdU incorporation compared to IL-6 alone (Figure 3.1C). 
Organoid survival (determined as described in Section 2.8.1) following STATTIC treatment in 
the presence or absence of IL-6, and IL-6 alone were comparable to control (Figure 3.2A). 
However, a small but significant increase in the percentage of caspase-3 positive cells (a 
marker of apoptosis) per organoid was observed following incubation with STATTIC 
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compared to control; the percentage of caspase-3 positive cells per crypt in organoids 
treated with IL-6 alone was comparable to control (Figure 3.2B).  
Whilst 17 hour treatment of organoids with STATTIC had no effect on basal proliferation (see 
Figure 3.1C), this was in contrast to the effects seen following treatment of organoids with 
STATTIC for 48h from the point of isolation, where a significant decrease in BrdU 
incorporation was observed compared to untreated organoids (Figure 3.3A). Chronic 
stimulation of organoids with IL-6 induced a significant increase in organoid proliferation 
following 5 days of IL-6 treatment (Figure 3.3B). 
 
Figure 3.1. IL-6 stimulates proliferation of small intestinal organoids via a STAT3-mediated 
signalling pathway. 
(A) Representative confocal images of BrdU incorporation (green) into the nuclei (DAPI; red) 
of small intestinal organoids cultured in the absence or presence of IL-6 (100 ng / ml). Co-
labelling of DAPI and BrdU positive cells shown in yellow, scale bar 10µm.  CD indicates crypt 
domain, VD indicates villi domains (B) Histogram showing the percentage of BrdU positive 
nuclei in mouse small intestinal organoids following 24 hours IL-6 (10-1000 ng / ml) 
stimulation compared to control (N=3, n≥30, ***P<0.001).  (C) Histogram showing 
percentage of BrdU positive nuclei in mouse small intestinal organoids following 24 hour IL-
6 stimulation (100 ng / ml) in the presence or absence of STATTIC (20μM) and compared to 
control (N=3, n≥118 ***P<0.001).  (A) and (B) obtained by AS. 
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Figure 3.2. Inhibition of STAT3 induces apoptosis of small intestinal organoids. 
(A) Histogram showing organoid survival following stimulation with IL-6 (100ng/ml) in the 
presence or absence of STATTIC (20μM), and compared to DMSO control (N=3, n≥118). (B) 
Histogram showing a significant increase in percentage of caspase-3 positive cells in 
organoids treated with STATTIC compared to control organoids (N=3, n≥118, **P<0.01). 
 
Figure 3.3. Chronic exposure of small intestinal organoids to STATTIC or IL-6 modulates 
proliferation in vitro. 
(A) Histogram showing a significant reduction in the percentage of BrdU positive nuclei in 
small intestinal organoids following 48 hour culture with STATTIC (20µM) in full growth factor 
media compared to control organoids (N=3, n≥124, ***P<0.001) AS. B) Histogram showing a 
significant increase in the percentage of BrdU positive nuclei in small intestinal organoids 
following stimulation with IL-6 (100ng/ml) for 5 days (N=4, n≥94 **P<0.01).
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3.2.2 IL-6 induces nuclear activation of pSTAT3 in Paneth cells of the small 
intestine via differential expression of the IL-6 receptor 
Next, the effects of IL-6 on pSTAT3 activation in the small intestinal epithelium were 
investigated using immunolabelling and visualisation of pSTAT3 activation in Day 1 mouse 
small intestinal organoids by confocal microscopy as described in Section 2.3.5. When no IL-
6 was added, pSTAT3 activation was not commonly observed in organoids (Figure 3.4A, left 
panel, white arrows). Following 1 hour of stimulation with IL-6, pSTAT3 was observed in the 
nucleus of UEA-1 and lysozyme positive cells, which was abrogated by a blocking peptide to 
pSTAT3 (Figure 3.4A, mid and right panels). All lysozyme positive cells also expressed UEA-1, 
and displayed morphology characteristic of Paneth cells (Figure 3.4A white light images, top 
row). As shown utilising a projection of images taken across multiple Z planes, following 1h 
IL-6 stimulation, all UEA-1 positive cells in a crypt domain were positive for nuclear pSTAT3 
(Figure 3.4B). No fluorescent labelling was observed in IgG controls for the Lysozyme 
antibody (Figure 3.4C). Whilst the majority of untreated control organoids expressed no 
pSTAT3 (as represented in Figure 3.4A), nuclear pSTAT3 fluorescence significantly above 
baseline was observed in UEA-1 positive cells of 9 out of 113 control organoids counted.  
In order to assess the temporal effects of IL-6 stimulation on pSTAT3 activation, organoids 
were exposed to IL-6 (100ng/ml or 1000ng/ml) for 30 minutes to 6 hours before fixation and 
immunolabelling for pSTAT3. Maximal activation of nuclear pSTAT3 in UEA-1 positive cells 
occurred 30 minutes following stimulation with IL-6, and persisted for 1 and 3 hours after 
stimulation (Figure 3.5A). Semi-quantitative analysis showed that the level of nuclear pSTAT3 
activation remained significantly higher than unstimulated controls for 30 minutes, 1 hour 
and 3 hours following stimulation with IL-6. After 6 hours of exposure to IL-6 there was no 
significant increase in pSTAT3 fluorescence in UEA-1 positive cells compared to control 
organoids. Furthermore, there was no significant difference in the level of pSTAT3 activation 
when organoids were stimulated with either 100 ng/ml or 1000ng/ml IL-6 (Figure 3.5B). 
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Figure 3.4. IL-6 induces nuclear activation of pSTAT3 in Paneth cells of the small intestine. 
(A) Representative confocal images showing pSTAT3 (green) immunofluorescent labelling in 
the nuclei (DAPI- red) of UEA-1 (pink), lysozyme (blue) cells in organoids following 1 hour IL-
6 (100 ng/ml) stimulation in the presence or absence of a pSTAT3 blocking peptide. (B) 
Confocal image projection pSTAT3 in the nuclei (DAPI-red) of all UEA-1(pink) lysozyme (blue) 
cells following 1h IL-6 (100 ng/ml) stimulation. (C) Representative confocal image showing 
absence of labelling with IgG control for lysozyme antibody (blue), nuclei (DAPI-red), E-
cadherin (white). Scale bar 10µm, images are representative of N>3 independent 
experiments, n≥30. 
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UEA1                Lysozyme               pSTAT3 DAPI
PROJECTION +IL-6
A
B
IgG control
C
Lysozyme
Chapter 3. Interleukin-6 Drives Small Intestinal Epithelial Regeneration 
 
86 
 
 
 
Figure 3.5. Nuclear activation of pSTAT3 in Paneth cells occurs 30 minutes after stimulation 
with IL-6. 
(A) Representative confocal images of pSTAT3 (green) in the nuclei (DAPI - red) of UEA-1 
(pink) positive cells in organoids stimulated with IL-6 (1000 ng/ml) for 0-6 hours,  E-cadherin 
- white.  (B) Histogram showing the time course of IL-6 induced pSTAT3 activation in UEA-1 
positive cells from 0 to 6 hours post-stimulation using 1000 or 100 ng/ml.  Data expressed as 
fluorescence intensity (a.u) and normalised to control UEA-1 positive nuclei (N=3, n≥104 
***P<0.001, #P>0.05 ns). Scale bar 10µm.  
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As pSTAT3 activation is known to be a downstream effect of IL-6 receptor activation, the 
expression of the IL-6 receptor within small intestinal organoids and in vivo in intestinal tissue 
sections was characterised using fluorescent microscopy. The localisation of the IL-6 receptor 
in organoids was restricted to the basal membrane of lysozyme positive cells of the small 
intestine in vitro (Figure 3.6A). There was also evidence of the IL-6 receptor being secreted 
from lysozyme positive cells, into the lumen of small intestinal organoids in vitro (Figure 
3.6B). When the IL-6 receptor was immunofluorescently labelled in vivo, a similar distribution 
to the in vitro organoid labelling was observed; IL-6 receptor expression was observed on the 
basal membrane of lysozyme positive cells, with no IL-6 receptor expression observed in 
Lgr5EGFP stem cells (Figure 3.6C). IL-6 receptor expression was also observed on the 
membrane of intracellular granules and on the membrane at the apical pole of lysozyme 
positive cells (Figure 3.6D).  
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Figure 3.6. Expression of the IL-6 receptor is restricted to Paneth cells. 
(A) Representative confocal images showing IL-6 receptor (red) expression in lysozyme 
(green) positive cells in cultured small intestinal organoids (representative image from one 
focal plane). (B) Consecutive z-stack confocal images showing IL-6 receptor (red) expression 
in the lumen of small intestinal organoids, white dashed oval. (C) Representative confocal 
images of small intestine taken from Lgr5EGFP (cyan) mice showing IL-6 receptor localisation 
(red) on the basal membrane of lysozyme positive cells (green). (D) Representative confocal 
images of IL-6 receptor (red) on intracellular granules and on the apical membrane of 
lysozyme positive cells (green). Confocal imaging data is representative of N=3 independent 
experiments, n≥10. Scale bar 10 µm.  
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Cells which do not express the IL-6R are still able to respond to IL-6 through trans-signalling, 
whereby soluble IL-6R binds IL-6 and can then activate signalling in any cell expressing gp130, 
which is constitutively expressed by the epithelium (Scheller et al., 2011). We therefore also 
confirmed that in our system, mouse small intestinal organoids show ubiquitous expression 
of the gp130 protein (Figure 3.7). The localisation of the gp130 protein was observed on the 
basal membrane of small intestinal organoids, as well as the baso-lateral membrane in all 
cells of the small intestinal organoids (Figure 3.7A). Expression of gp130 was observed on 
Lysozyme positive cells, on the basolateral membrane and in the intracellular space (Figure 
3.7B, yellow arrows). 
 
 
Figure 3.7. Gp130 is ubiquitously expressed by small intestinal organoids. 
(A) Representative confocal image showing gp130 (green) expression in small intestinal 
organoids, nuclei (DAPI-blue), image representative of a single focal plane. (B) 
Representative confocal image showing gp130 (green) expression in Lysozyme (red) positive 
cells of small intestinal organoids. Images were taken across consecutive z-planes of 1μm 
thick. Confocal imaging data is representative of N>3 independent experiments, n≥20. Scale 
bar 10µm. 
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The ability to modulate the IL-6 STAT3 signalling axis in mouse small intestinal organoids 
utilising an IL-6 receptor blocking antibody or IL-6 neutralising antibody in in vitro culture is 
demonstrated in Figures 3.8 and 3.9. Day 1 mouse small intestinal organoids were pre-
incubated with an IL-6 receptor blocking antibody or IgG control before stimulation with IL-
6 and subsequent immunofluorescence labelling of pSTAT3 (as described in Section 2.3.4). 
As observed previously, stimulation of organoids with IL-6 (in the presence of IgG control), 
induced pSTAT3 activation in UEA-1 positive cells (Figure 3.8A). Treatment of organoids with 
an IL-6 receptor blocking antibody and IL-6 abrogated the IL-6-induced pSTAT3 activation in 
UEA-1 positive cells (Figure 3.8A). Semi-quantitative analysis of pSTAT3 fluorescence 
intensity in the nuclei of UEA-1 positive cells (described in detail in Section 2.8.1, Figure 2.9) 
demonstrated that treatment of organoids with an IL-6 receptor blocking antibody (100µM) 
and IL-6 (1000ng/ml) significantly reduced pSTAT3 fluorescence in Paneth cells compared to 
IgG plus IL-6 (Figure 3.8B). This suggests that a concentration of 100µM IL-6 receptor blocking 
antibody is sufficient to inhibit IL-6 induced activation of pSTAT3 in vitro. A similar 
experimental approach was taken utilising the IL-6 neutralising antibody, whereby media 
containing IL-6 was pre-incubated with an IL-6 neutralising antibody or IgG control before 
addition to Day 1 mouse small intestinal organoids and subsequent immunofluorescent 
labelling of pSTAT3 and UEA-1. When organoids were stimulated with media containing IL-6 
pre-incubated with an IL-6 neutralising antibody, the IL-6-induced pSTAT3 activation in UEA-
1 positive cells was abrogated (Figure 3.9A). Semi-quantitative analysis of pSTAT3 
fluorescence intensity in the nuclei of UEA-1 positive cells showed a significant reduction in 
pSTAT3 intensity following treatment with an IL-6 neutralising antibody (100µM) with IL-6 
(1000ng/ml) compared to IgG plus IL-6 (Figure 3.9B).  Similarly, this suggests that 100µM IL-
6 neutralising antibody is sufficient to inhibit STAT3 activation in vitro. 
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Figure 3.8. Blocking the IL-6 receptor abrogates IL-6-induced pSTAT3 activation in Paneth 
cells. 
(A) Representative confocal images showing abrogation of IL-6 induced pSTAT3 (green) 
labelling in the nucleus (DAPI-red) of UEA-1 (pink) positive cells in organoids treated with an 
IL-6 receptor blocking antibody compared to IL-6 + IgG treated organoids. Red (top) and 
white (bottom) arrows denote lack of pSTAT3; yellow (top) and green (bottom) arrows 
denote pSTAT3 labelling. (B) Histogram showing a significant reduction in IL-6 (1000ng/ml) 
induced pSTAT3 fluorescence intensity (a.u.) in organoids treated with an IL-6 receptor 
blocking antibody (100µM) compared to IgG+IL-6 treated organoids. Fluorescence intensity 
was normalised to control (N=2, n≥32, ***P<0.001). Scale bars 10µm.  
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Figure 3.9. Neutralising IL-6 abrogates IL-6-induced pSTAT3 activation in Paneth cells. 
(A) Representative confocal images showing abrogation of IL-6 induced pSTAT3 (green) 
labelling in the nucleus (DAPI-red) of UEA-1 (pink) positive cells in organoids treated with an 
IL-6 neutralising antibody compared to IL-6 + IgG treated organoids. Red (top) and white 
(bottom) arrows denote lack of pSTAT3; yellow (top) and green (bottom) arrows denote 
pSTAT3 labelling. (B) Histogram showing a significant reduction in IL-6 (1000ng/ml) induced 
pSTAT3 fluorescence intensity (a.u.) in organoids treated with an IL-6 neutralising antibody 
(100µM) compared to IgG+IL-6 treated organoids. Fluorescence intensity was normalised to 
control (N=2, n≥44, ***P<0.001). Scale bars 10µm.  
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3.2.3 Autocrine IL-6 signalling in the small intestinal epithelium modulates crypt 
cell proliferation in vitro 
In order to determine whether autocrine IL-6 signalling played a role in crypt homeostasis, 
the expression of IL-6 mRNA and protein in small intestinal tissue was characterised. Firstly, 
conventional PCR was utilised to demonstrate the expression of IL-6 mRNA in small intestinal 
organoids in vivo in freshly isolated (0h) and in in vitro cultured small intestinal organoids 
(48h) (Figure 3.10A). Using Immunofluorescent labelling of the IL-6 protein, it was 
demonstrated that IL-6, was localised inside epithelial cells towards the basal pole of cells, 
and in extracellular discrete pools surrounding the basal membrane of organoids (see white 
arrows, (Figure 3.10B). When autocrine IL-6 signalling was blocked using an IL-6 receptor 
blocking antibody (Figure 3.10C) or an IL-6 neutralising antibody (Figure 3.10D), a significant 
decrease in the percentage of crypt nuclei incorporating BrdU was observed compared to 
the respective IgG control antibodies.  
The ability of these antibodies to functionally block IL-6 signalling in small intestinal 
organoids was assessed by incubating organoids with either the IL-6 receptor blocking 
antibody or the IL-6 neutralising antibody in combination with IL-6. In these experiments, a 
significant reduction in the percentage of organoid nuclei incorporating BrdU was observed 
in organoids treated with either the IL-6 receptor blocking antibody plus IL-6 or the IL-6 
neutralising antibody plus IL-6, compared to the respective IgG control plus IL-6 (Figure 3.11A 
and 3.11B respectively).  
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Figure 3.10. IL-6 signalling regulates small intestinal organoid proliferation. 
(A) PCR gel showing IL-6 transcript expression in in vivo / freshly isolated (0 h) and cultured 
(48 h) small intestinal crypts; PCR results obtained AG (B) Representative confocal image 
showing immunofluorescent labelling of IL-6 (red), nuclei (DAPI-blue) of small intestinal 
organoids and associated projection image in vitro. White arrows indicate extracellular pools 
of IL-6.  Scale bar 10 µm.  (C) Histogram showing percentage BrdU positive nuclei in mouse 
small intestinal organoids in the presence of an IL-6 receptor blocking antibody (100µM, N=3, 
n≥152, **P<0.01) and (D) an IL-6 neutralising antibody (100µM, N=3, n≥157, ***P<0.001) 
compared to respective IgG control.  
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Figure 3.11. IL-6 receptor blocking or IL-6 neutralising antibodies abrogate the IL-6-induced 
increase in organoid proliferation. 
Histograms showing percentage positive BrdU nuclei in mouse small intestinal organoids in 
the presence of IL-6 (100ng/ml) with (A) an IL-6 receptor blocking antibody, or (B) an IL-6 
neutralising antibody (100µM, N=3, n≥83, **P<0.01). 
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3.2.4 Lack of gut phenotype in IL6KO mice 
In order to understand the effects of perturbation of the IL-6 signalling pathway in vivo, small 
intestinal tissue was obtained from IL-6KO mice. No difference was observed in the average 
crypt length, the number of nuclei per crypt or the number of lysozyme positive cells per 
crypt in IL-6KO tissue compared to WT tissue (Figure 3.12). Next, the level of pSTAT3 
expressed within the small intestinal epithelium was determined using immunolabelling. 
Representative confocal images of low level pSTAT3 expression in UEA-1 positive cells in WT 
and IL-6KO tissue are shown in Figure 3.13A, high levels of expression was seen in a small 
population of crypts (Figure 3.13B). Zoomed projections of low and high pSTAT3 labelling are 
displayed in Figure 3.13C. The specificity of the pSTAT3 antibody labelling was confirmed 
using a blocking peptide to pSTAT3 which abrogated the pSTAT3 signal in UEA-1 positive cells 
(Figure 3.13D). Quantitative analysis of the number of UEA-1 cells expressing pSTAT3 at the 
base of small intestinal crypts in vivo revealed no difference in the number of UEA-1 positive 
cells expressing pSTAT3 in IL-6KO tissue compared to WT (Figure 3.1E). As the levels of 
pSTAT3 expression observed by the epithelium was generally low, the level of pSTAT3 
fluorescence was categorised into none, low, medium and high expression, with the aim of 
detecting subtle differences between IL-6KO tissue and control. Semi-quantitative analysis 
of pSTAT3 fluorescence intensity confirmed that expression of pSTAT3 in UEA-1 positive cells 
at the base of crypts was generally low, with a small percentage of cells expressing high levels 
of pSTAT3. No differences were observed between IL-6KO and control tissue (Table 3.1). 
 
Figure 3.12. Crypt morphology of IL-6KO tissue is the same as WT. 
Histogram showing (A) the average crypt length (B) the average number of crypt nuclei and 
(C) the average number of lysozyme positive cells per crypt in the small intestine of IL-6 
knockout mice and WT (N=3, n≥20)
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Figure 3.13. Levels of pSTAT3 activation in IL-6KO tissue is the same as WT. 
Representative confocal images of in vivo WT and IL-6KO small intestine: (A) Representative 
confocal images demonstrating low level pSTAT3 (green) labelling in UEA-1 (pink) positive 
cells of both WT and IL-6 KO mice.  Images are projections of several focal planes formed 
using image analysis software; (B) Representative confocal image of high pSTAT3 (green) 
fluorescent labelling observed in the mouse small intestine. (C) Representative confocal 
images of low pSTAT3 (green, LEFT from (A)), and high pSTAT3 (green, RIGHT from (B)) 
labelling in WT small intestine; brightness and contrast have been increased on images, white 
dashed region denotes nuclei. (D) A blocking peptide (BP) to pSTAT3 pre-incubated with the 
pSTAT3 antibody abrogated the pSTAT3 labelling in the nucleus of UEA-1 (pink) positive cells 
compared to tissue treated with pSTAT3 (green) alone.  No nuclear labelling was observed 
utilizing the secondary antibody (20Ab) alone; Scale bar 10µm. (E) Histogram showing the 
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average number of pSTAT3 positive Paneth cells per crypt in WT compared to IL6KO (N=3, 
n≥136). Confocal imaging data is representative of N=3 independent experiments.  
 
Table 3.1. Level of pSTAT3 activation was the same in IL-6KO tissue and WT. 
The percentage of UEA-1 positive cells at the base of small intestinal crypts in vivo expressing 
No, Weak (+), medium (++) and high (+++) pSTAT3 activation in IL-6KO and WT tissue (N=3, 
n≥136). Images were captured using the same acquisition settings, fluorescence intensity of 
pSTAT3 was assessed and assigned 0, +, ++ or +++.  
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3.2.5 IL-6 signalling modulates Lgr5EGFP stem cell number in vitro and in vivo 
Intestinal stem cells drive the renewal of the intestinal epithelium; therefore, the effects of 
modifying the IL-6 signalling axis on crypt stem cells both in vitro and in vivo were 
investigated. Following 17h stimulation with IL-6,  a significant increase in the percentage of 
Lgr5EGFP stem cells (Figure 3.14A) and the number of new buds formed per organoid (Figure 
3.14B), another indicator of stem cell number, was observed in vitro. Blocking IL-6 classical 
signalling by treatment of organoids with an IL-6 receptor blocking antibody in vitro also 
significantly reduced the number of new buds formed per organoid compared to IgG control 
(Figure 3.14C). No significant difference was observed in the number of new buds formed 
per organoid following treatment with an IL-6 neutralising antibody compared to IgG control 
(Figure 3.14D). 
In order to investigate the effects of perturbation of the IL-6 signalling pathway on stem cell 
number in vivo, an in vivo antibody approach was undertaken, whereby Lgr5EGFP mice were 
injected intraperitoneally with either an IL-6 receptor blocking or IL-6 neutralising antibody 
(or respective IgG control) over a period of 5 days (as described in detail in Section 2.3.1). 
Treatment of Lgr5EGFP mice with the IL-6 receptor blocking antibody induced a significant 
reduction in the number of Lgr5EGFP stem cells per crypt, the number of crypt nuclei, crypt 
length and villus height compared to IgG treated mice (Figure 3.15A-E respectively). Similar 
findings were observed when mice were treated with an IL-6 neutralising antibody, where a 
significant reduction in the number of Lgr5EGFP stem cells per crypt, the number of crypt 
nuclei and villus height were observed compared to IgG control (Figure 3.16A-C and F). No 
significant difference in the crypt length was observed in IL6 neutralising antibody treated 
mice compared to IgG control (Figure 3.16D).  
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Figure 3.14. IL-6 signalling modulates Lgr5EGFP stem cell number in vitro. 
(A) Histogram showing the effect of IL-6 (100 ng/ml) treatment on the percentage of 
Lgr5EGFP positive cells per crypt organoid compared to control (N=3, n≥30, ***P<0.001).  (B) 
Histogram showing the average number of buds per crypt organoid following treatment with 
IL-6 (100 ng/ml) (N=3, n≥30, ***P<0.001) or STATTIC (20 µM).  (C) Histogram showing the 
average number of buds per organoid in vitro when cultured in the presence of an IL-6 
receptor blocking antibody (100µM, N=3, n≥152, ***P<0.001) compared to IgG control. (D) 
Histogram showing the average number of buds per organoid in vitro when cultured in the 
presence of an IL-6 neutralising antibody (100µM, N=5, n≥271, ns) compared to IgG control.  
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Figure 3.15. Perturbing IL-6 signalling using an IL-6 receptor blocking antibody decreases 
Lgr5EGFP stem cells in vivo. 
(A) Representative confocal images showing a decrease in Lgr5EGFP (green) stem cells in 
small intestinal crypts following treatment with IL-6 receptor blocking antibody or IgG 
control, scale bar 10µm. (B) Histogram showing the average number of Lgr5EGFP positive 
stem cells per crypt (C) the average number of nuclei per crypt, (D) the crypt length and (E) 
the villus height in the small intestine of mice treated with a IL-6 receptor blocking antibody 
compared to respective IgG controls (N=3, n≥83, ***P<0.001; **P<0.01). Based on a single 
optical section on the equatorial plane along crypt-axis. 
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Figure 3.16. Perturbing IL-6 signalling using an IL-6 neutralising antibody decreases 
Lgr5EGFP stem cells in vivo. 
(A) Representative confocal images showing a decrease in Lgr5EGFP (green) stem cells in 
small intestinal crypts following treatment with IL-6 neutralising antibody or IgG control, 
scale bar 10µm. (B) Histogram showing the average number of Lgr5EGFP positive stem cells 
per crypt (C) the average number of nuclei per crypt, (D) the crypt length and (E) the villus 
height in the small intestine of mice treated with a IL-6 neutralising antibody compared to 
respective IgG controls (N=3, n≥108, ***P<0.001; **P<0.01). Based on a single optical 
section on the equatorial plane along crypt-axis. 
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3.2.6 Perturbation of the IL-6 signalling axis modulates Paneth cell number in 
vivo 
Paneth cells have previously been shown to be required for the maintenance of the stem cell 
niche (Sato et al., 2011), therefore the number of Paneth cells per small intestinal crypt 
following treatment with an IL-6 receptor blocking or IL-6 neutralising antibody was 
compared to IgG treated tissue. Use of the IL-6 receptor blocking antibody significantly 
reduced the number of in Lysozyme and UEA-1 positive cells per crypt compared to control 
(Figure 3.17A-C). Similarly, treatment of organoids with a neutralising antibody to IL-6 also 
significantly decreased the number of Lysozyme and UEA-1 positive cells per crypt compared 
to IgG control (Figure 3.17D-F). In order to determine whether cell death and proliferation 
was affected following antibody treatment, Immunofluorescent labelling of caspase-3, a 
marker of apoptosis, or Ki67, a marker of proliferation, was undertaken. A similar level of 
caspase-3 labelling was observed in both antibody treated mice compared to the respective 
IgG controls, whereby very low levels of caspase-3 were observed in in vivo crypts and villi. 
Explant sections cultured in conditions previously described to induce apoptosis (Sobolewski 
lab, unpublished) were utilised as a positive control for caspase-3 labelling (Figure 3.18A). A 
similar level of Ki67 labelling, was observed in the transit amplifying region of small intestinal 
crypts in vivo in antibody treated mice compared to the respective IgG controls (Figure 
3.18B). This indicates that cell proliferation and apoptosis is not affected in antibody 
compared to IgG treated mice as has previously been described using IL-6/IL-6R knockout 
mice (Kuhn et al., 2014). 
The decrease in Paneth cell number following in vivo treatment with IL-6 neutralising or IL-6 
receptor blocking antibody, and data demonstrating that Paneth cells are the site of pSTAT3 
activation in vitro begs the question of whether the pSTAT3 signal is abrogated in tissue 
obtained from mice treated with IL-6 receptor blocking or IL-6 neutralising antibody in vivo. 
Therefore, the level of pSTAT3 activation in antibody treated mice compared to IgG controls 
was determined. In one IgG control mouse, pSTAT3 was consistently detected in the nuclei 
of lysozyme positive cells (Figure 3.19A LEFT). However, pSTAT3 was below the levels of 
detection when the fluorescent labelling of pSTAT3 was repeated in two additional IgG 
treated mice. No pSTAT3 was detected in the nuclei of lysozyme cells from mice treated with 
an IL-6 receptor blocking antibody or an IL-6 neutralising antibody (Figure 3.19A 
MID/RIGHT). No pSTAT3 labelling was observed in the nuclei of Lgr5EGFP stem cells (Figure 
3.19B).
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Figure 3.17. IL-6 alters Paneth cell status in vivo. 
(A) Representative confocal images showing a reduction in Lysozyme (red) and UEA-1 (green) 
positive cells in small intestinal crypts following treatment with an IL-6 receptor blocking 
antibody compared to IgG control, nuclei (DAPI-blue). Scale bars 10µm. Histograms showing 
the average number of Lysozyme (B) and UEA-1 (C) positive cells per crypt following 
treatment with an IL-6 receptor blocking antibody and IgG control (N=3, n≥75, *P<0.05, 
***P<0.001). (D) Representative confocal images showing a reduction in Lysozyme (red) and 
UEA-1 (green) positive cells in small intestinal crypts following treatment with an IL-6 
neutralising antibody compared to IgG control, (DAPI-blue), scale bar 10µm. Histograms 
showing the average number of Lysozyme (E) and UEA-1 (F) positive cells per crypt following 
treatment with an IL-6 neutralising antibody and IgG control (N=3, n≥106, *P<0.05, 
***P<0.001). 
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Figure 3.18. Perturbation of the IL-6 signalling axis does not induce cell death in small 
intestinal tissue. 
(A) Representative confocal images of caspase-3 (red) labelling in small intestine crypts 
following treatment with an IL-6 receptor blocking antibody or IL-6 neutralising antibody 
compared IgG control, nuclei (DAPI-blue). (+ve indicates positive control for caspase-3 
antibody) (B) Representative confocal images of Ki67 (green) positive nuclei (DAPI-red) in 
small intestinal crypts from mice treated with the IL-6 receptor blocking antibody or IL-6 
neutralising antibody compared to IgG control, E-cadherin (blue). Confocal imaging data is 
representative of N=3 independent experiments, n≥30. Scale bars 10µm 
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Figure 3.19. Low levels of pSTAT3 activation are observed in vivo, no pSTAT3 was 
detectable following in vivo treatment with an IL-6 receptor blocking antibody or IL-6 
neutralising antibody. 
(A) Representative confocal image of pSTAT3 (green) in Lysozyme (pink) positive cells in small 
intestine of mice treated with IgG (left, N=1), an IL-6 receptor blocking antibody (mid, N=3), 
or an IL-6 neutralising antibody (right, N=3), nuclei (DAPI-red). (B) Representative confocal 
image showing pSTAT3 (green) activation in Lysozyme (pink) positive cells, Lgr5EGFP (cyan), 
scale bars 10µm, images are representative of N=1, n≥20.  
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3.2.7 IL-22 modulates crypt cell proliferation and pSTAT3 activation in vitro  
A number of other factors can activate the STAT3 signalling cascade (Nagalakshmi et al., 
2004; Pickert et al., 2009; Lindemans et al., 2015). STAT3 activation following DSS-induced 
experimental colitis in mice was shown to be dependent on IL-22, rather than IL-6 (Pickert et 
al., 2009). Therefore, the effects of IL-22 on small intestinal organoid proliferation and 
pSTAT3 activation were investigated. Addition of IL-22 (100ng/ml) to small intestinal 
organoids for 1 hour induced global pSTAT3 activation in the nuclei of all cells within the 
organoids (Figure 3.20A). Furthermore, addition of 0.1, 1, 10, 100 or 1000ng/ml IL-22 to small 
intestinal organoids for 24 hours significantly increased BrdU incorporation (Figure 3.20B). 
Treatment with 10ng/ml IL-22 also showed a significant increase in the number of buds per 
small intestinal organoid (Figure 3.20C).  
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Figure 3.20. IL-22 induces global pSTAT3 activation, BrdU incorporation and budding in 
small intestinal organoids. 
(A) Representative confocal images of small intestinal organoids following 1 hour IL-22 
(100ng/ml) stimulation, showing pSTAT3 (green) Immunofluorescent labelling in the nuclei 
(DAPI-red). Scale bar 50µm. Immunofluorescent images obtained by AS (B) Histogram 
showing the percentage of BrdU positive nuclei in small intestinal organoids following 24 
hour stimulation with IL-22 (0.1-1000ng/ml) compared to control (N=3, n≥54, ***P<0.001). 
(C) Histogram showing the average number of buds per small intestinal organoid following 
24 hour IL-22 (10ng/ml) treatment (N=3, n≥54 *P<0.05). 
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3.2.8 IL-6 induces crypt cell proliferation through a WNT signalling pathway 
Paneth cells are known to be a major source of WNTs and the WNT signalling pathway is a 
major regulator of epithelial renewal (Sato et al., 2011). Therefore, the possibility of the 
effects of IL-6 on epithelial renewal/ proliferation and stem cell number acting via the WNT 
pathway were investigated. The small molecule inhibitor IWP2 inhibits porcupine, which is 
responsible for the secretion of WNT protein, therefore inhibiting WNT signal activation 
(Kadowaki et al., 1996). A concentration of 5µM IWP2 was previously shown to be sufficient 
to inhibit WNT signalling in vitro (Chen et al., 2009).  When organoids were treated with IWP2 
(5µM) and IL-6 (100ng/ml), the IL-6-induced increase in proliferation was abrogated 
compared to IL-6 treated organoids (Figure 3.21A). The average number of buds per 
organoid was also significantly decreased in IWP2 and IL-6 compared to IL-6 alone (Figure 
3.21B). However, the percentage of caspase 3 positive cells and survival of organoids when 
treated with IWP2 with and without IL-6 were comparable to control (Figure 3.21C and D). 
The effects seen on organoids following treatment with IWP2 begs the question of whether 
components of the WNT signalling pathway are expressed by the small intestine before and 
after stimulation with IL-6. Immunofluorescent labelling revealed that the expression of 
WNT3 was localised on the basal membrane of all cells within small intestinal organoids and 
was comparable in organoids treated with and without IL-6 (Figure 3.22A). Semi-quantitative 
analysis of WNT3 immunofluorescent labelling on the basal membrane of small intestinal 
crypts (as described in Section 2.8.1) showed that the level of WNT3 was unchanged in IL-6 
treated organoids compared to control in all regions of the crypt (Figure 3.22B).  
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Figure 3.21. WNT inhibition abrogates IL-6-induced proliferation and budding of small 
intestinal organoids. 
Histograms showing the effect of IWP2 (5µM) on (A) the percentage of BrdU positive crypt 
nuclei (N=3, n≥118, ***P<0.001), (B) the average number of buds per crypt organoid (N=3, 
n≥118, *P<0.05), (C) the percentage of caspase-3 positive cells per crypt and (D) the average 
organoid survival, following IL-6 (100ng/ml) stimulation. Data are represented as mean +/- 
SEM (N=3, n≥118). 
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Figure 3.22. WNT3 expression is unchanged following stimulation with IL-6. 
(A) Representative confocal images of WNT3 (green) expression in small intestinal organoids 
following stimulation with IL-6 (100ng/ml) or untreated control. Lysozyme (red), nuclei 
(DAPI-blue). Scale bar 10µm. (B) Histogram showing that fluorescence intensity along crypt-
axis (a.u.) of WNT3 is unchanged following treatment with IL-6 compared to control (N=3, 
n≥20, ns). Confocal imaging data is representative of N=3 independent experiments.  
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3.3 Discussion 
This work demonstrates a previously unrecognised role for autocrine IL-6 signalling during 
homeostasis in the small intestine (Figure 3.23).  Stimulation of organoids with IL-6 increased 
in vitro proliferation and stem cell number via the STAT3 signalling pathway. IL-6 activated 
pSTAT3 in the nuclei of Paneth cells through differential expression of the IL-6 receptor 
located on the basal membrane of Paneth cells. IL-6 was also shown to be expressed in the 
intestinal epithelium at the mRNA and protein level. Blocking the IL-6 receptor or neutralising 
IL-6 with antibodies decreased organoid proliferation and crypt budding in vitro and also 
reduced stem cell number and Paneth cell number in vivo. The IL-6-induced increase in 
proliferation and budding was abrogated with IWP2, a pan WNT inhibitor. These data suggest 
a role of autocrine IL-6 signalling and the WNT signalling pathway in the regulation of small 
intestinal homeostasis.  
 
Figure 3.23. Autocrine IL-6 induces small intestinal crypt cell proliferation. 
IL-6 induces pSTAT3 activation in Paneth cells, which express the IL-6 receptor. This induces 
small intestinal crypt cell proliferation and ISC expansion through a WNT dependent 
pathway. 
Proliferation
ISC expansion
IL-6
pSTAT3
ISC
Paneth cell
Proliferation
IL-6 Receptor
IL-6
Chapter 3. Interleukin-6 Drives Small Intestinal Epithelial Regeneration 
 
113 
 
3.3.1 Classical IL-6 signalling modulates small intestinal homeostasis via 
differential activation of pSTAT3 in Paneth cells 
These findings demonstrate that IL-6 mediates effects on organoids in vitro through the 
STAT3 pathway. Crypt cell proliferation in response to IL-6 exhibited a bell-shaped 
concentration response curve, which has previously been described (van Dam et al., 1993). 
STAT3 mediated IL-6 signalling has previously been shown to protect healthy intestinal 
epithelial cells from apoptosis in DSS-induced colitis (Grivennikov et al., 2009), and epithelial 
STAT3 signalling was shown to be key for small intestinal stem cell survival (Matthews et al., 
2011). Interestingly, inhibition of STAT3 in our system also caused a significant increase in 
the percentage of caspase-3 positive cells per crypt indicating that more cells in the crypt 
were undergoing apoptosis. However, the percentage of cells undergoing apoptosis in these 
organoids was still low (6.0% ± 0.7) compared to the overall decrease in IL-6-induced 
proliferation observed following treatment with STATTIC (26.2% ± 2.0). Notably, organoid 
survival following treatment with STATTIC in the presence or absence of IL-6 was comparable 
to control. These studies therefore indicate that the major effects of IL-6/STAT3 signalling on 
the small intestinal epithelium is the induction of proliferation. Epithelial STAT3 signalling 
has also been shown to be important for crypt regeneration during intestinal mucosal wound 
healing (Jiang et al., 2009; Pickert et al., 2009). Using full growth factor media and chronic 
STAT3 inhibition with STATTIC it was demonstrated that epithelial STAT3 was important for 
crypt regeneration even in the absence of exogenous IL-6.  
An emerging role for IL-6 in the maintenance of homeostasis is beginning to be recognised 
(Giraud et al., 2007). The finding that the IL-6 receptor is differentially expressed on Paneth 
cells, which was shown to be the site of pSTAT3 activation following IL-6 stimulation,  
suggests that IL-6 plays a role in maintaining homeostasis via the classical IL-6 signalling 
pathway. Interestingly, expression of the IL-6 receptor was also observed in the lumen of 
small intestinal organoids in culture, suggesting that the IL-6 receptor can be secreted by 
Paneth cells in order to potentially bind IL-6 and induce trans-signalling. We demonstrate 
ubiquitous labelling of gp130; in our system if soluble IL-6 receptor was binding IL-6 and 
activating signalling via gp130 we would expect to see global pSTAT3 activation in all cells of 
the crypt. Interestingly, Aden et al. (2016) observed no pSTAT3 activation in organoids 
following treatment with IL-6; however, they did observe pSTAT3 activation following 
addition of hIL-6 (hyper-IL-6, a fusion protein of IL-6 linked to sIL-6R). The approach taken by 
Aden et al. (2016) was to investigate inducible pSTAT3 utilising a western blot on protein 
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lysate; it is possible that the levels of pSTAT3, which were observed only in Paneth cells in 
this study, a relatively small proportion of cells within the organoid, are not detectable using 
this method. However, activation of trans-IL-6 signalling utilising IL-6 fused to IL-6R (hIL-6) 
induced pSTAT3 activation in all cells within the organoid expressing gp130, which is 
therefore easily detectable by Western blot (Aden et al., 2016). The findings presented by 
Aden et al. (2016) also suggest that IL-6 classical signalling is not important for the 
regenerative response to mucosal injury induced by DSS, assessed using a mouse with an IEC 
specific deletion of the IL-6R. However, the effects of IL-6 receptor deletion in intestinal 
organoid renewal were not determined (Aden et al., 2016). Therefore, it is possible that 
classical IL-6 signalling mediates STAT3 signalling and proliferation during steady state 
renewal of crypts, and following tissue injury, IL-6 trans-signalling is activated in order to 
induce epithelial repair.  
We also detected pSTAT3 fluorescence significantly above baseline occasionally in 
unstimulated organoids. However, following treatment with IL-6, activation of pSTAT3 was 
observed in all UEA-1 positive Paneth cells at the base of organoids. This suggests that the 
STAT3 signalling pathway is activated transiently and dynamically during homeostasis and 
that this signalling is synchronised to occur simultaneously across all crypts in artificial 
experimental conditions. In order to enable spatial and temporal visualisation of gene 
expression, bacterial artificial chromosome (BAC) technology has recently been developed 
(Schwank et al., 2013). In the future, we hope to apply BAC technology to our small intestinal 
organoid culture, in order to add a fluorescent probe to pSTAT3. Transfection of fluorescently 
tagged pSTAT3 gene into organoid culture would allow visualisation of the spatial and 
temporal dynamics of pSTAT3 activation in real time during steady state renewal and in 
response to cytokine addition. 
Several publications have eluded to the fact that the intestinal epithelium expresses IL-6 
(Drastich et al., 2011), however the location of IL-6 expression in organoids has not yet been 
characterised. In this study, initial findings suggested that both freshly isolated (in vivo) and 
cultured (in vitro) small intestinal organoids express mRNA and IL-6 protein. The location of 
the IL-6 protein was restricted to the basal membrane at the base of small intestinal 
organoids, and in discrete pools in the surrounding matrix. Interestingly, Farin et al. (2016) 
recently confirmed that WNTs are tethered to the membrane of Paneth cells residing at the 
base of intestinal crypts, where they deliver WNT ligand to adjacent stem cells (Farin et al., 
2016). In this chapter, we show for the first time that IL-6 acts through the WNT signalling 
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pathway in order to modulate intestinal crypt cell proliferation. Further studies are required 
to fully elucidate the functional effects of this interaction. 
We were not able to detect IL-6 in the conditioned media from organoid culture using a 
commercially available ELISA (data not shown); we speculate that this is due to the low 
amount of secreted IL-6 from 20-50 organoids into a volume of 120µl volume of matrigel and 
media. We also noted that the IL-6 was located in pools close to the basal pole of the crypts 
but not at sites where there were no crypts present. Previous groups demonstrating 
detectable levels of IL-6 in culture supernatants using ELISA were using large tissue samples 
(Coeffier et al., 2002; Drastich et al., 2011) or high numbers of cells (Parikh et al., 1997). In 
order to detect secreted IL-6 in the culture supernatant, it could be speculated that high 
numbers of organoids would be required in a smaller volume of media. It is also likely that 
there would be high levels of contaminating factors in the culture supernatants and 
therefore the IL-6 protein secreted would need to be concentrated in order to detect using 
an ELISA. The detection of low levels of protein is now more easily investigated using mass 
spectroscopy, which may be a more relevant technique to detect secreted IL-6 protein in our 
system.  
3.3.2 IL-6 signalling modulates stem cell and Paneth cell number in vivo 
Perturbation of the IL-6 signalling axis utilising IL-6 or IL-6 receptor knockout mice has 
previously described a role for IL-6 in inflammation rather than homeostasis (Grivennikov et 
al., 2009; Jin et al., 2010; Lee et al., 2012; Kuhn et al., 2014). In line with previous studies, we 
show that small intestinal tissue obtained from IL-6KO mice was similar to tissue obtained 
from wild type mice. However, in this study we also used a blocking/ neutralising antibody 
approach to demonstrate a previously unrecognised role for autocrine IL-6 signalling in the 
maintenance of stem cell and Paneth cell number in vivo. It is possible that the lack of gut 
phenotype observed in IL-6KO mice may be explained by redundancy effects known to occur 
in knockout mouse models, and highlights the importance of interrogating this pathway 
using a variety of methods, as has been shown in other studies (Sommer et al., 2014). Future 
studies aim to use genetic manipulation techniques, such as Cre-recombinase-inducible 
retroviral vectors or CRISPR/Cas9, to induce a loss-of-function of IL-6/IL-6R in organoids and 
investigate whether redundancy mechanisms are in place (Koo et al., 2011; Driehuis and 
Clevers, 2017). The transient nature of IL-6/STAT3 signalling was demonstrated in this 
system, as activation of pSTAT3 in Paneth cells was observed consistently in one IgG treated 
mouse, but levels of pSTAT3 activation were below the limits of detection in two further IgG 
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treated mice. Further experiments are required in order to fully determine the effects of 
perturbation of the IL-6 signalling pathway on pSTAT3 activation in vivo.  
3.3.3 STAT3 activation by IL-22 
The STAT3 signalling pathway is also activated by a number other cytokines including IL-22 
(Nagalakshmi et al., 2004; Lindemans et al., 2015). Indeed, STAT3 activation following DSS-
induced experimental colitis in mice was shown to be dependent on IL-22, rather than IL-6 
(Pickert et al., 2009). We concur with Lindemans et al. (2015) and demonstrate that IL-22 
induces an increase in proliferation in both small intestine and colonic organoids. The 
expression of the IL-22 receptor has been shown to be widely distributed, on enterocytes in 
the transit amplifying progenitor crypt region as well as on intestinal stem cells at the base 
of crypts (Lindemans et al., 2015), in contrast to the restricted expression of the IL-6 receptor 
exclusively by Paneth cells. Interestingly, addition of IL-22 to small intestinal organoids 
induced global activation of pSTAT3 in all nuclei within intestinal organoids. Similar labelling 
was previously observed in dysplastic epithelial cells, which also exhibit global nuclei pSTAT3 
labelling, which was associated with increased levels of soluble IL-6 receptor suggesting that 
IL-6 trans-signalling induces widespread pSTAT3 activation in cancer (Becker et al., 2004). 
The relative contribution of different cytokines in regulating the STAT3 pathway in gut 
homeostasis and inflammation, in the small and large intestine remains the focus of future 
work.  
3.3.4 IL-6 induces crypt proliferation through a WNT dependent signalling 
pathway 
WNT signalling is the master regulator of intestinal tissue renewal. We demonstrate that 
changes in organoid proliferation and budding following IL-6 stimulation are abrogated by 
treatment with a WNT inhibitor, IWP2. This indicates that these effects are dependent on 
the WNT signalling pathway, activation of which is required for the maintenance of the stem 
cell niche (Sato et al., 2011). To our knowledge this is the first time that the mechanism of IL-
6-mediated intestinal stem cell proliferation has been shown to be through the WNT 
signalling pathway. Previously, IL-6 has been shown to upregulate WNT5A signalling through 
non-canonical WNT signalling mediator ROR2 in human adipose tissue-derived mesenchymal 
stem cells to induce calcification through a STAT3-dependent pathway (Fukuyo et al., 2014). 
Similarly, in malignant melanoma IL-6 was shown to upregulate WNT5A and induce 
melanoma cell migration and invasion (Linnskog et al., 2014). In these studies, an IL-6/sIL-6R 
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complex was utilised in order to activate IL-6 trans-signalling which induced non-canonical 
WNT signalling to drive inflammation and cancer. Interestingly, WNT5A has also previously 
been shown to play a major role in crypt regeneration in order to re-establish intestinal 
homeostasis in response to intestinal tissue injury, through the activation of TGF-β (Miyoshi 
et al., 2012).  A role for IL-6 in the negative regulation of canonical WNT signalling in primary 
human synovial fibroblasts and osteoclasts has previously been described. Osteogenic WNT 
signalling is important for joint remodelling and therefore IL-6 is thought to play a role in the 
pathogenesis and progression of osteoporosis (Malysheva et al., 2016). In this system, we 
speculate that IL-6 classical signalling is required to maintain homeostasis, therefore it is 
possible that an association with a different WNT, and possibly a different branch of pathway 
(i.e. canonical/non-canonical PCP/non-canonical calcium) can be activated by IL-6 during 
homeostasis compared to inflammation.  
Previous studies have identified that the most predominant WNT in the intestinal epithelium, 
WNT3 is expressed by Paneth cells at the base of intestinal crypts. WNT3 is tethered to the 
membrane of Paneth cells by Frizzled receptors, and delivered to adjacent Lgr5+ stem cells. 
Following cell division, WNT ligand is distributed to daughter cells where the signal is diluted 
(Farin et al., 2016). In agreement with these studies, the expression of WNT3 was restricted 
to the basal membrane of intestinal crypts, with more WNT3 present at the base of crypts 
compared to mid and top. We speculated that WNT3 expression may be altered in IL-6 
treated tissue, however the expression of WNT3 was comparable in IL-6 treated organoids 
compared to control. Future work aims to identify whether IL-6 mediates intestinal stem cell 
driven renewal through canonical or non-canonical WNT signalling, and to identify which 
WNT signalling pathway components are modulated by IL-6 stimulation of organoids.  
3.3.5 Modulation of the IL-6 signalling pathway for treatment of diseases 
Although Paneth cells are not an absolute requirement for cell survival, proliferation and 
stem cell activity (Durand et al., 2012; Kim et al., 2012), previous work has shown that they 
provide important regenerative factors for modulation of the stem cell niche (Sato et al., 
2011; Farin et al., 2016). This study has identified a novel role for IL-6 signalling in regulating 
Paneth cell number in vivo. Paneth cell metaplasia in the colon is a feature of IBD (Tanaka et 
al., 2001; Simmonds et al., 2014), in addition to elevated levels of IL-6 in the serum and 
tissues (Mudter and Neurath, 2007; Waldner and Neurath, 2014). We therefore speculate 
that alterations in the IL-6 signalling axis may be a contributing factor to this phenotype.  
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In the clinic, patients with rheumatoid arthritis have been treated with the IL-6 antibody 
tocilizumab have shown severe adverse side effects including perforation of the lower bowel 
(Emery et al., 2008; Gout et al., 2011), however the mechanism through which this occurs is 
unknown. Current antibody treatments do not distinguish between IL-6 classic and IL-6 trans 
signalling. It is therefore possible that side effects observed following IL-6 antibody 
treatment are due to inhibition of classic IL-6 signalling which is important for the 
maintenance of homeostasis. Pro-inflammatory responses from IL-6 signalling have 
previously been associated with IL-6 trans signalling (Rose-John, 2012); IL-6 trans signalling 
was shown to play a major role in the development of colitis-associated premalignant cancer 
in murine models (Matsumoto et al., 2010). More targeted treatments for inflammatory 
disorders that retain classic IL-6 signalling and therefore homeostatic crypt renewal, but 
inhibit trans IL-6 signalling through specific cell types appears to be the ideal scenario for the 
future (Schaper and Rose-John, 2015). 
 
3.4 Conclusions 
The results discussed in this chapter demonstrate a previously unrecognised role for IL-6 
signalling in the maintenance of small intestinal homeostasis. Understanding the 
mechanisms behind IL-6 modulation of intestinal renewal is vital for the potential 
interrogation of this pathway for the treatments of diseases. Indeed, the possibility of 
inhibiting IL-6 trans-signalling, whilst retaining the IL-6 classical signalling required for 
homeostasis could hold promise for the future development of treatments for IBD and 
cancer.  
 
 
Similarly to IL-6, another factor with a diverse range of functions which has also been linked 
to inflammatory diseases and cancer is Prostaglandin-E2. However, the enzyme responsible 
for PGE2 synthesis is constitutively present in the gastrointestinal tract during health, and 
PGE2 has many roles associated with homeostasis including fluid secretion, renewal and the 
amelioration of inflammation. This highlights the need for investigation into the roles of PGE2 
in intestinal homeostasis. The next chapter investigates the pathway through which PGE2 
exerts effects on intestinal renewal.  
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4 Chapter 4. PGE2 regulates proliferation of the colonic 
epithelium 
4.1 Introduction 
Prostaglandin-E2 is an endogenous signalling molecule with a diverse range of functions in 
health and disease. High levels of PGE2 have been associated with exacerbation of the 
inflammatory response, disrupted barrier function and promotion of tumour growth (Wang 
and Dubois, 2006). A role for PGE2 in the maintenance of tissue renewal and repair following 
injury is beginning to be recognised, however the mechanism through which intestinal 
homeostasis is maintained by PGE2 signalling is not yet fully understood.  
PGE2 is synthesised via the arachidonic acid pathway by COX enzymes (Smith et al., 2000). 
PGE2 mediates actions by binding to one of four G-protein-coupled receptors EP1-4, which 
have distinct signalling transduction pathways. EP1 receptor activation is coupled to 
intracellular calcium mobilisation through Gαq; EP2 and EP4 receptors are coupled to 
adenylate cyclase stimulation via Gs; and EP3 receptor is coupled to activation of adenylate 
cyclase through Gαs and inhibition of adenylate cyclase and intracellular calcium mobilisation 
through Gi. The generation of mouse models deficient in each EP receptor subtype, and the 
development of EP receptor selective agonists and antagonists provides a valuable tool to 
investigate the physiological role of each EP receptor subtype. 
Prostaglandin-E2 has been shown to play a homeostatic role in the crypt regenerative 
response following intestinal injury induced by DSS or biopsy wounding. Following DSS-
induced epithelial injury, innate sensing of microbes by myofibroblasts residing in the 
intestinal lamina propria induced the expression of COX-2, which synthesises PGE2 and 
induced a compensatory proliferation response in intestinal crypts through activation of the 
EP4 receptor subtype (Roulis et al., 2014). In a model of biopsy-induced mucosal wounding 
in mice that were deficient in the EP4 receptor subtype, multiple deficiencies in tissue repair 
including incomplete wound covering with wound associated epithelial (WAE) cells were 
observed (Manieri et al., 2012; Manieri et al., 2015). WAE cell differentiation was shown to 
be induced by EP4 receptor expression in mesenchymal cells in the lamina propria induced 
WAE cell differentiation (Manieri et al., 2012), later shown to be mediated through direct 
inhibition of GSK3β and nuclear β-catenin activation (Miyoshi et al., 2017).  
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PGE2 signalling through the EP1, EP2 and EP3 receptor subtypes have also been shown to 
induce epithelial regeneration in DSS-induced colitis. Induction of Ca2+ response in the rat 
ileum using Oxytocin (OT) ameliorated inflammation through a COX-2-dependent release of 
PGE2 release (Chen et al., 2015). This response was inhibited following inhibition of the EP1, 
EP2 and EP3 receptors with the selective PGE2 antagonist, AH6809, (Abramovitz et al., 2000), 
suggesting that PGE2 activates these EP receptor subtypes to induce intestinal regeneration 
(Chen et al., 2015). Furthermore, PGE2 signalling through the EP4 receptor subtype has been 
described to downregulate the immune response to reduce mucosal damage and severe 
colitis (Kabashima et al., 2002). These data suggest that PGE2 plays a homeostatic role in 
crypt regeneration and amelioration of inflammation following intestinal injury. However, 
the role of PGE2 in epithelial regeneration during steady-state renewal during health remains 
to be determined.  
Increased mucosal levels of PGE2 have also been shown to induce intestinal inflammation 
through disruption of barrier function, which is associated with IBD (McGuckin et al., 2009; 
Rodriguez-Lagunas et al., 2010). PGE2 signalling was shown to increase paracellular 
permeability of Caco-2 cells through EP1 and EP4 receptor signalling (Rodriguez-Lagunas et 
al., 2010).  EP4 receptor signalling has also been implicated in inflammation in a model of 
inducible colitis in mice, where naïve T cells are transferred into mice deficient in 
recombinase-activation gene 2. Transfer of T cells deficient in the EP4 receptor subtype 
exhibited less severe colitis than transfer of wild type T cells, indicating that EP4 receptor 
signalling plays a pathogenic role in this model of colitis (Yao et al., 2013). Further studies are 
required to investigate the role of EP4 receptor signalling in health and inflammation.  
The expression of COX enzymes for PGE2 synthesis are upregulated in colorectal cancer and 
are associated with unfavourable survival (Wang and Dubois, 2010). Inhibition of COX 
enzyme activity using NSAIDs has been shown to have potent anti-tumorigenic properties in 
initial clinical studies of patients with FAP (Bresalier et al., 2005; Solomon et al., 2005; Arber 
et al., 2006; Rostom et al., 2007). NSAIDs inhibit both endogenous COX-1 and inducible COX-
2 enzymes (Wang and Dubois, 2010; Gerbe et al., 2011); therefore it is possible that side 
effects observed following NSAID treatment may be due to inhibition of endogenous PGE2 
activity required to induce tissue renewal required to maintain homeostasis. The effects of 
selective COX-1 or COX-2 inhibition on tumorigenesis or steady-state tissue renewal have not 
yet been defined.  
Chapter 4. Prostaglandin-E2 Regulates Proliferation of the Colonic Epithelium 
 
121 
 
A number of previous studies have investigated the role of differential EP receptor signalling 
in tumorigenesis. Signalling through the EP1, EP2 and EP4 receptors have been shown to 
promote intestinal polyposis and induce the growth and metastasis of tumours through the 
activation of a number of signalling pathways required for cell invasion and migration 
(reviewed in O'Callaghan and Houston (2015)).  In contrast, activation of the EP3 receptor 
has been shown to reduce tumorigenesis in vivo and cell proliferation in tumour cell lines 
(Macias-Perez et al., 2008). Whilst the roles of EP receptor subtype activation in 
tumorigenesis have been relatively well characterised, the relative contributions of EP 
receptor activation by PGE2 in maintaining colonic crypt cell proliferation during homeostasis 
remains to be elucidated.  
Recently, 15-hydroxyprostaglandin dehydrogenase (15-PGDH) has been identified as an 
enzyme which acts as a negative regulator of prostaglandin levels and activity in vivo (Myung 
et al., 2006). The healthy colonic mucosa expresses high levels of 15-PGDH, however 15-
PGDH is lost in colorectal cancers and FAP. Recent studies suggest that inhibition of 15-PGDH 
accelerates hematopoietic recovery in mice following bone marrow transplant, and 
promotes tissue regeneration in mouse models of colitis and liver injury (Zhang et al., 2015). 
The role of inhibition of 15-PGDH in colonic crypt renewal during homeostasis has not yet 
been examined.  
This chapter aims to determine the role of autocrine and paracrine PGE2 signalling in the 
maintenance of mouse colonic crypt homeostasis. The relative contribution of each of the 
EP receptor subtypes, EP1-4, in colonic crypt renewal was also investigated. This chapter 
demonstrates a previously unrecognised role for autocrine PGE2 signalling in colonic crypt 
cell proliferation, through activation of EP1 and EP3 receptor subtypes.  
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4.2 Results 
The effects of PGE2 signalling on mouse and human colonic crypts were investigated using 
the isolated colonic crypt 3D culture model. Expression of the components of the PGE2 
signalling pathway by mouse colonic crypts was characterised at the mRNA and protein level. 
A pharmacological approach was undertaken in order to inhibit or activate EP receptor 
subtypes in the colonic epithelium in vitro; the effects on crypt cell proliferation as shown by 
incorporation of EdU, cell survival and budding were determined.  
4.2.1 Characterisation of PGE2 signalling pathway components in the mouse 
colonic epithelium 
Whilst the addition of exogenous PGE2 is widely accepted to stimulate epithelial cell 
proliferation, the role of autocrine PGE2 signalling in the maintenance of colonic crypt 
homeostasis remains largely unknown. In order to determine whether the mouse colonic 
epithelium is able to synthesis autologous PGE2, the expression of COX-1 and COX-2 enzymes 
were characterised. Firstly, conventional PCR was utilised to demonstrate expression of COX-
1 and COX-2 mRNA in freshly isolated mouse colonic crypts (Figure 4.1A). 
Immunofluorescent labelling of colonic crypts in vivo utilising antibodies to COX-1 and COX-
2 demonstrated that discrete cells within colonic crypts express COX-1 and COX-2 in vivo 
(Figure 4.1B TOP). Quantitative analysis of the number of cells within colonic crypts 
expressing COX-1 and COX-2 cells in vivo revealed that the numbers of COX-1 and COX-2 
expressing cells in mouse colonic crypts were comparable (Figure 4.1B BOTTOM). Next, the 
expression of COX-1 and COX-2 enzymes was determined in our in vitro isolated crypt culture 
system. The expression of COX-1 and COX-2 enzymes in vitro in isolated mouse colonic crypts 
was similar to that observed in vivo (Figure 4.1C TOP). Furthermore, when the number of 
COX-1 and COX-2 positive cells were quantified in vitro, we observed no significant difference 
between the number of cells expressing COX-1 and COX-2 enzymes (Figure 4.1C BOTTOM) 
as observed in vivo. We therefore conclude that colonic crypts are able to synthesis PGE2 
both in vivo and in our in vitro crypt culture system.   
PGE2 is known to signal through four EP receptor subtypes; EP1, EP2, EP3 and EP4 receptors. 
Therefore, the expression of each EP receptor subtype by the mouse colonic epithelium was 
investigated. Firstly, conventional PCR was utilised to demonstrate the expression of EP1, 
EP2, EP3 and EP4 mRNA in freshly isolated mouse colonic crypts (Figure 4.2A). Three 
different splice variants have been described for the EP3 receptor subtype (Namba et al., 
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1993); we therefore confirmed expression of mRNA for EP3α, EP3β and EP3γ variants (Figure 
4.2B).   
 
Figure 4.1. The mouse colonic epithelium expresses COX enzymes for PGE2 synthesis. 
(A) PCR gel showing expression of COX-1 and COX-2 transcripts in freshly isolated colonic 
crypts. Band sizes for PCR products: COX-1=96bp, COX-2=70bp (B) Representative confocal 
images of COX-1 (red, left) and COX-2 (green, mid) expression in colonic crypts in vivo, nuclei 
(DAPI-blue). Histogram showing the number of COX-1 or COX-2 positive cells per crypt in vivo 
(right), (N≥1, n≥6). (C) Representative confocal images of COX-1 (red, left) and COX-2 (green, 
right) expression in cultured colonic crypts, nuclei (DAPI-blue). Histogram showing the 
number of COX-1 or COX-2 positive cells per crypt in in vitro culture (right) (N=3, n≥17) 
experiments, scale bar 10µm. 
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Figure 4.2. Isolated colonic crypts express mRNA for prostaglandin E2 receptor subtypes. 
(A) PCR gel showing expression of EP1-4 receptor mRNA transcripts in freshly isolated colonic 
crypts. EP2 sample loaded at an approximately 80x greater concentration relative to other 
samples to enable band visualisation. Band sizes for PCR products EP1= 165bp, EP2= 402bp 
EP3= 438bp, EP4= 351bp. (B) PCR gel showing mRNA expression of EP3 variants (,,) in 
freshly isolated colonic crypts. Band sizes for PCR products EP3= 261bp, EP3= 349bp, EP3= 
311bp. PCR gels obtained by AG.
 
We next sought to characterise the expression of EP1, EP2, EP3 and EP4 receptors within the 
different cell types of the mouse colonic epithelium both in vivo, in fresh fixed tissue sections 
(cut using a cryostat), and in in vitro cultured crypts using Immunofluorescent labelling. In 
order to visualise mucus-secreting goblet cells of the epithelium, and COX-1 expressing cells, 
an antibody to Muc-2 or COX-1 was utilised; mice were Lgr5EGFP positive for visualisation of 
stem cells.  
The EP1 receptor was shown to be expressed by Lgr5EGFP stem cells (Figure 4.3A TOP, 
yellow arrows), Muc-2 positive cells (Figure 4.3A MID, white arrows) and COX-1 expressing 
cells (Figure 4.3A BOTTOM, cyan arrows) in the mouse colonic epithelium in vivo. Similar 
expression of the EP1 receptor was observed in vitro in isolated mouse colonic crypts (Figure 
4.3B), where the EP1 receptor was expressed by Lgr5EGFP (yellow arrows, TOP), Muc-2 
positive cells (white arrows, MID) and COX-1 expressing cells (cyan, BOTTOM).  
The EP2 receptor (Figure 4.4A) was not expressed by Lgr5EGFP cells (yellow arrows, TOP), or 
COX-1 expressing cells (BOTTOM). Muc-2 positive cells (MID) express the EP2 receptor in 
vivo in the mouse colonic epithelium. When isolated mouse colonic crypts were labelled with 
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the EP2 receptor antibody (Figure 4.4B), a similar labelling pattern was observed to that seen 
in vivo, where only Muc-2 positive cells (MID) expressed the EP2 receptor.  
Expression of the EP3 receptor (Figure 4.5A) was observed in Lgr5EGFP cells (yellow arrows, 
TOP), Muc-2 positive cells (MID) and COX-1 expressing cells (BOTTOM) in vivo in the mouse 
colonic epithelium. Similarly to that observed in vivo, isolated mouse colonic crypts also 
express EP3 receptor (Figure 4.5B) in Lgr5EGFP cells (yellow arrows, TOP), Muc-2 positive 
cells (MID) and COX-1 positive cells (BOTTOM).  
The EP4 receptor (Figure 4.6A), was expressed by Lgr5EGFP (TOP) and Muc-2 expressing cells 
(MID) in vivo in the mouse colonic epithelium. No EP4 receptor expression was observed in 
COX-1 positive cells (BOTTOM) in vivo. In vitro isolated mouse colonic crypts were shown to 
express the EP4 receptor in the same cell types as that observed in vivo; EP4 was expressed 
in Lgr5EGFP (TOP) and Muc-2 positive cells (MID), but not in COX-1 expressing cells 
(BOTTOM) (Figure 4.6B). 
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Figure 4.3. Characterisation of EP1 receptor expression in the colonic epithelium. 
(A) Expression of the EP1 receptor in vivo. The EP1 receptor (red, left panel) is expressed by 
Lgr5EGFP positive cells (green, yellow arrows), Muc-2 positive cells (white, white arrows), 
and COX-1 expressing cells (cyan, cyan arrows), nuclei (DAPI-blue). (B) Expression of the EP1 
receptor in vitro. The EP1 receptor (red, left panel) is expressed by Lgr5EGFP cells (green, 
yellow arrows), Muc-2 positive cells (white, white arrows) and COX-1 expressing cells (cyan, 
cyan arrows) in vitro, nuclei (DAPI-blue). Images are representative of N=3 experiments, 
n≥15, scale bar 10μm.
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Figure 4.4. Characterisation of EP2 receptor expression in the colonic epithelium. 
(A) Expression of the EP2 receptor in vivo. The EP2 receptor (red, left panel) is not expressed 
by Lgr5EGFP positive cells (green, yellow arrows) or COX-1 positive cells (cyan, cyan arrows). 
Muc-2 positive cells (white, white arrows) express EP2 receptor (red) in vivo, nuclei (DAPI-
blue). (B) Expression of the EP2 receptor in vitro. The EP2 receptor (red, left panel) is not 
expressed by Lgr5EGFP cells (green, yellow arrows) or COX-1 positive cells (cyan, cyan 
arrows). Muc-2 positive cells (white, white arrows) express EP2 receptor in vitro, nuclei 
(DAPI-blue). Images are representative of N=3 experiments, n≥15, scale bar 10μm. 
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Figure 4.5. Characterisation of EP3 receptor expression in the colonic epithelium. 
(A) Expression of the EP3 receptor in vivo. The EP3 receptor (red, left panel) is expressed by 
Lgr5EGFP positive cells (green, yellow arrows), muc-2 positive cells (white, white arrows), 
and COX-1 expressing cells (cyan, cyan arrows), nuclei (DAPI-blue). (B) Expression of the EP3 
receptor in vitro. The EP3 receptor (red, left panel) is expressed by Lgr5EGFP cells (green, 
yellow arrows), Muc-2 positive cells (white, white arrows) and COX-1 expressing cells (cyan, 
cyan arrows) in vitro, nuclei (DAPI-blue). Images are representative of N=3 experiments, 
n≥15,  scale bar 10μm. 
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Figure 4.6. Characterisation of EP4 receptor expression in the colonic epithelium. 
(A) Expression of the EP4 receptor in vivo. The EP4 receptor (red, left panel) is expressed by 
Lgr5EGFP positive cells (green, yellow arrows) and Muc-2 positive cells (white, white arrows). 
No EP4 expression is seen in COX-1 expressing cells (cyan, cyan arrows), nuclei (DAPI-blue). 
(B) Expression of the EP4 receptor in vitro. The EP4 receptor (red, left panel) is expressed by 
Lgr5EGFP cells (green, yellow arrows) and Muc-2 positive cells (white, white arrows). No EP4 
expression is observed in COX-1 expressing cells (cyan, cyan arrows) in vitro, nuclei (DAPI-
blue). Images are representative of N=3 experiments, n≥15, scale bars 10μm. 
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A summary of EP1, EP2, EP3 and EP4 receptor expression both in vivo and in vitro is provided 
in Table 4.1.     
Table 4.1. Summary table of EP receptor expression by specific cell types in the mouse 
colonic epithelium 
Receptor 
in vivo/ 
in vitro 
Lgr5EGFP 
cells 
Muc-2 
cells 
Cox-1 
cells 
EP1 
in vivo   
in vitro   
EP2 
in vivo   
in vitro   
EP3 
in vivo   
in vitro   
EP4 
in vivo   
in vitro   
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4.2.2 Autocrine PGE2 signalling induces mouse colonic crypt cell proliferation  
The mouse colonic epithelium expresses all the components required for PGE2 signalling 
during homeostasis; however, the role of autocrine PGE2 signalling in maintaining crypt 
homeostasis has not yet been determined. Inhibition of COX enzyme activity, and therefore 
in vivo PGE2 synthesis, using NSAIDs has been shown to inhibit tumour growth and increase 
survival of colorectal cancer patients (Bresalier et al., 2005; Solomon et al., 2005; Arber et 
al., 2006; Rostom et al., 2007). However, the roles of specific COX enzyme inhibition in 
colonic crypt renewal during homeostasis remain to be investigated. In order to determine 
the effects of COX enzyme inhibition on proliferation of mouse colonic crypts, crypts were 
cultured with specific COX-1 or COX-2 inhibitors (10µM/ 20µM), or a COX-1/COX-2 inhibitor 
(10µM) for 48h, and EdU (10µM) was added for 17h on Day 1 (as described in Section 2.3.7). 
Concentrations of inhibitors were determined to minimise any non-selective inhibition and 
were the same or lower than previously utilised in the literature (Liu et al., 2010; Keysselt et 
al., 2017). A Click-IT reaction was performed on Day 2 for visualisation of EdU incorporating 
cells (as described in Section 2.5).  
Inhibition of COX-1 and COX-2 enzymes with aspirin significantly decreased EdU 
incorporation compared to control (Figure 4.7A).  To determine the effects of COX-1 enzyme 
inhibition on EdU incorporation, crypts were incubated with valeryl salicylate, a highly 
selective COX-1 inhibitor. Treatment of crypts with valeryl salicylate significantly reduced 
EdU incorporation compared to control treated crypts (Figure 4.7B). The effects of inhibition 
of the COX-2 enzyme on crypt survival, proliferation and budding were determined using the 
specific COX-2 inhibitor NS-398. NS-398 (20µM) was added to isolated crypts and survival 
over 6 days was assessed using time-lapse microscopy. A significant reduction in percentage 
organoid survival following 3 and 6 days in culture with NS-398 was observed compared to 
control (Figure 4.7C). In addition, a significant decrease in the number of nuclei incorporating 
EdU and the number of new buds formed per organoid was observed following treatment 
with NS-398 compared to control (Figure 4.7D and E respectively). 
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Figure 4.7. Cox enzyme inhibition inhibits survival, proliferation and budding of mouse 
colonic crypts. 
Histogram showing a significant decrease in percentage of EdU positive nuclei following 
treatment with aspirin (10μM) (N=3, n≥210, *P<0.05) (B) Histogram showing a significant 
decrease in EdU incorporation of colonic crypts following treatment with valeryl salicylate 
(10µM) (N=3, n≥161, **P<0.01). Treatment of colonic crypts in culture with NS-398 (20μM) 
significantly reduced: (C) organoid survival (N=3, n=381, *P<0.05), AL (D) EdU incorporation 
of mouse colonic crypt (N=3, n≥186 ***P<0.001) and (E) mean number of new buds formed 
per organoid (N=3, n=63, **<0.01), compared to control, AL. Data are represented as mean 
+/- SEM. 
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The role of autocrine PGE2 signalling in colonic crypt renewal was determined utilising a 
blocking antibody to PGE2 (Mnich et al., 1995) or IgG control. Following 2 days in culture, EdU 
was added to crypts for 17h and nuclei incorporating EdU was visualised using a Click-iT 
reaction and epifluorescent microscopy. A significant reduction in the percentage of nuclei 
incorporating EdU was observed following treatment with the blocking antibody to PGE2 
compared to IgG control (Figure 4.8).
 
Figure 4.8. PGE2 is required for mouse colonic crypt cell proliferation in vitro. 
Histogram showing the percentage of EdU positive cells per crypt following treatment with 
a blocking antibody to PGE2 (50μM) compared to IgG control (N=3, n≥133, **P<0.01).
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4.2.3 Selective activation of EP1 and EP3 receptor induces mouse colonic crypt 
renewal 
The next step was to determine the role of selective activation of EP receptor subtypes in 
mouse colonic crypt renewal; therefore, a pharmacological approach utilising selective EP 
receptor agonists and antagonists was undertaken. The concentrations of agonists and 
antagonists utilised was selected in order to minimise cross-reactivity between EP receptor 
subtypes (Funk et al., 1993; Kiriyama et al., 1997; Abramovitz et al., 2000; Juteau et al., 2001; 
Kabashima et al., 2002; Billot et al., 2003; Gil et al., 2008; Dey et al., 2009; af Forselles et al., 
2011; Birrell et al., 2013). 
Firstly, in order to determine the role of autocrine EP receptor signalling in proliferation, 
crypts were incubated for 48h with selective antagonists to inhibit activation of each EP 
receptor subtype (as described in Section 2.3.7). When crypts were treated with a selective 
antagonist to either the EP2 or EP4 receptor, no difference was observed in the number of 
new buds formed per organoid (Figure 4.9A). Furthermore, EP2 or EP4 receptor inhibition 
had no effects on the percentage of nuclei incorporating EdU (Figure 4.9B and C 
respectively). However, when crypts were treated with antagonists which preferentially 
inhibit the EP1 or EP3 receptor, a significant reduction in the percentage of nuclei 
incorporating EdU was observed following treatment with either the EP1 or EP3 receptor 
antagonist (Figure 4.10A and B respectively). 
Chapter 4. Prostaglandin-E2 Regulates Proliferation of the Colonic Epithelium 
 
135 
 
 
Figure 4.9. EP2 or EP4 receptor antagonism has no effects on organoid budding or 
proliferation of mouse colonic crypts. 
(A) Histogram showing no difference in the number of new buds formed by colonic crypts 
following treatment with an EP2 antagonist (PF04418948, 10µM) or and EP4 antagonist 
(ONO-AE3-208, 10μM), (N=3, n≥57) AL ,(B) Histogram showing no change in EdU 
incorporation of colonic crypts following treatment with an EP2 antagonist (N=5, n≥139), or 
(C) an EP4 antagonist (N=4, n≥45) AL. 
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Figure 4.10. EP1 or EP3 receptor antagonism reduces proliferation of mouse colonic crypts. 
(A) Histogram showing a significant reduction in EdU incorporation of colonic crypts 
following treatment with an EP1 antagonist (SC19220, 20µM) compared to control crypts 
(N=3, n≥144, ***P<0.001) (B) Histogram showing a significant reduction in EdU incorporation 
of colonic crypts following treatment with an EP3 antagonist (L-798106, 1μM) compared to 
control crypts (N=1, n≥26), AS.  
Next, the effects of selective activation of EP receptor subtypes on mouse colonic crypt cell 
proliferation were determined (as described in Section 2.3.7). When cultured crypts were 
incubated with a selective EP2 receptor agonist or a selective EP4 receptor agonist for 17h 
following 5h in growth factor free media, no significant difference in proliferation was 
observed compared to control treated crypts (Figure 4.11). However, treatment of organoids 
with a selective EP1 receptor agonist or selective EP3 receptor agonist significantly increased 
proliferation compared to control crypts (Figure 4.12).  
In order to determine which EP receptor subtype is responsible for the PGE2-induced 
increase in EdU incorporation, crypts were incubated in growth factor free media for 5h 
before pre-incubation with the EP1 or EP3 receptor antagonist, or control. Crypts were then 
stimulated with PGE2 with an EP1 or EP3 receptor antagonist or control for 17h in the 
presence of EdU. A significant increase in EdU incorporation was observed following 
treatment with PGE2. Pre-incubation of crypts with either an EP1 or an EP3 receptor 
antagonist before addition of PGE2 abrogated the PGE2-induced increase in EdU positive 
nuclei. A significant reduction in EdU incorporation was observed in organoids treated with 
the EP3 receptor antagonist, however no significant reduction was observed following 
treatment with the EP1 receptor antagonist utilising this experimental protocol (Figure 4.13). 
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Figure 4.11. Selective activation of EP2 or EP4 receptor has no effect on mouse crypt cell 
proliferation. 
Histograms showing no difference in proliferation when cells were treated with (A) an EP2 
receptor agonist (butaprost, 12µM, N=4, n≥175), or (B) an EP4 receptor agonist (TCS-25110, 
13μM, N=4, n≥179). 
 
Figure 4.12. Selective activation of EP1 or EP3 receptor increased mouse crypt cell 
proliferation. 
Histograms showing a significant increase in proliferation when cells were treated with (A) 
an EP1 receptor agonist (iloprost, 10µM, N=3, n≥93, ***P<0.001), or (B) an EP3 receptor 
agonist (sulprostone, 10μM, N=4, n≥192, **p<0.01).
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Figure 4.13. PGE2-induced increase in mouse colonic crypt cell proliferation is abrogated 
by an EP1 or EP3 antagonist. 
Histograms showing the percentage of EdU positive nuclei in colonic crypts following 
stimulation with PGE2 (10µM) in the presence or absence of an EP1 antagonist (SC19220, 
20µM) or an EP3 antagonist (L-798106, 20μM) and compared to control (N=5, n≥213, 
***P<0.001 compared to control, $$$P<0.001, $$P<0.01 compared to PGE2).
 
4.2.4 A role for autocrine PGE2 in human colonic crypt renewal? 
We next sought to determine whether a similar paradigm exists in the human colonic 
epithelium. Human colonic crypts were isolated from tissue samples obtained from patients 
undergoing colorectal resection at the NNUH and placed in culture in the presence or 
absence of PGE2 (1µM). On Day 2 of culture, EdU (10µM) was added to the media for 2h 
before fixation and a Click-iT reaction undertaken to determine EdU incorporation. A 
significant increase in the percentage of nuclei incorporating EdU per crypt was observed 
following treatment with PGE2 (Figure 4.14B). As described earlier, 15-PGDH is an enzyme 
expressed by the epithelium which is known to breakdown endogenous PGE2. The expression 
of 15-PGDH in isolated human colonic crypts or mucosal biopsy was determined using PCR. 
Expression of mRNA for 15-PDGH was observed in both crypts and biopsy, no expression was 
observed using a water negative control (Figure 4.14A). Recent advances have lead to the 
development of small molecular inhibitors which are able to antagonist 15-PGDH. In this 
study, we cultured human crypts with CAY10397, a 15-PGDH inhibitor, in order to determine 
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the role of autocrine PGE2 signalling in EdU incorporation of crypts. Initial results (N=1), 
suggest that when crypts were cultured with PGE2 with and without CAY10397, or CAY10397 
alone, an increase was observed in the total number of nuclei incorporating EdU per crypt 
(Figure 4.14B). When the percentage of nuclei incorporating EdU was examined in each 
region of the crypt, a greater increase in EdU incorporation was observed at the base of 
crypts following treatment with CAY10397, or CAY10397+PGE2. Treatment with PGE2 
induced the highest magnitude of increase in the percentage of nuclei incorporating EdU at 
the supra-base and mid regions of the crypts (Figure 4.14C). Further repeats of this 
experiment are required in order to determine whether the increase in proliferation 
following treatment with PGE2, with and without CAY10397, is statistically significant.  
 
Figure 4.14. Initial experiments in human colonic crypts suggest that autocrine PGE2 
mediates human colonic crypt proliferation. 
(A) PCR gel showing 15-PGDH mRNA transcript expression in isolated human colonic crypts 
or mucosal biopsy, PCR band size 15-PGDH=145bp (B) Histogram showing the total 
percentage of nuclei incorporating EdU per crypt following treatment with PGE2 (1µM), 
CAY10397 (50μM), or PGE2+CAY10397 compared to control (N=1, n≥18)). (C) Histogram 
showing the percentage of nuclei incorporating EdU at the base, supra-base, mid and top 
region of crypts following treatment with PGE2, CAY10397 or PGE2+CAY10397 compared to 
control (N=1, n≥18). 
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4.2.5 EP receptor expression is conserved across the mouse and human colonic 
epithelium 
In order to determine whether results obtained in our mouse study were comparable to 
human, the expression of EP receptor subtype in human colonic crypts was characterised. 
Immunofluorescent labelling of isolated human colonic crypts utilising antibodies for EP1-4 
receptors, Lgr5 and Muc-2 was undertaken. Similarly to the expression pattern observed in 
mouse colonic crypts, the EP1 receptor was expressed in Lgr5 positive and Muc-2 positive 
cells of human colonic crypts (yellow arrows, Figure 4.15). The expression of EP2 receptor 
remained restricted to Muc-2 positive (yellow arrows) cells of human colonic crypts (Figure 
4.16).  In addition, the EP3 receptor was expressed in both Lgr5 positive and Muc-2 positive 
cells of human colonic crypts (yellow arrows, Figure 4.17). The EP4 receptor subtype was 
expressed by Lgr5 positive cells; less intense labelling of the EP4 receptor was observed in 
Muc-2 positive cells of human colonic crypts (Figure 4.18).  
 
Figure 4.15. Stem cells and goblet cells of human colonic crypts express EP1 receptor. 
(A) Representative confocal image showing EP1 receptor (red, left panel)  expression by Lgr5 
positive cells (green), nuclei (DAPI-blue) in isolated human colonic crypts (yellow arrows). (B) 
Representative confocal image of EP1 receptor (red) in Muc-2 positive cells (green), nuclei 
(DAPI-blue) in isolated human colonic crypts (yellow arrows). Images are representative of 
N=3 experiments, n≥15, scale bar 10μm. 
Lgr5EP1 DAPI EP1 MERGE
A
B
Muc-2EP1 DAPI EP1 MERGE
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Figure 4.16. Goblet cells of human colonic crypts express EP2 receptor. 
(A) Representative confocal image showing a lack of EP2 receptor (red)  expression by Lgr5 
positive cells (green), nuclei (DAPI-blue) in isolated human colonic crypts (green arrows). (B) 
Representative confocal image of EP2 receptor (red) in Muc-2 positive cells (green), nuclei 
(DAPI-blue) in isolated human colonic crypts (yellow arrows). Images are representative of 
N=3 experiments, n≥15, scale bar 10μm.
 
Muc-2
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DAPI EP2 MERGE
DAPI EP2 MERGE
A
B
Chapter 4. Prostaglandin-E2 Regulates Proliferation of the Colonic Epithelium 
 
142 
 
 
Figure 4.17. Stem cells and goblet cells of human colonic crypts express EP3 receptor. 
(A) Representative confocal image showing EP3 receptor (red, left panel)  expression by Lgr5 
positive cells (green), nuclei (DAPI-blue) in isolated human colonic crypts (yellow arrows). (B) 
Representative confocal image of EP3 receptor (red) in Muc-2 positive cells (green), nuclei 
(DAPI-blue) in isolated human colonic crypts (yellow arrows). Images are representative of 
N=3 experiments, n≥15, scale bar 10μm. 
Muc-2
Lgr5EP3
EP3
DAPI EP3 MERGE
DAPI EP3 MERGE
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Figure 4.18. EP4 is expressed by the human colonic epithelium. 
(A) Representative confocal image showing EP4 receptor (red, left panel)  expression by Lgr5 
positive cells (green), nuclei (DAPI-blue) in isolated human colonic crypts (yellow arrows). (B) 
Representative confocal image of EP4 receptor (red) in Muc-2 positive cells (green), nuclei 
(DAPI-blue) in isolated human colonic crypts (yellow arrows). Images are representative of 
N=2 experiments, n≥15, scale bar 10μm. 
A summary table detailing conservation of EP receptor subtype expression in Lgr5 or Muc-2 
expressing cells mouse and human colonic epithelium is provided in Table 4.2.
Table 4.2. Summary table demonstrating conservation of EP receptor expression by 
specific cell types in human and mouse colonic crypts. 
Receptor 
Human/ 
Mouse 
Lgr5+ 
cells 
Muc-2 
cells 
EP1 
Human  
Mouse  
EP2 
Human low 
Mouse  
EP3 
Human  
Mouse  
EP4 
Human  
Mouse  
Muc-2
Lgr5EP4
EP4
DAPI EP4 MERGE
DAPI EP4 MERGE
A
B
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4.3 Discussion 
In this chapter, we demonstrate for the first time a role for autocrine PGE2 signalling in the 
maintenance of colonic homeostasis (Figure 4.19). The mouse colonic epithelium expresses 
COX enzymes for the synthesis of PGE2 both in vivo and in our in vitro crypt culture system. 
The receptors for PGE2, EP1, EP2, EP3 and EP4 were all shown to be expressed by the colonic 
epithelium both in vivo and in vitro. EP1 and EP3 receptors expression was observed on stem 
cells, goblet cells, and COX-1 expressing cells. Inhibition of endogenous PGE2 using a blocking 
antibody approach in vitro reduced colonic crypt cell proliferation. In addition, inhibition of 
COX-1 and/or COX-2 enzymes reduced crypt cell proliferation, budding and organoid 
survival. PGE2 induced colonic crypt cell proliferation, which was abrogated by inhibition of 
EP1 or EP3 receptor signalling using selective antagonists. These data suggest that PGE2 
signalling through the EP1/3 signalling axis is important for mouse colonic crypt homeostasis. 
 
Figure 4.19. PGE2 induces colonic crypt cell proliferation during homeostasis. 
The colonic epithelium expresses COX enzymes for PGE2 synthesis, and EP1-4 receptor 
subtypes for PGE2 signalling. EP1 and EP3 are expressed on all cell types in the colonic 
epithelium; restricted expression of EP2 is observed on goblet cells, EP4 receptor is 
expressed on all cell types with the exception of COX-1-expressing cells. Autocrine PGE2 
induced colonic crypt cell proliferation through activation of the EP1/EP3 receptor subtypes. 
 
The differential expression of Cyclooxygenase enzymes by Doublecortin-like kinase 1 
protein+ tuft cells of the intestinal epithelium has recently been described (Gerbe et al., 
2011); COX-1 is constitutively expressed, and COX-2 is inducible upon tissue stress or damage 
(Wang and Dubois, 2010). Interestingly, when the expression of COX-1 and COX-2 were 
Proliferation
EP1/3/4 receptorPGE2
ISC
EP2 receptor
Tuft cell
Proliferation
Goblet cell
COX2
PGE2
EP1/3 receptor
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characterised in the mouse colonic epithelium in vivo and in in vitro isolated colonic crypts, 
no significant difference between the numbers of cells positive for COX-1 or COX-2 was 
observed. Previous studies have suggested that COX-1 and COX-2 are co-expressed by the 
same cells; unfortunately, we were unable to confirm COX-1 and COX-2 co-expression due 
to differences in antigen retrieval methods required. Gerbe et al (2011) reported that a rare 
population of cells exists within the epithelium which are DCLK1 positive and COX-1 negative. 
These cells were located mainly in the base of crypts, and were defined as differentiating tuft 
cells. Whilst COX-2 positive cells were confirmed to be tuft cells as determined by co-
expression of the tuft cell marker SOX-9, no data was provided as to the number of COX-2 
positive cells per crypt compared to COX-1 positive cells, or indeed if these cells co-expressed 
COX-1 (Gerbe et al., 2011). Further experiments are required in order to determine whether 
COX-1 cells in vivo co-express COX-2 during homeostasis, and to explore the possibility that 
the distinct subset of differentiating tuft cells which do not express COX-1 may be the COX-
2 positive cells.  
Previously, the use of NSAIDs, which inhibit both COX-1 and COX-2 enzyme activity, have 
been shown to significantly reduce the risk of developing colorectal cancer (Flossmann et al., 
2007; Rostom et al., 2007; Chan et al., 2008). However, the long-term use of NSAIDs was 
associated with an increased risk of cardiovascular thromboembolic events. We therefore 
sought to determine the effects of selective COX enzyme inhibition on mouse colonic crypt 
cell proliferation. In line with the literature, inhibition of COX-1 and COX-2 enzymes using 
aspirin induced a significant decrease in proliferation. Interestingly, we also observed a 
significant reduction in proliferation of colonic crypts following treatment with a selective 
inhibitor of COX-1 (valeryl salycilate) or COX-2 (NS-398). This suggests that the basal activity 
of either COX-1 or COX-2 enzymes alone is insufficient to maintain homeostatic levels of 
proliferation. In contrast to what has been previously described in the literature, this 
suggests a role for both COX-1 and COX-2 enzyme activity for the maintenance of crypt 
renewal during health. Although further experiments would be required to confirm this, we 
would speculate that selective inhibition of COX-1 or COX-2 as an anti-cancer therapy would 
not necessarily prevent side effects observed following treatment with NSAIDs. 
Studies have suggested that all four EP receptor subtypes are expressed at the mRNA level 
in colonic mucosal tissue (Shoji et al., 2004; Sugimoto and Narumiya, 2007; Olsen Hult et al., 
2011). The EP3, EP2 and EP4 receptor subtypes were also previously shown to be expressed 
by epithelial cells within the colonic epithelium using an antibody labelling approach (Shoji 
et al., 2004; Olsen Hult et al., 2011), however no previous studies have characterised the 
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differential expression of EP receptor subtypes in cell types of the mouse intestinal 
epithelium. In this thesis, the presence of all four EP receptor subtypes were confirmed to 
be expressed in isolated mouse colonic crypts, at the mRNA level and in specific cell types at 
the protein level. The EP3 receptor is known to have three different isoforms, EP3α, β and γ 
(Namba et al., 1993), all of which were shown in our studies to be expressed at the mRNA 
level by the colonic epithelium. The EP3 receptor isoforms are known to signal through 
slightly different pathways; EP3α and β inhibit adenylate cyclase whereas the EP3γ variant 
inhibits adenylate cyclase at low PGE2 concentrations, and stimulates adenylate cyclase at 
high PGE2 concentrations. Overexpression of each of EP3 receptor splice variant in tumour 
cells has been described to decrease tumorigenic potential in vivo. In this study, no 
differences were observed between the effects of modulating EPα, β and γ in tumour cells 
(Macias-Perez et al., 2008). It would be of great interest to determine the relative expression 
levels of each of these isoforms in the healthy colonic epithelium using quantitative RT-PCR 
in order to further elucidate the role of EP3 receptor activation in homeostasis.  
The drivers of intestinal tissue renewal are stem cells, which are located at the base of colonic 
crypts. Interestingly, only EP1, EP3 and EP4 receptor subtypes were expressed by Lgr5EGFP 
stem cells in the mouse colonic epithelium, which suggests that these receptor subtypes may 
be important for stem cell driven tissue renewal. In agreement, when autocrine signalling 
through the EP1 or EP3 receptor was inhibited using addition of selective antagonists into 
culture immediately following crypt isolation, a significant decrease in mouse crypt cell 
proliferation was observed. Selective activation of the EP1 or EP3 receptor induced a 
significant increase in proliferation, suggesting that signalling through the EP1/3 receptors 
are important for colonic crypt renewal during homeostasis. However, some cross-reactivity 
between the EP1 and EP3 receptor subtypes has previously been described with use of the 
EP1 agonist (iloprost) and EP3 agonist (sulprostone), therefore further experiments are 
required to determine whether selective EP1 or EP3 receptor activation induces crypt cell 
proliferation (Abramovitz et al., 2000). The PGE2-induced increase in crypt cell proliferation 
observed in our studies was abrogated by the addition of a selective EP1 or EP3 antagonist, 
suggesting that PGE2 signals through EP1 and EP3 receptor subtypes to induce proliferation. 
However, in this experiment, treatment of colonic crypts with the EP1 or EP3 receptor 
antagonist in the absence of PGE2 did not decrease crypt cell proliferation (Figure 4.13). This 
is likely to be due to differences in experimental protocol, whereby a shorter incubation with 
EP1 or EP3 receptor antagonists was utilised following 24h in culture. Addition of the EP1 
receptor antagonist for a short temporal stimulation did not significantly decrease crypt cell 
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proliferation compared to PGE2 stimulated crypts. This suggests that a longer incubation time 
is required for EP1 receptor inhibition to induce a decrease in crypt cell proliferation. The 
concentrations of EP1 and EP3 receptor antagonists in this experiment were higher than 
previously utilised in the literature (Bassil et al., 2008; Rodriguez-Lagunas et al., 2010); 
however, no significant cross-reactivity with other EP receptor subtypes is thought to occur 
following the use of SC19220 or L-798106 at higher concentrations (Funk et al., 1993; Juteau 
et al., 2001).  
Signalling through the EP1 receptor has previously been described to promote cell invasion 
and migration associated with tumour metastasis (Yang et al., 2010; Kim et al., 2011; Zhang 
et al., 2014). However, the findings described in this chapter indicate that EP1 receptor 
signalling is also important for maintaining crypt homeostasis. This suggests that inhibition 
of EP1 receptor signalling for the prevention of tumour metastasis may be associated with a 
downregulation of normal intestinal tissue renewal and therefore may not be a suitable 
target for anti-cancer therapy. Interestingly, previous studies have demonstrated a decrease 
in tumour cell proliferation following selective activation of EP3 receptor signalling (Macias-
Perez et al., 2008). This finding, along with our studies which suggest a role for EP3 receptor 
signalling in mouse crypt cell proliferation during homeostasis, suggest that EP3 receptor 
activation may be important only for proliferation of cells within the healthy colonic 
epithelium. Therefore, future treatment of cancer patients with an EP3 receptor agonist may 
represent an attractive target to reduce tumour growth whilst protecting normal crypt cell 
proliferation. However, further work would be required to determine whether EP3 receptor 
activation also induces crypt cell proliferation during homeostasis in human colonic crypts.  
Expression of the EP1 and EP3 receptor on COX-1 expressing cells in the mouse colonic 
epithelium suggests that PGE2 signalling through the EP1 and EP3 signalling axis may be 
involved in a positive feedback loop, whereby activation of EP1 and EP3 receptors may be 
able to induce further PGE2 secretion. This remains the subject of future work. As described 
earlier, COX-2 is thought to be induced in tissue stress, and is elevated in colorectal cancer. 
It would therefore be of interest to determine the expression of EP receptors on COX-2 
positive cells, as this may be indicative of which EP receptor subtypes are important for PGE2 
signal transduction in cancer.  
The presence of EP4 receptor expression on Lgr5EGFP stem cells indicated a possible role for 
EP4 in stem cell driven tissue renewal, although semi-quantitative analysis revealed that the 
EP4 receptor expression is significantly lower in the base, supra-base and mid regions of 
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mouse colonic crypts compared to top in vivo and in vitro (Appendix A). This suggests that 
although the EP4 receptor is expressed by stem cells, this expression is lower than in other 
cells of the crypt suggesting that the primary role of EP4 receptor activation may not be in 
stem cell renewal. Indeed, when the EP4 receptor was inhibited no change in proliferation, 
organoid survival or budding was observed. Previous studies by Hawcroft et al. (2007) 
showed that treatment with an EP4 agonist (TCS-2510) had no effects on cell proliferation in 
a colon cancer cell line (Hawcroft et al., 2007). In agreement with this, no change in crypt cell 
proliferation was observed following treatment with the EP4 receptor agonist in these 
studies. However, previous studies have identified a role for EP4 receptor signalling in the 
crypt regenerative response to injury through the differentiation of WAE cells (Manieri et al., 
2012; Manieri et al., 2015). EP4 receptor signalling has also previously been shown to 
ameliorate colitis in DSS-induced colitis (Kabashima et al., 2002), but is implicated in 
pathogenesis of colitis induced by T cell transfer into recombinase-activation gene 2 deficient 
mice (Yao et al., 2013). It is possible that in tissue injury or inflammation, PGE2 activates the 
EP4 receptor on stem cells to induce proliferation and crypt regeneration; it would therefore 
be of interest to observe the effects of EP4 receptor modulation in crypts isolated from colitic 
tissue.  
The localisation of EP2 receptor subtype was restricted to Muc-2 positive goblet cells of 
colonic crypts. Interestingly, no changes in proliferation were observed following treatment 
of colonic crypts with either a selective EP2 agonist or EP2 antagonist, suggesting that this 
receptor subtype is not important for this aspect of intestinal tissue renewal. We would 
speculate that the restricted expression of EP2 receptor to goblet cells may suggest a role 
for activation of the EP2 receptor subtype in mucus secretion and therefore maintenance of 
the epithelial barrier during homeostasis. In agreement with the EP2 receptor playing a role 
in epithelial barrier function, previous studies by Lejeune et al. (2014) demonstrated, using 
a pharmacological interrogation of Caco-2 cells, that downregulation of the EP2 receptor was 
associated with a decrease in TER by inducing the degradation of the tight junction protein 
Claudin-4 (Lejeune et al., 2014). However, these studies were limited to the use of cell lines, 
and as such the effects on tight junction protein expression following EP2 receptor inhibition 
of colonic crypts would be required to further elucidate the mechanism of EP2 receptor 
signalling. A role for EP2 receptor signalling has been described in intestinal polyposis 
(Sonoshita et al., 2001) and the lack of changes in homeostatic proliferation suggests that 
specific abrogation of EP2 receptor signalling may be a promising target for the development 
of anti-cancer therapies.   However, the effects of inhibition of EP2 receptor signalling on 
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epithelial barrier function would need to be fully evaluated before the development of such 
treatments.  
As described previously, the WNT signalling pathway is thought to be the master regulator 
of intestinal renewal. Activation of PGE2 is known to augment WNT signalling in order to 
induce hematopoietic stem cell proliferation and differentiation during development and in 
organ regeneration (Goessling et al., 2009). It is therefore possible that the effects of 
autocrine PGE2 signalling on colonic crypt cell proliferation described in this thesis are also 
mediated through the WNT signalling pathway. However, previous studies suggest that PGE2 
effects on WNT signalling are mediated through cAMP/PKC signalling, indicating involvement 
of EP2 and EP4 receptor transduction pathways (Goessling et al., 2009). This is in contrast to 
results shown in this thesis, where activation of EP2 and EP4 receptor signalling did not 
induce crypt cell proliferation. During steady-state renewal in the colonic crypt, autocrine 
PGE2 was shown to signals through the EP1 and EP3 receptor subtypes to induce 
proliferation. The downstream effects of activation of EP1 and EP3 receptor subtypes are 
known to induce an increase in intracellular calcium through binding of  Gα proteins 
(Sugimoto and Narumiya, 2007), which has previously been associated with the crypt 
regenerative response to injury (Chen et al., 2015). Calcium signalling is required for a 
number of cellular processes, including proliferation and apoptosis in all mammalian cell 
types (Roderick and Cook, 2008). However, previous studies have identified that the EP3 
receptor also binds Gi proteins, which have been linked to inhibitory functions of EP3 
receptor activation through inhibition of adenylate cyclase. Future work aims to identify the 
downstream signalling transduction pathways through EP1/EP3 receptor activation induces 
crypt cell proliferation. Initial experiments will determine whether intracellular calcium 
signalling is increased following EP1/EP3 receptor activation during calcium sensitive dyes 
such as Fura-2-AM in combination with live imaging. Furthermore, enzymatic fluorometric 
assays may be utilised to determine adenylate cyclase activity in response to treatment with 
EP1/EP3 receptor activation.  
4.3.1 Autocrine PGE2 signalling is important for human colonic crypt proliferation  
The validation of our mouse studies with human experiments are of critical importance when 
considering the interrogation of this pathway for the development of treatments for human 
disease. In agreement with findings observed in mouse studies, prostaglandin-E2 was also 
shown to play a role in human colonic crypt cell proliferation. Addition of PGE2 induced an 
increase in human colonic crypt cell proliferation. Inhibition of autologous PGE2 breakdown 
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using an antagonist to 15-PGDH induced crypt cell proliferation. The expression of EP 
receptor subtypes by the colonic epithelium was highly conserved across the mouse and 
human epithelium.   
These findings demonstrate a role for PGE2 signalling in colonic crypt homeostasis. 
Exogenous addition of PGE2 was shown to induce a significant increase in proliferation, which 
was most evident in the supra-base and mid regions of the crypts, suggesting that it may play 
a role in the proliferation of progenitor cells and differentiated cells which are present in 
these regions. Utilising a newly developed small molecular inhibitor, CAY10397, to inhibit the 
breakdown of endogenous PGE2 by the 15-PGDH enzyme, autocrine PGE2 signalling was 
shown to be important for colonic crypt renewal. This effect was most evident at the base of 
crypts, where intestinal stem cells reside. The regenerative potential of small molecule 
inhibitors of 15-PGDH has previously been applied to mouse models of liver injury and colitis, 
where SW033291-treated mice had an increased rate of liver regeneration and were 
protected from colitis by maintaining cell proliferation within DSS-treated mucosa (Zhang et 
al., 2015). However, the 15-PGDH enzyme is lost in colorectal cancers and FAP, therefore 
further studies are required to determine the effects of small molecule inhibition of 15-PGDH 
on the risk of developing cancer. 
The differential expression of EP receptor subtypes was highly conserved across mouse and 
human samples. In agreement with our mouse data, stem cells of human colonic crypts 
expressed EP1, EP3 and EP4 whereas the EP2 receptor was restricted to Muc-2 positive 
goblet cells. The next steps for the human studies are to determine the roles of selective EP 
receptor activation on colonic crypt renewal in the human colonic epithelium. 
4.3.2 Limitations of the study and next steps 
A pharmacological approach was undertaken in this study to determine the contribution of 
selective EP receptor activation and inhibition on colonic crypt renewal during homeostasis. 
Whilst we were able to conclude that PGE2 promotes colonic crypt cell proliferation, which 
is likely to be through the EP1 and EP3 receptor signalling pathways, the study is limited by 
the specificity of pharmacological agents commercially available. The concentrations of 
drugs utilised were optimised to minimise activation of other receptor subtypes, however 
the exact efficacies of each agonist and antagonist to specific receptor subtype in our system 
were not determined. Agonist and antagonist efficacies could be determined in the future 
using a ligand binding affinity assay (Strange, 2008). Future work in our lab will add 
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antagonists for EP receptor subtypes along with each agonist in order to further minimise 
any cross-reactivity. Furthermore, the development of novel agents which are specific to 
each EP receptor subtype would further support our findings. 
A future aim of this area of work would be to utilise a combination of selective activation and 
inhibition of EP receptor subtypes in order to determine the relative contributions of each 
EP receptor subtype in cell proliferation of healthy and tumour tissue. The development of 
3D tumoroid culture in the Williams’ laboratory amongst others, enables these studies to be 
completed on paired samples from tumour and ‘healthy’ tissue obtained from the same 
patient. The development of elegant techniques which allow gene knock out in organoids, 
such as the use of Cre recombinase-inducible retrovirus vectors or CRISPR/Cas9 system, 
provides useful tools to investigate the roles of specific EP receptor deletion in organoid and 
tumoroid growth (reviewed in (Driehuis and Clevers, 2017). The use of these techniques in 
order to determine the functional role of EP receptor subtypes in health and cancer remains 
the focus of future work.  
4.4 Conclusions 
This chapter has identified a novel role for autocrine PGE2 in the maintenance of colonic crypt 
homeostasis through the EP1/3 signalling axis. Human studies in this chapter support 
findings from mouse studies, and validate the use of mouse models for the interrogation of 
the PGE2 pathway.  
 
 
 
The next chapter looks at a potential source of IL-6 and PGE2 in the intestinal mucosa. An 
abundance of immune cells are resident in the lamina propria underlying the intestinal 
epithelium. One immune cell subtype, which is resident along the gastrointestinal tract from 
birth and is known to secrete both IL-6 and PGE2, is the eosinophil. Whilst eosinophils have 
been best characterised for their role in allergy, parasitic infection and inflammatory 
diseases, a role for eosinophils in the maintenance of homeostasis is beginning to be 
recognised. The next chapter examines the spatial characteristics of eosinophils in the 
intestinal mucosa, and begins to look at the effects of tissue resident eosinophils on the 
epithelium. 
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5 Chapter 5. The role of eosinophils in human colonic crypt 
homeostasis  
5.1 Introduction 
The intestinal epithelium forms a vital barrier between luminal microbial content and 
underlying immune cells in the lamina propria. A plethora of immune cells reside in the 
lamina propria during health. Immune cells are known to express factors important for crypt 
cell renewal (Rosenberg et al., 2013), and evidence is beginning to emerge for a role of 
intestinal immune cells in the modulation of crypt homeostasis renewal (Pull et al., 2005; 
Seno et al., 2009; Kuhn et al., 2014; Skoczek et al., 2014). Approximately 20-40% of the 
immune cells residing within the intestinal lamina propria are eosinophils (Carlens et al., 
2009). Eosinophils are potent effector cells, most commonly associated with helminth 
infection, allergic asthma and Inflammatory Bowel Diseases (IBDs); however, they are also 
present in abundance during health and in quiescent IBD (Al-Haddad and Riddell, 2005). As 
such, roles are emerging for eosinophils in tissue remodelling (Rosenberg et al., 2013), the 
regulation of inflammation namely through secretion of IL-6 (Chu et al., 2011), and 
maintenance of the epithelial barrier (Furuta et al., 2005; Wallon et al., 2011). However, the 
roles of eosinophils in maintenance of colonic crypt homeostasis remain largely unknown.  
The accumulation of eosinophils in sites of renewal and regeneration led Lee et al. (2010) to 
suggest that the role of eosinophils is to modulate Local Immunity And/or 
Remodelling/Repair; the LIAR hypothesis. Lee et al. (2010) speculated that signals derived 
from cells undergoing apoptosis recruit eosinophils to the site and induce accumulation; 
proliferating cells secrete factors which are sufficient to prolong survival and maintain 
eosinophils in the niche. This suggests that eosinophil accumulation is therefore not simply 
a defence mechanism against pathogenic challenge and in allergic exacerbations as has been 
described in the past, but a strategy to maintain tissue homeostasis in health and disease 
(Lee et al., 2010).  
When eosinophils are activated in tissues, the cytotoxic granule content is released into the 
surrounding environment, where components including MBP, ECP and EDN are known to 
have cytotoxic effects on both pathogens and host tissues (Gleich et al., 1979; Levy et al., 
2001; Kato et al., 2012). As well as cytotoxic effects, activated eosinophils have also been 
shown to increase epithelial cell permeability though the secretion of MBP and CRF (Furuta 
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et al., 2005; Wallon et al., 2011). However, the granule content also contains a number of 
other factors, including EGF, which is known to be important for epithelial crypt cell 
regeneration (Sato et al., 2011; Rosenberg et al., 2013). Eosinophils also express a wide 
variety of receptors and ligands which have importance in health and disease (reviewed in 
Rosenberg et al. (2013)). Of note, eosinophils are a major source of secreted IL-6, and lipid 
bodies present in eosinophil cytoplasm contain PGE2, which have been shown in this thesis 
to modulate intestinal renewal during homeostasis (Chapter 3 and Chapter 4 respectively). 
Eosinophils have a major function in the regulation of immune cells during homeostasis. 
Recent studies have shown that eosinophils maintain plasma cells in the bone marrow and 
lamina propria through secretion of IL-6 and APRIL (Chu et al., 2011). The recruitment of TH2 
cells in response to chemoattractants CCL17 and CCL22 is promoted by eosinophils (Jacobsen 
et al., 2008). Furthermore, eosinophils also promote dendritic cell maturation through the 
granule protein EDN (Yang et al., 2003; Lotfi and Lotze, 2008; Yang et al., 2008). Release of 
IL-5 and IL-13 by eosinophils recruits alternatively activated macrophages to adipose tissues, 
where they have an increased survival (Wu et al., 2011). 
Previous studies have utilised isolated eosinophils from the blood of healthy donors and co-
cultured them with an epithelial cell line in order to determine the effects of eosinophil 
secreted products on epithelial cells (Jawien et al., 2002; Furuta et al., 2005). However, 
phenotypic differences are observed between blood and tissue resident eosinophils, 
including an increased survival (Wu et al., 2011) and expression of different receptors 
(Carlens et al., 2009; Wallon et al., 2011). Therefore, the gold standard for the investigation 
of the effects of tissue resident eosinophils on crypts would be to isolate eosinophils from 
the underlying lamina propria and add them into co-culture with isolated intestinal crypts. 
Previous studies have isolated eosinophils from the lamina propria of the mouse intestine 
for the study of effects of eosinophils on plasma cell survival (Chu et al., 2011); however, 
there is no documented literature on the isolation of human mucosal eosinophils and co-
culture with isolated intestinal crypts.  
Interactions between immune cells in the underlying lamina propria and ISCs at the base of 
colonic crypts have previously been shown to induce crypt regeneration during homeostasis 
(Skoczek et al., 2014). Skoczek et al. (2014) demonstrated that following luminal microbial 
input, monocytes and eosinophils move closer to the stem cell niche, where monocytes were 
shown to induce stem cell expansion and an increase in crypt cell proliferation. In an in vitro 
co-culture system of isolated mouse colonic crypts and bone marrow derived monocytes or 
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THP-1 cells, monocytes were shown to induce crypt cell proliferation (Skoczek et al., 2014). 
Whether similar interactions between eosinophils and human colonic crypts occur remains 
to be elucidated.  
The aim of this chapter was to determine the roles of eosinophils in intestinal homeostasis. 
Therefore, a protocol for the isolation and purification of tissue resident eosinophils was 
attempted. The data presented in this chapter demonstrate a spatial relationship between 
eosinophils and functional regions along the colonic crypt-axis in vivo.  
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5.2 Results 
An Immunofluorescent labelling approach was undertaken in order to determine the spatial 
characteristics of eosinophils within the human colonic lamina propria during health and IBD. 
A human isolated crypt co-culture system with HL-60-eosinophils or isolated tissue resident 
eosinophils was developed and initial experiments to investigate the effects of eosinophils 
on human colonic crypt cell proliferation undertaken. 
5.2.1 Eosinophils reside in sites of renewal and regeneration in vivo 
Eosinophils have previously been described to reside in sites of tissue renewal and 
regeneration, including the intestinal lamina propria (Lee et al., 2010). However, the spatial 
distribution of eosinophils along the crypt axis in the lamina propria surrounding human 
colonic crypts remained to be characterised. Tissue was obtained from patients undergoing 
colorectal resection at the NNUH, immediately fixed in paraformaldehyde and embedded 
in paraffin and 5μm thick sections obtained with a microtome (described in Section 2.4.2). 
Immunofluorescent labelling of lamina propria eosinophils was undertaken utilising the 
markers C-C chemokine receptor type 3 (CCR3), major basic protein (MBP) and Sialic acid-
binding Ig-like lectin 8 (Siglec-8) (as described in Section 2.3.5). The number of CCR3, MBP 
or Siglec-8 positive cells in the lamina propria surrounding the base, mid and top regions of 
crypts was quantified. Quantification of the number of CCR3+ cells in the base, mid and top 
regions along the crypt-axis (white dashed line) revealed a significant increase in the 
number of CCR3 positive cells at the base of crypts compared to mid and top regions of 
crypts (Figure 5.1). Whilst CCR3 is a marker specific to eosinophils, it is also expressed on 
other immune cell subtypes which are known to reside in the colonic lamina propria (Agace 
et al., 2000), therefore further characterisation of eosinophils was determined using an 
antibody for the eosinophil granule protein MBP. The number of MBP positive cells in the 
lamina propria surrounding crypts was significantly increased in the base and top regions 
compared to mid region (Figure 5.2). Another marker which is specific to eosinophils is 
Siglec-8.  Quantification of the number of Siglec-8+ cells in the base, mid or top region (see 
white dashed lines, Figure 5.3A) of the crypt revealed that significantly less Siglec-8+ cells 
were observed at the mid and top regions of the crypt compared to base region. A 
significant increase in the number of Siglec-8+ cells was observed at the top region of crypts 
compared to mid region (Figure 5.3B). Co-expression of eosinophil markers was not 
possible in this system due to the inherent autofluorescent properties of eosinophils using 
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excitation wavelengths 525nm and 595nm, described below, therefore Immunofluorescent 
labelling of eosinophils was only possible using filters to detect emission at 647nm.
 
Figure 5.1. Spatial distribution of CCR3+ cells in the healthy colonic mucosa. 
(A) Immunofluorescent labelling of CCR3+ cells (far red) and nuclei/DAPI (blue) in the human 
colonic mucosa. Scale bar 50µm. (B) Histogram showing the number of CCR3+ cells in the 
base, mid and top regions of colonic crypts (N=4, n=29, ***P<0.001 compared to base 
region). Mean values ± SEM were plotted for each crypt region.  (C) No labelling was observed 
following utilising the Alexa Fluor 647 secondary antibody (20 Ab) alone. 
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Figure 5.2. Spatial distribution of MBP+ cells in the healthy colonic mucosa. 
(A) Immunofluorescent labelling of MBP+ cells (far red) and nuclei/DAPI (blue) in the human 
colonic mucosa. (B) Histogram showing the number of MBP+ cells in the base, mid and top 
regions of colonic crypts (N=4, n=34, ***P<0.001 compared to mid region). Mean values ± 
SEM were plotted for each crypt region. Scale bar 50µm. 
 
Figure 5.3. Spatial distribution of Siglec-8+ cells in the healthy colonic mucosa. 
(A) Immunofluorescent labelling of Siglec-8+ cells (far red) and nuclei/DAPI (blue) in the 
human colonic mucosa. Images representative of N=2 experiments. (B) Histogram showing 
the number of Siglec-8+ cells in the base, mid and top regions of colonic crypts in control 
compared to mid region (N=2, n=21,***P<0.001, **P<0.01, *P<0.05 compared to indicated 
region). Mean values ± SEM were plotted for each crypt region. Scale bar 50µm.
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During the Immunofluorescent antibody experiments, a population of autofluorescent cells 
was observed in the colonic lamina propria using epifluorescent filters to detect light in the 
green and red channels, and excitation wavelengths of 525nm and 595nm using laser 
scanning microscopy. A representative image of autofluorescent cells in the lamina propria 
between colonic crypts (white dashed line) using excitation wavelengths 525nm and 595nm 
for multiphoton microscopy is provided in Figure 5.4A.  Merging the 525nm and 595nm 
images revealed co-localisation of autofluorescence between the two wavelengths (Figure 
5.4A). Similarly to the spatial relationship observed following quantification of Siglec-8 
positive cells in the colonic lamina propria (Figure 5.3), when the number of autofluorescent 
cells were quantified in each region of crypts, a significant increase in the number of 
autofluorescent cells residing in the regions surrounding the base region was observed 
compared to mid and top (Figure 5.4B). The identity of these cells was then investigated 
using Immunofluorescent labelling of immune cells. Approximately 90% of autofluorescent 
cells were shown to co-localise with Siglec-8+ cells in the lamina propria surrounding crypts 
in the base, mid and top regions (Figure 5.4C), suggesting that eosinophils are 
autofluorescent in the colonic lamina propria. This paves the way for some exciting studies 
whereby eosinophil dynamics can be studied in real-time (without the need for 
immunofluorescent labelling of eosinophils) and the effects of luminal addition of PAMPS or 
commensal/pathogenic microbes on spatial and temporal characteristics of eosinophils may 
be determined. 
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Figure 5.4. Autofluorescent cells in the lamina propria of healthy colonic tissue are Siglec-
8+ eosinophils. 
(A) Representative fluorescent image of autofluorescent cells in the lamina propria of 
healthy colonic explants using excitation wavelengths 525nm and 595nm, white denotes the 
colonic epithelium. (B) Histogram showing the number of autofluorescent cells in the base, 
mid and top regions of colonic crypts in control compared to mid region (N=2, n=21, 
***P<0.001 compared to mid region, $$P<0.01 compared to base region). Mean values ± 
SEM were plotted for each crypt region. (C) Histogram showing the percentage of 
autofluorescent cells that were also Siglec-8 positive (N=2, n=21). Multi-photon imaging data 
is representative of N=2 biopsy samples. Scale bar 50μm 
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Whilst eosinophils are known to be an abundant population in the intestinal lamina propria 
during health (Carlens et al., 2009), eosinophils have been shown to accumulate in IBD 
(Desreumaux et al., 1999). The next step was to determine whether a similar spatial 
relationship was observed between eosinophils and the colonic epithelium during active 
IBD. Therefore, tissue from patients with active IBD was obtained, and Immunofluorescent 
labelling for Siglec-8 undertaken (Figure 5.5A). Quantitative analysis of the number of 
Siglec-8 positive cells in the lamina propria surrounding the base, mid and top region of 
colonic crypts revealed that a significant increase in the number of Siglec-8 positive cells 
was present at the base region of crypts compared to mid and top regions in sections 
obtained from IBD tissue. Furthermore, a significant increase in the number of Siglec-8 
positive cells were observed at the base, mid and top regions of crypts compared to the 
respective regions in sections from healthy tissue (Figure 5.5B). A significant increase in the 
total number of Siglec-8+ cells surrounding each crypt was observed in IBD tissue compared 
to control (Figure 5.5C).
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Figure 5.5. Characterisation of tissue resident Siglec-8+ cells in the colonic mucosa of 
healthy and IBD patients. 
(A) Immunofluorescent labelling of Siglec-8+ cells (pink) and nuclei (DAPI-blue) in the colonic 
mucosa of tissue obtained from healthy (control, left) and IBD (right) patients, white dashes 
represent base, mid and top regions. (B) Histogram showing the number of Siglec-8+ cells 
observed in the base, mid and top regions colonic crypts in vivo of IBD and control sections 
(N≥2, n≥21, ***P<0.001, **P<0.01, *P<0.05 compared to indicated regions) mean values ± 
SEM were plotted for each crypt region. (C) The total number of Siglec-8+ cells per crypt in 
IBD samples compared to control (N≥2, n≥21***P<0.001). Scale bars 50µm. 
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5.2.2 Distribution of eosinophils in vitro is similar to that observed in vivo 
As described previously, HL-60 cells differentiate into an eosinophil-like phenotype 
following 5 days in culture with 0.5mM butyric acid (Fischkoff, 1988). In order to determine 
the effects of eosinophils on colonic crypts in vitro, HL-60-eosinophils were added into co-
culture with isolated human colonic crypts. Following 24h in co-culture, images were taken 
using timelapse microscopy (Figure 5.6A). Crypts were split into three equal regions to 
represent the base, mid and top hierarchy of the crypts and HL-60-eosinophils within a 2-
cell thick radius (see white dotted line, Figure 5.6A) were counted in order to characterise 
the spatial distribution of HL-60-eosinophils along the crypt axis in vitro. Interestingly, initial 
results suggested that following 24h in co-culture with human colonic crypts, HL-60-
eosinophil distribution mirrored that observed in vivo; HL-60-eosinophils were present in 
high numbers in the base and top regions compared to mid region surrounding human 
colonic crypts (Figure 5.6B). This suggests that the HL-60-eosinophil-crypt co-culture model 
is a good representation of in vivo eosinophil-crypt behaviour and therefore a good system 
to investigate the effects of eosinophils on human colonic crypts in vitro.  
 
Figure 5.6. Distribution of HL-60-eosinophils observed in in vitro co-culture is similar to that 
observed in vivo. 
(A) DIC image of immune cells (red arrows) in co-culture with human colonic crypts following 
24h in co-culture. (B) Histogram showing the number of HL-60-eosinophils surrounding 
human colonic crypts at the base and top region of crypts compared to mid region following 
24h in co-culture. Scale bar 50μm (N=1, n=15).
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Previous studies have shown that physical interactions occur between immune cells and 
stem cells in the base of mouse colonic crypts (Skoczek et al., 2014).  Immunofluorescent 
labelling of MBP and OLFM4 revealed that physical associations were observed between 
MBP+ cells and the base of crypts close to the stem cell niche in vivo (Figure 5.7A, red 
arrow).  Similarly physical interactions were observed between HL-60-eosinophils and the 
colonic crypt base in in vitro co-culture studies (Figure 5.7B). It has previously been shown 
that Lgr5EGFP positive stem cells extend epithelial processes into the surrounding lamina 
propria to physically interact with monocytes in vitro (Skoczek et al., 2014). Similarly, in this 
study E-cadherin+ processes were shown to extend into the surrounding matrix and 
physically interact with HL-60-eosinophils (Figure 5.7C).  
 
Figure 5.7. Physical interactions between eosinophils and crypt stem cells are observed in 
vivo and in in vitro co-culture. 
(A) Representative confocal image showing MBP (red) positive cell in the lamina propria 
residing in close proximity to OLFM4 (green) positive cells at the base of colonic crypts in 
vivo. (B) White light DIC image of HL-60-eosinophil-crypt co-culture. HL-60-eosinophils form 
interactions (red arrows) with the stem cell niche of isolated colonic crypts in co-culture.  (C) 
Representative immunofluorescent image of HL-60-eosinophil crypt co-culture. Crypts 
extend E-cadherin (green) positive processes towards HL-60-eosinophils in surrounding 
matrigel, nuclei (DAPI-blue). Confocal imaging data are representative of N=3, n≥10, 
experiments. Scale bars 50µm, *scale bar 10µm. 
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5.2.3 Characterisation of isolated human tissue resident eosinophils 
The observation of physical interactions between eosinophils and human colonic crypts begs 
the question of the effects of eosinophils on crypt cell renewal. The use of reductionist co-
culture studies provides the ideal methodology to determine the roles of immune cells in 
crypt renewal. However, no previous co-culture studies have been attempted using immune 
cells isolated from the intestinal lamina propria in co-culture with isolated human crypts. 
Therefore, the aim of this study was to develop a protocol for the isolation of immune cells 
from the mucosal lamina propria and subsequent purification of eosinophils (see Section 
2.6.2), with the intention of adding purified eosinophils into reductionist co-culture with 
isolated human colonic crypts. Previously, the immune cell content of the intestinal lamina 
propria has been described to be comprised 20-40% eosinophils (Carlens et al., 2009), and 
data has suggested that the number of eosinophils present falls in the descending colon from 
the ascending colon (Saad, 2011; Matsushita et al., 2015). However, no data was available 
regarding the percentage composition of immune cells in the lamina propria from different 
regions of the large intestine i.e. ascending or descending colon. Therefore, immune cells 
were isolated from the underlying lamina propria of tissue taken from the ascending and 
descending colon. The proportion of each immune cell subtype was quantified using 
morphological characterisation of H&E stained cytospins. Immune cell content included 
eosinophils, neutrophils, basophils, macrophages, monocytes, dendritic cells and 
lymphocytes. The percentage of eosinophils in the mixed immune cell population was 
increased in the ascending colon lamina propria compared to the descending colon, although 
this was not statistically significant (Figure 5.8A). Eosinophils have been shown to be present 
with a greater abundance in tissue taken from patients with IBD (Figure 5.5); therefore, 
immune cells were also isolated from the colon of patients with IBD or no IBD. As suggested 
earlier, an increased proportion of eosinophils was observed in immune cells isolated from 
patients with IBD compared to healthy, although these results are not yet significant (Figure 
5.8B).  
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Figure 5.8. More eosinophils are present in the ascending colon than descending colon, and 
in IBD compared to non-IBD. 
(A) Histogram showing the average percentage of eosinophils present in a mixed immune 
cell population isolated from the mucosal lamina propria of descending colon (DC) or 
ascending colon (AC) before purification. (B) Histogram showing the average percentage of 
eosinophils present in a mixed immune cell population isolated from the ascending colon 
lamina propria of IBD or non-IBD patients. Data was obtained from a minimum of N=3 
experiments, n>1200 immune cells counted.
 
5.2.4 The effects of eosinophils on human colonic crypt renewal 
In order to determine whether eosinophils induced crypt cell proliferation, and the number 
of eosinophils required in order to illicit a response, HL-60-eosinophils were added into co-
culture with isolated human colonic crypts. Addition of 50,000 HL-60-eosinophils induced a 
marginal increase in crypt cell proliferation at the base of crypts, that was not statistically 
significant (Figure 5.9A). Therefore, isolated human colonic crypts were co-cultured with 
either 50,000 or 100,000 HL-60-eosinophils. No significant increase in crypt cell proliferation 
was observed at the base of crypts following co-culture with 50,000 HL-60-eosinophils, or 
100,000 HL-60-eosinophils (Figure 5.9B).  
In order to determine whether HL-60-eosinophils express factors that can potentially induce 
renewal of colonic crypts, RT-PCR using primers for crypt regenerative factors was 
undertaken. HL-60-eosinophils expressed mRNA for WNT3A (Figure 5.10A). The expression 
of COX-1 mRNA by HL-60-eosinophils was also confirmed (Figure 5.10B). 
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Figure 5.9. HL-60-eosinophils in co-culture with human colonic crypts induces a slight 
increase in proliferation. 
(A) Histogram showing the percentage of nuclei incorporating EdU  following co-culture with 
50,000 HL-60-eosinophils, (N=1, n>14) (B) Histogram showing the percentage of nuclei 
incorporating EdU following co-culture with 50,000 or 100,000 HL-60-eosinophils, (N=4, 
n≥20). 
 
 
Figure 5.10. HL-60-eosinophils express crypt regenerative factors. 
(A) Expression of WNT3A mRNA by RT-PCR using cDNA from butyric acid treated HL-60 cells; 
expected PCR band size WNT3A=404 bp (B) Expression of COX-1 mRNA by RT-PCR using cDNA 
from HL-60/Eos; expected PCR band size COX-1=76bp.
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In this chapter, a novel protocol was developed to isolate immune cells from the underlying 
lamina propria of the colonic mucosa, and purify the tissue resident eosinophils for use in 
co-culture studies with isolated colonic crypts (summarised in Section 2.6.2). The protocol 
remains in the developmental phase, and future work aims to further purify and increase the 
yield from the mucosa. For initial experiments, a population of immune cells with an 
eosinophil purity of 85% were added into co-culture with isolated human colonic crypts. 
Siglec-8 positive eosinophils isolated from the human colonic mucosa were added into co-
culture with isolated human colonic crypts and the effects on crypt proliferation assessed 
using EdU incorporation (Figure 5.11A). The percentage of nuclei incorporating EdU in the 
base, supra-base, mid and top regions of the crypts was quantified. Addition of 50,000 
immune cells per well induced no change in human colonic crypt cell proliferation (Figure 
5.11B).  
In order to determine whether the population of purified eosinophils express markers 
characteristic of eosinophils, RT-PCR using primers for markers specific to eosinophils was 
utilised. Isolated tissue resident immune cells, with an eosinophil purity of 55-65%,  
expressed a number of receptors for and ligands for chemotaxis, including CCR1, CCR3, CCR7, 
CCR9, CCL2, CCL5 (Figure 5.12); which have all been previously described to be expressed by 
eosinophils (Akuthota et al., 2013; Rosenberg et al., 2013; Baumann et al., 2015). The 
important roles of eosinophils in the maintenance of plasma cells through secretion of IL-6 
begs the question of whether eosinophils isolated from the mucosa of healthy individuals 
express IL-6. Using PCR, tissue resident immune cells, of which 55-65% were eosinophils, 
were shown to express mRNA for IL-6 (Figure 5.12). The mixed immune cell population was 
also shown to express CCR10 and CCRL2, which have not previously been described to be 
expressed by eosinophils (Appendix B).
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Figure 5.11. Co-culture of tissue resident eosinophils induced no change in proliferation of 
human colonic crypts. 
(A) Representative confocal image of EdU (red) incorporating nuclei (DAPI-blue) of human 
colonic crypts following co-culture with Siglec-8 (green) positive cells. (B) Histogram showing 
the percentage of nuclei incorporating EdU following co-culture with 85% pure eosinophil 
population, compared to control with no immune cells, N=1, n≥9. Scale bar 10µm. 
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Figure 5.12. Isolated tissue resident immune cells express characteristic markers of 
eosinophils, including IL-6. 
Expression of eosinophil characteristic marker mRNA by RT-PCR using cDNA from isolated 
tissue resident immune cells, eosinophil purity was between 55 and 65% for all samples used. 
Expected PCR band sizes: CCR1=358bp; CCR3=323bp; CCR7=497bp; CCR9=413bp; 
CCL2=219bp; CCL5=201bp; IL-6=86bp 
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5.3 Discussion 
In this chapter, a novel spatial relationship between eosinophils and the colonic epithelium 
has been described; with more eosinophils present at the colonic stem cell niche and at the 
surface epithelium (Figure 5.13). An accumulation of eosinophils was observed in tissue 
obtained from IBD patients, and for the first time, this chapter quantifies a 1.2 fold increase 
in the number of eosinophils present at the base of crypts from IBD patients compared to 
healthy patients. The use of a reductionist system whereby HL-60-eosinophils were co-
cultured with isolated human colonic crypts revealed that the spatial distribution following 
24h in culture was the same in vitro as that observed in vivo, with physical interactions 
observed between the epithelium and HL-60-eosinophils (Figure 5.13). A human tissue 
resident eosinophil isolation technique was also developed, whereby immune cells 
expressing a number of markers characteristic of eosinophils were isolated from the colonic 
mucosa. Furthermore, this chapter describes for the first time, the development of the 
reductionist co-culture system to include tissue-resident eosinophils in co-culture with 
isolated human colonic crypts.   
 
Figure 5.13. Eosinophils reside in sites of renewal and regeneration during homeostasis. 
Eosinophils and monocytes reside at the base (site of renewal) and top (site of regeneration) 
along the crypt-axis in the human colonic mucosa. In in vitro co-culture, eosinophils and 
monocytes migrate to the crypt base and top following 24h in co-culture, where the 
epithelium is seen to extend epithelial processes towards immune cells in the underlying 
lamina propria. 
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These findings demonstrate that eosinophils specifically home to sites of renewal and 
regeneration during health. We observed a significant increase in the number of eosinophils 
present in the lamina propria at the base, the major site of stem cell driven tissue renewal, 
and top, where cells undergo apoptosis and are shed into the gut lumen, regions of crypts in 
vivo. This complements the LIAR hypothesis, previously described by Lee et al. (2010), 
whereby eosinophils are thought to be recruited to sites of renewal and regeneration 
through factors secreted when cells undergo apoptosis, and retained at the site through 
factors derived from proliferating cells (Lee et al., 2010). In our in vitro co-culture system, 
HL-60-eosinophils were shown to reside at the base and top regions of the crypt following 
24h in culture. Human colonic crypts have previously been shown to express Eotaxin-1, the 
major chemoattractant for eosinophils (El Hadi, personal communication). The expression of 
CCR3 by isolated eosinophils indicates that they are able to respond to Eotaxin-1 expression 
by the epithelium, which may induce migration towards crypts and possibly potentiate 
physical interactions between eosinophils and epithelial cells.  
Previously, physical interactions between monocytes and stem cells were shown to induce 
stem cell expansion and crypt cell proliferation in the mouse colonic mucosa (Skoczek et al., 
2014). The presence of physical interactions between HL-60-eosinophils and colonic 
epithelial cells in our in vitro co-culture suggests that a similar paradigm may exist between 
eosinophils and human colonic crypts. Furthermore, HL-60-eosinophils were shown to 
express mRNA for factors known to induce crypt cell proliferation; COX-1 for PGE2 synthesis, 
shown in Chapter 4 of this thesis to induce proliferation, and WNT3a, which is the master 
regulator of intestinal renewal (Schepers and Clevers, 2012). However, initial experiments 
revealed no differences in proliferation of isolated human colonic crypts following addition 
of 100,000 HL-60-eosinophils into co-culture. When 50,000 HL-60-eosinophils were added 
into co-culture a small but not significant increase was observed in crypt cell proliferation 
compared to crypts alone. Skozcek et al. (2014) undertook a dose response experiment 
whereby 50,000-600,000 monocytes were added into co-culture with isolated mouse colonic 
crypts. In this system, addition of any number of monocytes between 50,000 and 600,000 
per well induced a significant increase in crypt cell proliferation (Skoczek et al., 2014). It is 
possible that a higher number of HL-60-eosinophils is required to induce crypt cell 
proliferation through increased secretion of crypt regenerative factors. Future work aims to 
determine whether eosinophils induce crypt regeneration, and if so, use a conditioned media 
experimental approach in order to determine whether functional effects are dependent on 
physical interactions or secreted crypt regenerative factors.   
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Another crypt regenerative factor, which was shown in this thesis to induce crypt cell 
proliferation through autocrine and paracrine pathways, is IL-6 (Chapter 3). In mouse 
studies, eosinophils have been shown to be a major paracrine source of IL-6, which 
modulates gut immunity through increasing plasma cell survival; however, the role of 
eosinophil secreted IL-6 on epithelial renewal was not determined (Chu et al., 2011). In this 
chapter, isolated tissue resident eosinophils were shown to express mRNA for IL-6 thus 
confirming eosinophils as a paracrine source of IL-6 in the human intestine. A role for 
eosinophils in modulating gut immunity was supported by data in this Chapter showing that 
isolated tissue resident eosinophils express factors and receptors for chemotaxis including 
CCR1, CCR3, CCR7, CCR9, CCL2 and CCL5. This suggests that eosinophils play a major role in 
the recruitment of other immune cells to the intestinal stem cell niche. The purified immune 
cell population also expressed CCR10 and CCRL2 (Appendix B); CCR10 expression by 
eosinophils was previously shown to be induced in IBD (Rehman et al., 2013), and CCRL2 
expression is characteristic of dendritic cells and macrophages, and has not previously been 
shown to be expressed by eosinophils (Otero et al., 2010). Due to the significant 
contaminating immune cell population in these samples, it is possible that CCR10 and CCRL2 
are expressed on contaminating immune cells. Further experiments are required to 
determine the functional expression of chemoattractant factors and receptors on 
eosinophils in the mixed immune cell population. 
Future work aims to utilise the reductionist co-culture system in order to investigate the role 
of paracrine eosinophil secretion of IL-6 and PGE2 in epithelial renewal. The addition of 
antibodies to block the IL-6 receptor or neutralise secreted IL-6, or block PGE2, as used in in 
vitro studies in Chapters 3 and 4 respectively, will be added into eosinophil-crypt co-culture 
and the effects on intestinal crypt cell proliferation and intestinal stem cell expansion will be 
determined. Furthermore, the reductionist co-culture system provides an ideal platform in 
order to investigate the relative contribution of eosinophils and other immune cells in 
epithelial renewal. Indeed, other immune cell populations i.e. monocytes, B cells could also 
be isolated and added into co-culture and the effects on crypt renewal, chemotactic factor 
secretion and immune cell migration investigated. 
5.3.1 Roles for eosinophils in IBD 
Accumulation of eosinophils in the intestinal lamina propria is characteristic of acute IBD and 
has been associated with disease severity and a poorer prognosis (Desreumaux et al., 1999). 
Enteric neural dysfunction and associated mucus secretion is characteristic of IBD, and 
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eosinophils were previously shown to co-localise with neurons in the intestinal mucosa 
during active IBD (Smyth et al., 2013). In our system, we observed a 1.2 fold, significant 
increase in the number of eosinophils present at the base of crypts in the colonic lamina 
propria of patients with acute IBD. The accumulation of eosinophils could be associated with 
an increase in the frequency of physical interactions occurring between eosinophils and 
epithelial cells, an increase in secreted crypt regenerative factors or increased mucus 
secretion through neural interactions. Previous studies have suggested that eosinophils are 
present in higher numbers in IBD remission than in acute IBD, suggesting that eosinophils 
play a role in epithelial repair in response to tissue injury (Lampinen et al., 2005). It is also 
possible that differences in the secreted crypt regenerative factors or chemotactic factors 
expressed by eosinophils are observed in acute IBD compared to IBD remission and health, 
as has been previously suggested (Carlens et al., 2009). For example, during health 
eosinophils are known to express the IL-6R on their surface membrane, suggesting that they 
are able to induce and respond to IL-6 classical signalling (Melo et al., 2013). IL-6R cleavage 
is associated with activation of IL-6 trans signalling and inflammation. It would be of interest 
to characterise whether expression of the IL-6R is lost on eosinophils obtained from IBD 
tissue. This could indicate that eosinophils contribute to IL-6 classic signalling in homeostasis, 
and IL-6 trans signalling during inflammation. In addition, eosinophils are thought to induce 
tissue damage through activation and release of toxic granule contents in active IBD. 
Previously, the accumulation of eosinophils was shown to increase epithelial permeability 
through MBP secretion (Furuta et al., 2005). Therefore, ‘healthy eosinophils’ may be 
protective and have roles in crypt regeneration, but ‘IBD eosinophils’ may induce tissue 
damage and altered barrier function. 
Future work aims to explore the possibility that eosinophils resident in the inflamed mucosa 
confer a different function on cells within the colonic epithelium to eosinophils resident in 
the healthy colonic mucosa. In order to investigate this, a future program of work aims to 
isolate tissue resident eosinophils from the inflamed mucosa of IBD patients, and co-culture 
these cells with isolated colonic crypts from either inflamed or healthy mucosa. Similarly, 
eosinophils isolated from the healthy colonic mucosa can be added into culture with IBD 
crypts. In these co-culture studies the effects of eosinophils on crypt proliferation, barrier 
function through mucus secretion and cell permeability, and the reciprocal effects of the 
epithelium on eosinophil survival, migration and differential receptor expression will be 
determined in health and inflammation (depicted in Figure 5.14). 
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Figure 5.14. Proposed experimental plan for tissue resident eosinophil-crypt co-culture. 
Crypts isolated from IBD patients (1), can be added into co-culture with eosinophils isolated 
from patients with normal histopathology (2) to determine the effects of normal eosinophils 
on IBD crypts. Crypts isolated from individuals with normal histopathology (3) can be added 
into co-culture with eosinophils isolated from patients with IBD (4) to determine the effects 
of IBD eosinophils on normal crypts. 
 
5.3.2 Limitations of the current study & next steps 
In this study, human tissue resident eosinophils were isolated and purified from the colonic 
mucosa. The development of this protocol paves the way for a number of elegant co-culture 
studies with healthy and inflammatory eosinophils and isolated crypts. However, the 
maximum purity achieved using the protocol developed in this programme of work 
(described in detail in Chapter 2, Section 6.2), was 85% eosinophils. Therefore, whilst the 
addition of this population into co-culture with crypts is able to give an insight into the roles 
of eosinophils in the maintenance of renewal, we are unable to define the relative 
contribution of contaminating cell types within the ‘pure’ population. This is of particular 
importance given the recent findings from Skoczek et al. (2014), which describe an important 
role for monocytes in the maintenance of mouse colonic crypt homeostasis.  
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The generation of a pure tissue resident eosinophil population would provide the gold 
standard for the investigation of the functional roles of tissue resident eosinophils in a 
number of systems. Therefore, the employment of additional techniques in order to further 
purify the eosinophil population isolated from the intestinal lamina propria is a crucial next 
step for the eosinophil studies. In this study, flow cytometric cell sorting using the 
autofluorescent property of eosinophils was attempted. However, this technique was 
unsuccessful due to an induction of apoptosis in the mixed immune cell population when 
attempted, likely due to the mechanical stress imposed on the cells during the sorting 
procedure (data not shown). Therefore, further work is required in order to attempt to 
optimise the procedure for autofluorescence-based eosinophil cell sorting. Flow cytometric 
cell sorting has previously been utilised for the purification of isolated mouse intestinal 
eosinophil, using specific antibodies for markers of immune cells, which were used for co-
culture studies with other immune cells (Carlens et al., 2009; Chu et al., 2011). This suggests 
that eosinophils are able to withstand the mechanical process of cell sorting. Detailed 
functional analysis would be required following flow cytometric cell sorting of eosinophils in 
order to confirm that crucial receptors and factors are not lost from eosinophils during the 
sorting process. Of particular interest to our future studies are the roles of eosinophil 
paracrine secretion of PGE2 and IL-6 in epithelial renewal, therefore the expression of these 
factors would be confirmed at the mRNA and protein levels in the pure eosinophil 
population. Upon the generation of a pure eosinophil population, eosinophils would be 
added into co-culture with isolated human colonic crypts in order to assess the role of 
eosinophils in colonic crypt renewal.   
Another exciting next step for the eosinophil studies is the dynamic real-time imaging of 
eosinophil migration using multiphoton microscopy and the inherent autofluorescent 
properties of eosinophils (Ethier et al., 2014). Multiphoton microscopy uses two photons of 
light to excite fluorophores within tissue, which induces emission of a photon with a longer 
wavelength than confocal microscopy. The longer wavelength ensures less scattered light 
and less photobleaching of fluorophores. This allows for deep tissue imaging up to 500μm 
which is extremely valuable when considering in vivo imaging (Oheim et al., 2006). 
Eosinophils were shown in our system to home to sites of renewal (crypt base) and cell 
shedding (crypt top) both in vivo and in vitro co-culture. In in vitro co-culture, epithelial 
processes were shown to extend into the surrounding matrix and physically interact with 
eosinophils. This suggests that a dynamic spatial relationship is present between eosinophils 
and the epithelium, which begs the question of whether this process could be imaged live. 
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We therefore conducted proof of principle experiments whereby a colonic biopsy was fixed 
and imaged using a multiphoton microscope without any addition of fluorescent probes. We 
were able to visualize autofluorescent cells (which were shown in this study to be 
eosinophils) deep within the tissue into the submucosal layers. This paves the way for 
exciting live tissue imaging of tissue resident eosinophils within the colonic mucosa. Lamina 
propria monocytes and eosinophils migrate towards the stem cell niche following addition 
of luminal microbes to the air apical interface of a mouse colonic explant culture (Skoczek et 
al., 2014). Future work aims to identify the spatial and temporal effects of eosinophils 
following addition of commensal or pathogenic microbes to the luminal surface of live 
human colonic mucosa biopsies using multi-photon microscopy. The roles of eosinophils in 
wound healing could also be determined using this imaging technique through mechanical 
wounding of the air apical surface of the biopsy and eosinophil migration visualised in real 
time.  
 
5.4 Conclusions 
Eosinophils are known to have a number of functions in health and disease. In this chapter, 
a previously undefined spatial relationship between eosinophils and the base and top of 
crypts was described. A novel tissue resident eosinophil-crypt co-culture methodology was 
developed and initial experiments undertaken to begin to determine the relationship 
between eosinophils and human colonic crypts. The role of tissue resident eosinophils on 
isolated human colonic crypt renewal in inflammation and health remains the subject of 
future work. Previous work in this thesis has identified a novel role for autocrine IL-6 and 
PGE2 signalling in the maintenance of small intestinal and colonic crypt renewal (Chapter 3 
and Chapter 4 respectively). The roles of paracrine IL-6 and PGE2 signalling were also 
investigated, however the source of paracrine IL-6 and PGE2 in vivo remains to be 
determined. Future work aims to elucidate the role of eosinophil-secreted IL-6 and PGE2 on 
small intestinal and colonic crypt renewal.  
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6 Chapter 6. General Discussion and Future Work 
The major findings described in the preceding Chapters demonstrate that IL-6 (Chapter 3) 
and PGE2 (Chapter 4) contribute to homeostasis in the small and large intestine in an 
autocrine and paracrine manner, and suggest a dynamic role for eosinophils (Chapter 5). 
Overall, these findings provide a more comprehensive view of how autocrine and paracrine 
signalling pathways act in concert to maintain intestinal renewal. In keeping with this notion, 
the findings from each chapter are now discussed in a more integrated fashion. Moreover, a 
model for the concerted regulation of intestinal barrier function by IL-6 and PGE2 is 
formulated and is based on findings from this thesis in conjunction with other published 
work. In doing so, significant gaps in our current understanding are highlighted and 
suggestions are made on how these may be addressed. The implications for restoration of 
homeostasis in diseased states is also commented upon.  
6.1 Key Findings and Concepts 
The intestinal epithelium forms a vital barrier between host tissues and the microbial content 
of the gut lumen in vivo. Continuous epithelial renewal is modulated by innate sensing of gut 
luminal microbes, which induces cytokine secretion by epithelial cells or recruited immune 
cells residing in the underlying lamina propria. This initiates crypt cell proliferation, cell 
migration, differentiation and cell shedding in order to maintain the epithelial barrier and 
therefore intestinal homeostasis. Results described in detail in Chapters 3 and 4 suggest that 
intestinal renewal is modulated by IL-6 and PGE2 during homeostasis, and are summarised in 
Figure 6.1. The next step is to explore how autocrine and paracrine actions of IL-6 and PGE2 
converge on epithelial cell types to maintain intestinal barrier function. In order to explore 
how these pathways interact, the cellular sources, cellular targets, signal transduction 
pathways and physiological outcomes of IL-6 and PGE2 must be considered. To a first 
approximation, conservation of findings emanating from investigation of the small and large 
intestine (e.g. a goblet cell in the small intestine is similar to a goblet cell in the large 
intestine) will be assumed in order to facilitate a discussion of the possible interactions 
between IL-6 and PGE2.  
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Figure 6.1. Summary of key findings 
(1) Autocrine IL-6 signalling induces small intestinal crypt cell proliferation through activation 
of the IL-6 receptor on Paneth cells and pSTAT3 activation in a WNT dependent manner 
(Chapter 3). (2) The colonic epithelium expresses all the components required for PGE2 
signalling, COX enzymes and EP1-4 receptors. Autocrine PGE2 signalling induced colonic crypt 
proliferation through EP1 and EP3 receptor subtypes (Chapter 4). (3) Eosinophils reside along 
the crypt-axis and home to the colonic crypt base and top during homeostasis where they 
form physical interactions with epithelial cells (Chapter 5).  
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6.1.1 Sources of IL-6 and PGE2 in intestinal mucosa  
Identifying the cellular sources of IL-6 and PGE2 can give clues regarding the stimuli that 
trigger their release and their proximal cellular targets. The epithelium was shown to be an 
important autocrine source of both IL-6 and PGE2 in in vitro organoid culture; the tuft cell 
source of PGE2 synthesis was visualised by COX-1/2 enzyme expression, and discrete pools 
of IL-6 surrounding the basal epithelial membrane at the stem cell niche were observed by 
immunolabelling. Given that tuft cells are located above the stem cell niche, it is unlikely that 
PGE2 and IL-6 originate from the same cell types. Nevertheless, immunolabelling to 
determine co-expression of IL-6 protein and COX-1/2 cells would confirm whether COX-1/2 
cells are a source of IL-6. Furthermore, RT-PCR detection of IL-6 transcripts within mRNA 
isolated from small intestinal organoids suggest that the epithelium is a source (at least in 
part) of IL-6. Single cell RT-PCR could be used as an approach to identify the cellular sources 
of IL-6, and could also be used to confirm tuft cells as a source of PGE2 (i.e. enriched for COX-
1/2 expression).  
The proximal location of IL-6 and PGE2 cellular sources suggest that the secretion of one 
cytokine could influence the secretion of the other, and vice versa. In a model of breast 
cancer, expression of COX-2 by tumour-associated macrophages (TAM) induced the 
reciprocal expression of COX-2 and secretion of PGE2 by cancer cells (Li et al., 2015). 
Significantly, epithelial COX-2 activity also stimulated IL-6 secretion by TAM (Gan et al., 
2016). Moreover, IL-6 has been shown to induce COX-2 expression and PGE2 secretion in 
macrophages (Falcone et al., 2007). Hence, the potential exists for a positive feedback loop 
between IL-6 expression/secretion and COX-2 expression/PGE2 secretion in the same (i.e. 
autocrine) and/or neighbouring cells (paracrine). This paradigm could form an important 
amplification step in the mucosal immune surveillance system. Figure 6.2A illustrates a 
scenario where sensing of low levels of a given Microbe-Associated Molecular Pattern 
(MAMP) by tuft cells stimulates low levels of PGE2 secretion and, similarly, sensing of a 
different MAMP by a nearby cellular source of IL-6, stimulates low levels of IL-6 secretion. It 
is feasible that in isolation, low levels of each MAMP would not induce sufficient secretion 
of either IL-6 or PGE2 in order to modulate barrier function. However, in the presence of a 
positive feedback loop i.e. amplification, the levels of IL-6 and PGE2 secreted would be more 
likely to reach threshold levels to enact an appropriate response to maintain epithelial 
barrier homeostasis. Therefore, subthreshold levels of different MAMPs could potentially 
modulate barrier function by recruitment and cooperation of cytokines by different cellular 
sources through the formation of a positive feedback loop.  
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A similar paradigm could apply to paracrine input from subepithelial sources of IL-6 and PGE2. 
Immune cells residing in the underlying lamina propria during health, including eosinophils, 
monocytes and macrophages, represent a paracrine source of potential crypt regenerative 
factors. Published evidence, in combination with data obtained in these studies, suggests 
that eosinophils may be an important paracrine source of IL-6 and PGE2 in the intestinal 
mucosa (Rosenberg et al., 2013; Chu et al., 2014). Eosinophils were shown in Chapter 5 to 
home to the colonic stem cell niche in vivo and in a reductionist in vitro co-culture model. It 
is possible that innate sensing of MAMPs stimulates the epithelium to secrete an 
intermediate factor or chemoattractant, which induces the recruitment of eosinophils (and 
other immune cells) to the stem cell niche (Figure 6.2B). Recruited or resident eosinophils 
(or other immune cells) at the stem cell niche are well positioned to secrete paracrine factors 
for crypt regeneration, including IL-6 and PGE2, where the close proximity to the stem cell 
niche allows easy access of IL-6 and PGE2 ligand to potential targets, i.e. receptors expressed 
by specific cell types within the epithelium. In support of this, the epithelium expresses 
Eotaxin-1 (El Hadi, personal communication) for the recruitment of eosinophils and CCR3 
(the receptor for eotaxin-1) was expressed by eosinophils isolated from the intestinal lamina 
propria. The expression of IL-6 and COX enzymes were confirmed in primary eosinophils and 
HL-60-eosinophils, which indicates that following recruitment to the crypt base, eosinophils 
potentially secrete IL-6 and synthesise PGE2 in close proximity to the stem cell niche (Figure 
6.2B). This indicates a possible dynamic spatial relationship between eosinophils and the 
epithelium at the stem cell niche, which may contribute to tissue homeostasis through the 
secretion of IL-6 and PGE2. 
Alternative paracrine sources of IL-6 and PGE2 are monocytes, macrophages or 
myofibroblasts (Figure 6.2B) (Ishikawa et al., 2011; Roulis et al., 2014; Hunter and Jones, 
2015; Li et al., 2015; Villarino et al., 2015). A role for monocytes in crypt renewal during 
homeostasis in response to innate microbial sensing has previously been described (Skoczek 
et al., 2014). Monocytes are known to be a major source of IL-6 in vivo, as such IL-6 
represents a potential candidate as a regenerative factor secreted by monocytes in this 
system, although this has not yet been investigated. Macrophages and myofibroblasts have 
also been shown previously to secrete crypt regenerative factors, including IL-6 and PGE2, 
and have been associated with induction of epithelial repair processes in response to 
intestinal injury (Ishikawa et al., 2011; Roulis et al., 2014; Li et al., 2015). However, Ishikawa 
et al. (2011) induced a COX-2 deletion in all cells of myeloid origin, therefore the specific 
immune cell sources of COX-2 in epithelial regeneration was not fully investigated. Specific 
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genetic ablation of COX enzymes in each myeloid cell subtype would be required to 
determine the individual roles of eosinophils, neutrophils, monocytes and macrophages in 
PGE2-induced crypt regeneration. 
Regardless of the cellular sources of PGE2 and IL-6, their impact on epithelial barrier function 
can be predicted from the relationship between epithelial cell function and receptor subtype 
expression.  
 
Figure 6.2. Potential sources of IL-6 and PGE2 in the intestinal mucosa. 
(A) Following innate sensing of MAMPs, the epithelium secretes IL-6 and synthesises PGE2 in 
order to induce a physiological response. IL-6 is secreted in discrete pools surrounding the 
ISC niche, and PGE2 is synthesised by COX enzymes expressed on tuft cells. Whether IL-6 is 
able to induce PGE2 secretion and vice versa, in a positive feedback loop, remains to be 
determined (B) Alternatively, microbial sensing induces expression of chemoattractants (or 
other factors) which recruit immune cells including eosinophils to the stem cell niche. 
Eosinophils (EOS) or other immune cells (OIC) may then secrete IL-6 and PGE2 in a paracrine 
manner. 
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6.1.2 Differential expression of IL-6R and EPR subtypes in the intestinal 
epithelium  
The intestinal epithelium is comprised of a number of epithelial cell types, which have 
distinct functions that are highly conserved across the small and large intestine. It is logical 
to suggest that the co-expression of receptors for IL-6 and PGE2 on the same cell is predictive 
for regulation of physiological function by these cytokines. Also, the cell type and identity of 
the co-expressed cytokine receptors will be indicative of the cellular signals that are 
permissive for a given physiological outcome following receptor activation.  
For example, restricted expression of the IL-6R was observed in Paneth cells of the small 
intestine. Whilst there are no Paneth cells in the large intestine, CD24+ Goblet-Like Cells 
(GLCs) which reside in the stem cell niche at the base of crypts are thought to be the Paneth 
cell equivalent in the colon (Sato et al., 2011), suggesting that GLCs may be the site of IL-6R 
expression in the colon. GLCs express markers of goblet cells including Muc-2 and cKit (King 
et al., 2012; Rothenberg et al., 2012). All four EP receptor subtypes were expressed on Muc-
2 positive cells at the base of colonic crypts (interestingly, EP2 was exclusively expressed on 
goblet cells). This suggests the EP1-4 receptor subtypes and IL-6R may be co-expressed by 
GLCs in the colonic epithelium (Figure 6.3). Future experiments could utilise an 
immunolabelling approach to determine whether co-expression of the IL-6R and EP1-4 
receptors is observed on CD24+ GLCs in the colon, and Paneth cells in the small intestine.   
Whilst expression of the IL-6R was not observed on any other cell types of the SI epithelium, 
endogenous expression of the gp130 receptor is observed throughout the epithelium, 
suggesting that IL-6 trans signalling may be activated in other epithelial cell types, which 
express differential EP receptor subtypes. Lgr5+ colonic stem cells were shown to express 
EP1, EP3 and EP4 receptor subtypes. Lgr5 expression in stem cells is conserved across the 
colon and small intestine, therefore it is likely that EP1, EP3 and EP4 receptor subtype 
expression on stem cells is also conserved in the small intestine. The EP1 and EP3 receptor 
subtypes were also expressed on COX-1 positive cells of the colonic epithelium, suggesting 
that they may induce an autocrine positive feedback loop in order to induce further PGE2 
synthesis. It remains to be seen whether EP1 and EP3 receptor expression of COX-1 positive 
cells is conserved in the small intestinal epithelium.   
Co-expression of EP receptors and the IL-6R/gp130 on the same cell type(s) in the small 
intestine and colon suggests the possibility of integrated PGE2 and IL-6 signalling transduction 
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in the modulation of various physiological functions required to maintain epithelial 
homeostasis in the intestine.  
 
Figure 6.3. Differential IL-6 and EP receptor expression by specific cell types in the intestinal 
epithelium. 
Paneth cells are the site of restricted IL-6R expression in the SI epithelium. The expression of 
EPR on Paneth cells remains to be determined. ISC express EP1, EP3 and EP4 receptor 
subtypes. Muc-2 positive goblet cells expressed all EP receptor subtypes EP1-4. NB.* EP2 
expression was restricted to Muc-2 positive goblet cells. CD24+ goblet-like cells (GLCs) likely 
express EP1, EP2, EP3 and EP4 receptors, and the IL-6R as GLCs are to be the Paneth cell 
equivalent in the colon. COX-1 positive cells expressed the EP1 and EP3 receptor subtypes. 
The gp130 receptor is endogenously expressed by all cell types in the intestinal epithelium. 
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6.1.3 Integrated signalling transduction pathways of IL-6 and PGE2  
Another question, which remains to be investigated, is whether downstream integration of 
the IL-6 and PGE2 signalling pathways occurs during homeostasis. Following receptor 
activation, the downstream signalling cascades of IL-6 and PGE2 are activated. Up to this 
point, the pathways through which IL-6 and PGE2 transduce signals have been described as 
largely independent; IL-6 through the JAK/STAT pathway, and PGE2 through individual EP 
receptor subtypes to activate downstream intracellular calcium mobilisation or adenylate 
cyclase stimulation. In reality, convergence is likely to occur between the signal transduction 
cascades. This may be directly through co-activation of similar downstream signal 
transduction pathways, or through induction of a common intermediate signalling molecule 
(summarised in Figure 6.4).  
Activation of the JAK/STAT pathway by IL-6 induces phosphorylation of STAT3 and 
translocation into the nucleus (Scheller et al., 2011; Garbers et al., 2015). Previous studies 
have suggested that PGE2 also induces pSTAT3 activation in colorectal cancer cells through 
transactivation of the EGF signalling pathway (Oshima et al., 2011). In order to investigate 
whether PGE2/EP activates pSTAT3 during homeostasis, a similar approach to that 
undertaken in Chapter 3 could be utilised e.g. intestinal organoids/crypts could be 
stimulated with PGE2 or EP receptor selective agonists, and pSTAT3 activation in specific cell 
types determined using immunofluorescent labelling.  
Following activation of JAK/STAT signalling, and translocation into the nucleus, pSTAT3 is 
known to directly induce transcription factors including c-Myc, CyclinD1, CyclinB1 and Cdc2 
(Bromberg et al., 1999; Bowman et al., 2001; Masuda et al., 2002). Activation of these target 
genes directly induces cell proliferation (Figure 6.4, scenario 1), which again is testable in the 
crypt/organoid in vitro culture systems. IL-6 stimulation of small intestinal organoids was 
shown to induce crypt cell proliferation. However, in the absence of intestinal tissue injury, 
Paneth cells (which were identified as the site of IL-6R expression, and pSTAT3 activation) 
are not thought undergo proliferation (Roth et al., 2012). This indicates that IL-6-induced 
increase in proliferation is likely to be through pSTAT3-mediated induction of an 
intermediate signalling molecule that induces proliferation of neighbouring stem cells.  
The WNT signalling pathway is the master regulator of intestinal tissue renewal (Schepers 
and Clevers, 2012). Therefore, it is not surprising that downstream signalling of both IL-6 and 
PGE2 is now thought to be mediated by involvement of the WNT signalling pathway (Chapter 
3 and (Goessling et al., 2009)). It is therefore possible that IL-6 and PGE2 signalling are 
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integrated at the level of secretion of WNT as a common intermediate signalling molecule. It 
remains to be seen whether canonical or non-canonical WNT signalling transduction is 
initiated following activation by IL-6 or PGE2, and whether the secretion of common or 
different WNT ligands are induced following activation of IL-6 and PGE2 signalling.  
The major activator of canonical WNT signalling is WNT3 (Sato et al., 2011). Although results 
in this thesis did not show a detectable change in WNT3 expression in SI organoids following 
IL-6 stimulation, this may have been due to limitations in the sensitivity of the 
Immunofluorescent labelling technique used. Future studies aim to utilise a more sensitive 
detection method, i.e. ELISA or q-RT-PCR in order to determine whether WNT3 secretion is 
induced following IL-6 or PGE2 stimulation. WNT3 secretion by Paneth cells (or potentially 
CD24+ cells in colon) is known to bind to Frizzled receptors on neighbouring ISC (Farin et al., 
2016). This leads to inhibition of GSK3, allowing nuclear accumulation of β-catenin. β-catenin 
then induces downstream transcription of TCF/LEF transcription factors, which subsequently 
induces proliferation (reviewed in Nusse (2012)). This potential signalling transduction 
pathway is depicted in Figure 6.4, scenario 2.  
Previous studies have alluded to a role for non-canonical WNT5A in epithelial regeneration 
(Miyoshi et al., 2012).  IL-6 trans-signalling has also previously been shown to upregulate 
WNT5A in models of chronic inflammation and melanoma cell migration (Linnskog et al., 
2014). It is therefore possible that in this system, pSTAT3 activation through IL-6 classical 
signalling also activates WNT5A secretion of Paneth/CD24+ cells and the non-canonical WNT 
pathway in order to induce downstream effects on proliferation (Figure 6.4 scenario 3). WNT 
signalling augmented by PGE2 (with or without STAT3 involvement) may also be through the 
WNT5A non-canonical pathway. Future studies aim to use a WNT array to determine 
whether expression levels of canonical and non-canonical WNT associated genes are altered 
in response to IL-6 or PGE2 stimulation of organoids. 
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Figure 6.4. Integrated signalling of IL-6 and PGE2 induces crypt cell proliferation? 
Potential activation of STAT3 by PGE2 activation of EPR on ISC induces phosphorylation of 
STAT3 and translocation into the nucleus where (1) pSTAT3 induces direct activation of 
proliferation-associated target genes. IL-6 and PGE2 have both been shown to require 
involvement of the WNT signalling pathway. (2) A potential scenario is that IL-6/PGE2 
activates pSTAT3, which induces WNT3 secretion from CD24+ cells (or Paneth cells in SI) 
where WNT binds to Frizzled receptors on ISC. This activates canonical WNT signalling, which 
subsequently induces proliferation. (3) In contrast, non-canonical WNT signalling could 
become activated by secretion of WNT5A, which has also been shown to induce crypt 
regeneration.
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6.1.4 Physiological Functions of IL-6 and PGE2 signalling activation 
The physiological functions investigated within this thesis were largely focussed on cellular 
proliferation and ISC expansion required for epithelial renewal, in response to IL-6 and PGE2 
stimulation of small and large intestinal crypts/organoids, respectively. Further to the data 
presented in Chapter 3 detailing a role for IL-6 in small intestinal homeostasis, initial 
experiments have shown that exogenous addition of IL-6 to isolated mouse colonic crypts in 
culture also induces colonic crypt proliferation during homeostasis (Figure 6.5). The role of 
autocrine IL-6 in crypt cell proliferation and stem cell expansion in the colon remain to be 
determined. The experiments undertaken in Chapter 4 were focussed on the role of PGE2 
activation in crypt cell renewal in the colonic epithelium, as this is the site of colon cancer 
initiation, which PGE2 has been shown to be a driving factor of (Wang and Dubois, 2010). 
However, the role of PGE2 signalling in small intestinal renewal during homeostasis and 
disease has not yet been investigated.  
 
Figure 6.5. IL-6 induces proliferation of colonic organoids 
Histogram showing the percentage of BrdU positive nuclei in colonic organoids following 24 
hours stimulation with IL-6 (100 ng/ml) compared to control (n=3,**P<0.01; ***P<0.001) figure 
obtained by AS.  
 
Other physiological functions required for maintenance of the epithelial barrier, i.e. 
apoptosis and cell shedding or mucus secretion, have not yet been fully investigated. 
Activation of the STAT3 pathway is known to induce the production of factors to prevent 
apoptosis and prolong survival (reviewed in Jarnicki et al. (2010)). Data in this thesis alluded 
to a role for STAT3 in prevention of apoptosis in small intestinal organoids (quantified using 
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caspase-3 as a marker of apoptosis); however, the percentage change in caspase-3 positive 
cells was minimal in comparison to the percentage change in BrdU incorporation, indicating 
that the major physiological function initiated following STAT3 activation was cell 
proliferation. Furthermore, the restricted expression of the EP2 receptor subtype on goblet 
cells of the colonic epithelium suggests that EP2 receptor signalling may play a major role in 
mucus secretion, which is required for maintenance of epithelial barrier homeostasis 
(Johansson et al., 2013). The effects of IL-6 or PGE2 signalling in apoptosis, cell differentiation 
and mucus secretion remain the focus of future studies.  
It is possible that physiological processes required to maintain epithelial barrier homeostasis 
require combined activation by these two cytokines. Alternatively, compensatory 
mechanisms may exist between IL-6 and PGE2 during homeostasis in order to ensure 
sufficient proliferation, i.e. where IL-6 is lost in the SI, PGE2 induces SI renewal to maintain 
crypt homeostasis. An obvious initial experiment to conduct in order to determine the role 
of IL-6 cross-talk with PGE2 signalling in intestinal homeostasis, would be to simultaneously 
add exogenous IL-6 and PGE2 to intestinal crypt culture and determine the effects on the 
signalling pathways discussed above and physiological processes underpinning barrier 
function such as cell proliferation and stem cell expansion. In addition, treatment of 
colonic/SI organoids with the IL-6R-blocking antibody or IL-6-neutralising antibody in 
combination with exogenous addition of PGE2 would be required in order to determine 
whether PGE2-induced increase in proliferation is dependent on IL-6. Similarly, addition of 
the PGE2 blocking antibody to organoid culture in combination with exogenous IL-6 addition 
would identify whether the IL-6-induced increase in proliferation is dependent on PGE2.  
These experiments could be conducted in combination with experiments detailed in section 
6.1.3 for investigation into the downstream signalling integration between IL-6 and PGE2. For 
example, the potential activation of pSTAT3 in response to PGE2 may require input from 
endogenous IL-6 signalling. Therefore, immunofluorescent pSTAT3 labelling experiments in 
response to PGE2 stimulation would be conducted in the presence and absence of an IL-6 
blocking antibody.  
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6.1.5 An Integrated Model for IL-6/PGE2-mediated regulation of epithelial barrier 
homeostasis 
The discussion in the preceding sections gives rise to a model whereby IL-6 and PGE2 
signalling act in concert to maintain epithelial barrier homeostasis (depicted in Figure 6.6). 
Innate sensing of microbial patterns from commensal bacteria residing in the gut lumen 
initiates physiological processes which are required for the maintenance of the epithelial 
barrier (1). The epithelium is an important autocrine source of IL-6 and PGE2 (2). Whether a 
positive feedback loop exists between IL-6 and PGE2, through induction of endogenous IL-6 
signalling in response to PGE2 secretion, or vice versa remains to be seen. Potential 
subepithelial paracrine sources of PGE2 and IL-6 are eosinophils, which home to the crypt 
stem cell niche and crypt top along the crypt-axis in the underlying lamina propria of the 
intestinal mucosa (3). Provision of IL-6 or PGE2 ligand in close proximity to the stem cell niche, 
through epithelial or subepithelial sources, induces receptor subtype(s) activation in 
differential cell types of the epithelium. Potential receptor co-expression of IL-6R and EP 
receptor subtypes on CD24+ cells in the colon represents possible integration between PGE2 
and IL-6 signalling transduction for physiological function (4). IL-6 and PGE2 (via EGFR 
transactivation) could act in synergy to activate STAT3 (5). STAT3 activation mediates crypt 
cell proliferation, possibly through the secretion of WNT ligands derived from the stem cell 
niche, which could serve as common intestinal (stem) cell mitogens downstream of IL-6 and 
PGE2 receptor activation. The roles of IL-6 and PGE2 signalling in the regulation of other 
processes that underpin epithelial barrier function such as cell differentiation, apoptosis or 
mucus secretion remain to be elucidated. 
Chapter 6. General Discussion and Future Work 
 
190 
 
 
Figure 6.6. Integrated model for the dynamic regulation of intestinal homeostasis by IL-6 
and PGE2. 
(1) Innate sensing of MAMPS initiates physiological processes for epithelial barrier 
maintenance. (2) The epithelium is an autocrine source of IL-6 and PGE2. (3) Potential 
subepithelial sources of IL-6 and PGE2 are eosinophils, which reside at the intestinal stem cell 
niche and crypt top during health. (4) Potential co-expression exists for the IL-6R and EP1-4 
receptor subtypes on CD24+ cells of the colon. (5) IL-6 (and PGE2) activates STAT3 which 
mediates cell proliferation, possibly through the secretion of WNTs as a potential common 
intermediate signalling molecule.  
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secreted (through an increase in immune cells) results in increased signalling through the 
same pathway, and therefore induce a higher magnitude of the same physiological responses 
observed in health. Alternatively, different signal transduction pathways may be activated in 
health and disease to induce different (patho) physiological functions.  
6.2.1 Increase in concentration of factors secreted in IBD and cancer 
Eosinophils are a paracrine source of both IL-6 and PGE2 in the intestinal lamina propria that 
are known to reside in high numbers in the lamina propria in health and in IBD (Rosenberg 
et al., 2013; Chu et al., 2014). The striking spatial relationship observed between eosinophils 
and the ISC niche described in this thesis suggests that eosinophils may play a role in 
maintaining the stem cell niche during health. This spatial relationship was also observed 
between monocytes and the crypt base of the human colonic epithelium in vivo and in in 
vitro co-culture with the THP-1 monocytic cell line (Appendix C and D), in agreement with 
published work (Skoczek et al., 2014). In tissue sections obtained from patients with active 
IBD, a 1.2 fold increase in the number of eosinophils was observed at the stem cell niche 
(29.8+/-3.3 IBD compared to 13.4+/- 0.9 control, P<0.001). In IBD tissue, a significant 
increase in the number of CD14+ monocytes was also observed in all functional regions 
compared to healthy tissue in vivo (Appendix C). The increase in numbers of eosinophils 
and monocytes present at the ISC in IBD suggests may indicate an increase in secreted crypt 
regenerative factors (IL-6 and PGE2).   
Cell shedding is another process of vital importance to maintain the balance of cell growth 
and apoptosis in the intestine, which prevents the accumulation of cells and cancer-driving 
genetic mutations. Interestingly, a significant increase in the number of eosinophils and 
monocytes present at the top region of crypts (the site of cell shedding) was observed in 
IBD samples compared to control. This indicates that in IBD, eosinophils and monocytes 
may play a role in re-establishing homeostasis following inflammation through modulating 
stem-cell driven proliferation and cell shedding.  
Future studies aim to identify whether a potential increase in secreted concentrations of IL-
6 and PGE2 by eosinophils, monocytes (and macrophages) at functional regions of crypts 
play a role in the modulation of crypt renewal to re-establish homeostasis following 
inflammation. Alternatively, increased paracrine secretion of IL-6 and PGE2 at functional 
regions of crypts by immune cells may induces a pathogenic response, i.e. inflammation or 
uncontrolled crypt cell proliferation, in inflammation and cancer.  
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6.2.2 Differential activation of IL-6 trans-signalling or the EP2/4 receptor 
signalling axis in inflammation and cancer 
The data presented in this thesis, in combination with previous work in the literature, 
suggests that in health and disease, IL-6 and PGE2 may act through different signal 
transduction pathways in order to induce physiological functions in the prevention or 
pathogenesis of inflammation or cancer. Novel data has been described in this thesis, to 
support the paradigm that IL-6 classic signalling is important for epithelial renewal during 
homeostasis. The pro-inflammatory responses of IL-6 signalling are thought to be mediated 
through IL-6 trans-signalling (Jones et al., 2005; Scheller et al., 2011), which could be 
investigated in future experiments utilising the hIL-6 fusion protein (IL-6 linked to IL-6R by a 
flexible peptide chain) (Fischer et al., 1997). We speculate that addition of hIL-6 into organoid 
culture would induce global pSTAT3 activation in all cells of organoids through binding to 
endogenously expressed gp130, potentially mimicking the result obtained by Aden et al 
(2016), where hIL-6 induced an increase in pSTAT3, which was detectable by western blot 
(Aden et al., 2016). It would be of interest to compare the magnitude of epithelial response 
to IL-6 to hIL-6 with respect to proliferation, apoptosis and inflammatory markers or tissue 
damage.  IL-6 trans-signalling has also previously been shown to enhance the growth of 
tumour initiating cells. It is possible that the paradigm we observe during homeostasis, 
whereby IL-6 binds the IL-6R on Paneth cells, which activates pSTAT3 and induces crypt cell 
proliferation, induces a tightly regulated renewal required to maintain the epithelial barrier. 
We speculate that in cancer, the IL-6R is cleaved from the membrane of Paneth cells and 
lamina propria immune cells, which enables activation of IL-6 trans signalling in all cells of 
the small intestinal epithelium. This may then induce uncontrolled proliferation through 
increased secretion of WNTs or direct activation of proliferative genes. Immunofluorescent 
labelling of the IL-6R in tissue derived from tumours would enable us to determine whether 
IL-6 trans-signalling contributes to tumorigenesis. 
Cleavage of the IL-6R in IL-6 trans signalling is dependent on ADAM10/17 proteases 
(Matthews et al., 2003; Chalaris et al., 2010). Interestingly, EP4-mediated PGE2 signalling was 
previously shown to upregulate expression of ADAM proteases (including ADAM10/17), 
which was shown to induce transactivation of the EGFR pathway (Oshima et al., 2011). 
Transactivation of the EGFR by PGE2 also induces STAT3 activation (Normanno et al., 2006). 
The upregulation of ADAM proteases provides a potential mechanism for the PGE2-induced 
transactivation of STAT3 through activation of IL-6 trans signalling, and suggests the presence 
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of positive feedback loop between PGE2 and IL-6 signalling which may be implicated in cancer 
(Figure 6.7). 
The roles of IL-6 classic and trans signalling in cell shedding have not yet been determined. 
STAT3 activation also plays a role in the regulation of anti-apoptotic and pro-survival factors 
(Yu et al., 2009). In agreement with this, the number of cells undergoing apoptosis 
(determined by caspase-3 activation) was increased following STAT3 inhibition with STATTIC- 
treatment of SI organoids. In the case of tumorigenesis, it is possible that a cumulative effect 
of uncontrolled proliferation, combined with prevention of apoptosis, is initiated by IL-6 
trans-signalling which induces tumour growth in the intestine. The novel roles described in 
this thesis for IL-6 signalling in the maintenance of small intestinal renewal during 
homeostasis are of importance when considering the perturbation of the IL-6 signalling 
pathway as a therapeutic target. For these reasons, the abrogation of inflammatory IL-6 trans 
signalling, whilst maintaining IL-6 classical signalling required for intestinal renewal during 
homeostasis appears to be an attractive strategy for developing treatments for inflammatory 
diseases and cancer.  
A novel role for differential EP1/EP3 receptor activation by PGE2 during health has been 
described. Autocrine and paracrine PGE2-induced crypt cell proliferation was mediated 
through activation of EP1 and EP3 receptor subtypes, and EP2 and EP4 receptor subtype 
activation/inhibition induced no change in basal crypt cell proliferation compared to control 
crypts during homeostasis. Previous studies have suggested that signalling through the EP2 
and EP4 receptor subtypes induce intestinal polyposis, tumour cell proliferation and tumour 
invasion (Sonoshita et al., 2001; Kamiyama et al., 2006; Hawcroft et al., 2007; Chang et al., 
2015; Lee et al., 2016). Therefore, PGE2 may activate EP1/3 receptor subtypes during health, 
and EP2/4 receptor subtypes during cancer in order to induce crypt cell proliferation. This 
suggests that targeting PGE2 signalling through the EP2 or EP4 receptor subtypes may inhibit 
tumorigenesis and tumour cell proliferation, whilst maintaining EP1/3 receptor signalling 
required for basal cell proliferation in steady state renewal. However, EP2 receptor signalling 
has previously been associated with maintenance of the mucosal barrier (Lejeune et al., 
2014), a paradigm supported by our finding that expression of the EP2 receptor was 
restricted to goblet cells of the colonic epithelium, which are vital for the replenishment of 
mucus layers to protect the epithelium (Johansson et al., 2013). In addition, the EP4 receptor 
subtype has also been described to ameliorate severe colitis and reduce mucosal damage 
following DSS-induced colitis (Kabashima et al., 2002). Therefore, whilst EP2/EP4 receptor 
signalling abrogation may reduce proliferation in tumour cells, the effects on epithelial 
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barrier function and inflammation would need to be fully investigated before targeting of 
this pathway for the development of anti-cancer therapies. 
 
 
Figure 6.7. In tissue injury or cancer, IL-6 trans-signalling and PGE2 potentially contribute 
to inflammation and carcinogenesis 
In cancer, EP4-mediated PGE2 signalling induces upregulation of ADAM protease, which 
cleave the IL-6R from the Paneth cell and eosinophil membrane. Secreted IL-6 and can then 
bind and activate downstream signalling in all cells of the epithelium. This induces global 
pSTAT3 activation to induce activation of genes for proliferation and survival, possibly 
potentiating carcinogenesis. In tumorigenesis, COX-2 potentially activates the EP2 and EP4 
receptor subtypes in GLCs and ISC at the crypt base to induce uncontrolled cell proliferation 
and carcinogenesis through transactivation of the EGF signalling pathway and IL-6 trans-
signalling.   
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6.3 Concluding Remarks 
In summary, a reductionist approach has been utilised to investigate a role in intestinal 
homeostasis for two cytokines previously associated with inflammation and cancer. Novel 
contributions for IL-6 and PGE2 were demonstrated in the renewal of the intestinal 
epithelium. Autocrine and paracrine IL-6 (classic) signalling was shown to induce crypt cell 
proliferation, through activation of pSTAT3 in Paneth cells of the small intestine. A previously 
unrecognised role for PGE2 signalling, through activation of EP1/3 receptor subtypes was 
revealed in colonic crypt proliferation during homeostasis. Eosinophils are a potential 
paracrine source of IL-6 and PGE2, which form a dynamic spatial relationship with the 
intestinal stem cell niche and shedding zone of the intestinal epithelium. An integrated 
model for IL-6/PGE2-mediated regulation of epithelial barrier homeostasis has been 
proposed and future studies will determine the molecular and cellular interactions in these 
respective pathways and assess the impact on intestinal homeostasis and pathogenesis. It is 
envisaged that this knowledge will pave the way for the development of novel preventative 
and therapeutic strategies.  
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Appendix A. EP Receptor Gradient Intensity Analysis 
 
Figure A.0.1. Analysis of gradient intensity of EP receptor labelling along crypt-axis in vivo 
and in vitro. 
Histograms (LEFT) and representative fluorescence images (RIGHT) of EP receptor 
fluorescence intensity of: (A) EP1 in vivo, (B) EP1 in vitro, (C) EP2 in vitro, (D) EP2 in vitro, (E) 
EP3 in vivo, (F) EP3 in vitro, (G) EP4 in vitro, (H) EP4 in vivo. EP receptor labelling shown in 
red, white dash denotes crypt outline. (n=3, *P<0.05, **P<0.005, ***P<0.001) scale bar 
10μm. 
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Appendix B. Chemoattractant markers expressed by isolated 
immune cells 
 
Figure B.0.1. Immune cells isolated from the colonic lamina propria express markers 
characteristic of immune cells. 
Expression of immune cell characteristic mRNA by RT-PCR using cDNA from isolated tissue 
resident immune cells, eosinophil purity was between 55 and 65% for all samples used. 
Expected PCR band sizes: CCR10=285bp, CCRL2=272bp. 
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Appendix C. Monocyte distribution along the crypt axis in vivo 
 
Figure C.0.1. Characterisation of tissue resident CD14+ cells in the colonic mucosa of 
healthy and IBD patients. 
(A) Immunofluorescent labelling of CD14+ cells (pink) and nuclei (DAPI-blue) in the colonic 
mucosa of tissue obtained from healthy (control, left) and IBD (right) patients, white dashes 
represent base, mid and top regions. Images representative of n=3 experiments. (B) 
Histogram showing the number of CD14+ cells per crypt in the base, mid and top regions of 
IBD and control sections, mean values ± SEM were plotted for each crypt region (n=3, 
***P<0.001 compared to indicated crypt regions, $$$P<0.001 compared to mid region of 
control crypts, &P<0.05 compared to top region of control crypts). (C) Histogram showing 
the total number of CD14+ cells per crypt in IBD samples compared to control 
(n=3,***P<0.001). Scale bar 50µm.
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Appendix D. Monocyte distribution along the crypt-axis in 
vitro 
 
Figure D.0.1. A similar spatial distribution to that observed in vivo is observed between 
monocytes and the epithelium in vitro. 
Histogram showing a significant increase in the number of THP-1 cells surrounding the base 
of human colonic crypts in co-culture compared to mid and top region (n=3, *P<0.01). 
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Appendix E. Interleukin-6 Signaling Regulates Small Intestinal 
Crypt Homeostasis  
Chapter 3 includes work from the following jointly authored publication in The Journal of 
Immunology: 
Jeffery, V., A. J. Goldson, J. R. Dainty, M. Chieppa and A. Sobolewski (2017). "IL-6 Signaling 
Regulates Small Intestinal Crypt Homeostasis." J Immunol 199(1): 304-311. 
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IL-6 Signaling Regulates Small Intestinal Crypt Homeostasis
Victoria Jeffery,*,† Andrew J. Goldson,‡ Jack R. Dainty,x Marcello Chieppa,{ and
Anastasia Sobolewski*,†,‡
Gut homeostasis is a tightly regulated process requiring finely tuned complex interactions between different cell types, growth
factors, or cytokines and their receptors. Previous work has implicated a role for IL-6 and mucosal immune cells in intestinal
regeneration following injury and in promoting inflammation and cancer. We hypothesized that IL-6 signaling could also mod-
ulate crypt homeostasis. Using mouse in vitro crypt organoid and in vivo models, this study first demonstrated that exogenous IL-6
promoted crypt organoid proliferation and increased stem cell numbers through pSTAT3 activation in Paneth cells. Immunolab-
eling studies showed that the IL-6 receptor was restricted to the basal membrane of Paneth cells both in vitro and in vivo and that
the crypt epithelium also expressed IL-6. Either a blocking Ab to the IL-6 receptor or a neutralizing Ab to IL-6 significantly
reduced in vitro basal crypt organoid proliferation and budding, and in vivo significantly reduced the number of nuclei and the
number of Lgr5EGFP-positive stem cells per crypt compared with IgG-treated mice, with the number of Paneth cells per crypt
also significantly reduced. Functional studies demonstrated that IL-6–induced in vitro crypt organoid proliferation and crypt
budding was abrogated by the Wnt inhibitor IWP2. This work demonstrates that autocrine IL-6 signaling in the gut epithelium
regulates crypt homeostasis through the Paneth cells and the Wnt signaling pathway. The Journal of Immunology, 2017, 199:
000–000.
T
heintestinal epithelium is the most rapidly renewing tissue
in the body, with the entire epithelium being replaced
every 5–7 d. This renewal takes place by way of Lgr5-
positive stem cells located at the base of intestinal crypts; stem
cells proliferate, migrate along the crypt-villus axis, differentiate
(into Tuft cells, enteroendocrine cells, Paneth cells, enterocytes,
and goblet cells), and are shed into the gut lumen (1). Through the
secretion of Wnts, epithelial Paneth cells play a major role in the
maintenance of the crypt stem cell niche (2). Previous work has
also shown that other growth factors and cytokines, as well as
immune cells are key in modulating epithelial stem cell–driven
tissue renewal during homeostasis (3–8). Understanding the
mechanisms by which these pathways are regulated in the epi-
thelium through autocrine (and paracrine) signaling is not fully
understood.
Seminal work in the Drosophila gut has shown regenerative
responses following infection are regulated by JAK/STAT signal-
ing in gut epithelial stem cells through the release of enterocyte-
derived Upd3, an IL-6–like cytokine (9, 10). In the mammalian
gut both IL-6 and STAT3 have been shown to play a role in the
proliferation of the colonic epithelium following injury and to
promote the survival of epithelial cells (11–14) during inflam-
mation and inflammatory bowel disease (15, 16).
IL-6 is a pleiotropic cytokine involved in a plethora of cellular
and immune responses in health, disease, and cancer (17–19). IL-6
signaling involves the convergence of a number of signaling
components (20). IL-6 first binds to a membrane-bound non-
signaling a-receptor IL-6 (mbIL-6R) located on the target cell.
Next, this IL-6R/IL-6 complex binds to the ubiquitously expressed
type I transmembrane transducer protein gp130, which results
in activation of downstream signaling components JAK/STAT,
ERK, and PI3K signaling pathways. Cells that express both the
IL-6R and gp130 are responsive to IL-6; this is termed classic
signaling and is traditionally associated with homeostasis. IL-6
can also signal via trans signaling, where the soluble IL-6 re-
ceptor, shed from the cell membrane via proteolytic cleavage of a
membrane-bound precursor, binds to IL-6. This IL-6/soluble IL-6
receptor complex can then activate IL-6 signaling in any cell
expressing gp130; this trans-signaling pathway is associated with
inflammation and cancer (21).
The aim of this study was to determine whether IL-6 classic
signaling could modulate small intestinal crypt homeostasis. This
work demonstrates a previously unidentified role for autocrine IL-6
signaling in the maintenance of the crypt stem cell niche, through
the differential expression of the IL-6 receptor and downstream
STAT3 signaling in Paneth cells and the Wnt signaling pathway.
Materials and Methods
Mice and in vivo studies
LGR5-EGFP-Ires-CreERT2 (Jackson Laboratory) or C57BL/6 mice aged
8–12 wk were used. Generation and genotyping of the LGR5-EGFP-Ires-
CreERT2 allele has been described previously (1). All animal experiments
were conducted in accordance with the Home Office Animals Scientific
Procedures Act of 1986 with approval of the University of East Anglia
Ethical Review Committee, Norwich, U.K. and under Home Office project
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license number 80/2545. Blocking Abs for IL-6 and IL-6 receptor or IgG
controls (Bio X Cell) were administered to mice three times on alternate
days by i.p. injection at a concentration of 58 mg/g. Animals were eu-
thanized by Schedule One approved methods on day 6, and tissue pro-
cessed immediately. In addition, small intestinal tissue from IL-6 knockout
mice (B6.129S2-Il6tm1Kopf/J; Jackson Laboratory) was used to count the
number of lysozyme-positive cells per small intestinal crypt.
Reagents
Crypt culture media and supplements. Advanced DMEM/F12, GlutaMAX,
B27, and N2 were purchased from Invitrogen. Murine recombinant epi-
dermal growth factor, noggin, IL-6, and IL-22 were all obtained from
PeproTech and mouse recombinant R-spondin 1 from R&D Systems.
Growth factor–reduced Matrigel was purchased from VWR International.
Immunolabeling. Primary and secondary Abs were as follows: rat anti-BrdU
(Abcam), mouse anti-lysozyme (Abcam), goat anti–E-cadherin (R&D),
rabbit IgG, rabbit anti–IL-6 receptor, anti–IL-6 (Bio X Cell), rabbit anti-
pSTAT3 Tyr705, pSTAT3 Y705 blocking peptide, and rabbit anti–cleaved
caspase-3 (Cell Signaling). Immunolabeling was visualized by using an
appropriate combination of species-specific Alexa Fluor–conjugated sec-
ondary Abs (488, 568, and 647 nm), raised in mouse, donkey, or goat
(Invitrogen). FITC-conjugated Ulex europaeus lectin (UEA-1) was pur-
chased from Sigma. Vectashield-mounting medium with DAPI was pur-
chased from Vector Laboratories; STATTIC and IWP2 were purchased
from Tocris Bioscience.
Crypt isolation and culture
Small intestinal crypts were isolated from the proximal small intestine of
LGR5EGFP mice as previously described (2). Briefly, the mouse small
intestine was opened longitudinally, washed with PBS, cut into 2–4 mm
pieces and incubated with 1 mM EDTA in PBS (pH 7.4) for 30 min at 4˚C.
Crypts were liberated by serial rounds of pipetting in ice cold PBS and
removal of the crypt enriched supernatant; the solution was then filtered
through a 70 mm cell strainer followed by centrifugation. Next, 50–100
crypts were embedded in a 200 ml droplet of growth factor–reduced
Matrigel (VWR) and seeded on No. 0 coverslips (VWR) contained within
a 12-well plate (Nunc). After polymerization at 37˚C for 5–10 min, crypts
were flooded with 0.5 ml of mouse crypt culture medium (MCM): ad-
vanced F12/DMEM containing B27, N2, n-acetylcysteine (1 mM), HEPES
(10 mM), penicillin/streptomycin (100 U/ml), GlutaMAX (2 mM), epi-
dermal growth factor (50 ng/ml), noggin (100 ng/ml), and R-spondin 1
(1 mg/ml).
In IL-6–neutralizing or IL-6 receptor–blocking Ab experiments, crypts
were incubated for the entire 48 h period in MCM and appropriate Ab or
respective IgG control before addition of BrdU (1 mM) for 17 h.
Following 48 h culture with MCM, crypts were stimulated with IL-6 at
concentrations of 10 ng/ml to 1 mg/ml for 15 min to 17 h for pSTAT3
experiments, and for proliferation experiments placed into 10% MCM for
5 h, after which BrdU (1 mM) was added for 17 h. For STAT3 inhibition
studies, crypts were preincubated with STATTIC (20 mM) or IWP2 (5 mM)
for 1 h prior to addition of IL-6 (100 ng/ml) stimulation for 17 h (as de-
scribed previously).
For pSTAT3 activation studies, the IL-6–neutralizing Ab was pre-
incubated with IL-6 (100 ng/ml) for 1 h before addition to the crypts for
1 h. For receptor Ab studies, crypts were preincubated for 1 h with the IL-6
receptor–blocking Ab before addition of IL-6 (100 ng/ml) for 1 h. The
same protocol was used for proliferation experiments, prior to the addition
of IL-6 and BrdU (1 mM) 17 h.
For chronic IL-6 stimulation, crypts were incubated for 5 d with MCM
containing 100 ng/ml IL-6 before addition of BrdU (1 mM) for 17 h;
medium was changed every 2 d.
Immunolabeling
Mouse Lgr5EGFP small intestines were fixed in 4% paraformaldehyde,
frozen in isopentane, and stored at 220˚C. Following the culture period,
small intestinal crypts were fixed with 4% paraformaldehyde. Next, 8–20
mm cryosections of small intestinal tissue (CM 1100C cryostat; Leica) or
small intestinal crypts were permeabilized with 0.5% Triton–X (Sigma),
blocked with 10% FBS, and stained with primary Abs diluted (1:100) in
PBS overnight at 4˚C, followed by the corresponding secondary
fluorescence-conjugated Abs (1:200 in PBS) for 2 h as previously de-
scribed (3, 4, 22).
Microscopy
Following immunofluorescent staining, samples were visualized by laser
scanning confocal (510 META; Zeiss) or epifluorescence (Nikon Ti)
microscopy. For confocal microscopy a 340 1.3 NA oil objective or 363
1.4 NA 0.75 mm WD oil immersion objective was used to obtain confocal
images. Image stacks were taken at 1–3 mm intervals, which allowed se-
lection of precise focal planes. A 340 1.1 NA oil objective was used to
image samples on the epifluorescent microscope.
Image analysis
For all experiments, between 20 and 100 crypts (in vivo) or organoids
(in vitro) were counted per condition and each experiment was performed at
least three separate times (i.e., at least three different mice were used).
In vitro. ImageJ software was used to count the total number of DAPI-
labeled cell nuclei in the crypt equatorial plane. The number of cells
that were positive for BrdU or Lgr5EGFP was then expressed as a per-
centage of the total nuclei number. For semiquantitative analysis of pSTAT3
activation, regions of interest were drawn around the entire Paneth cell
nuclei and the average fluorescence intensity of the region calculated.
In vivo. Lgr5EGFP stem cells, lysozyme-, or UEA-1–positive Paneth cells
were counted by taking a z-stack across the equatorial plane of the crypt
and counting the number of nuclei in this stack that were positive for each
marker. To determine the crypt length and villus height in vivo, at least 25
well-orientated crypts and villi were measured using the segmented line
tool (Fiji 1.50e) from three animals in each treatment group.
mRNA isolation and quantification
Isolation. RNA was isolated from freshly liberated or cultured small in-
testinal crypts using the Isolate II RNA mini kit (Bioline). Total RNAyield
was determined using a NanoDrop ND-1000 spectrophotometer (Thermo
Fisher Scientific) and purity assessed by the ratio of absorbance at 260–280
nm. cDNA was generated from 0.5 mg RNA using the RT2 First Strand
cDNA synthesis kit (Qiagen).
Quantification. End-point PCRs were performed in a final volume of 25 ml,
comprising 200 nm forward and reverse primers, 200 mM dNTP, 0.5 U Taq
polymerase, PCR buffer (Roche), 2.5 mM MgCl2, 0.5 ml cDNA using a
Tprofessional TRIO thermal cycler (Biometra) with the following thermal
profile: one cycle at 94˚C for 3 min, 30 cycles at 94˚C for 25 s, 58˚C for 30
s, and 72˚C for 50 s, and 1 cycle at 72˚C for 5 min. The primer sequences
used are as follows; IL-6 forward primer: 59-GCTACCAAACTGGATA-
TAATCAGGA-39; reverse primer: 59-CCAGGTAGCTATGGTACTCCA-
GAA-39. PCR products were run on a 2% agarose gel visualized by
ethidium bromide staining.
Statistics
Experiments were performed at least three times. Data are expressed as
mean 6 SE and significance determined by a Student t test or by one-way
ANOVA with post hoc Tukey analysis, with p values , 0.05 considered
significant.
Results
IL-6 stimulates proliferation of small intestinal organoids via a
STAT3-mediated signaling pathway
First we determined the effect of exogenous IL-6 on the BrdU
incorporation of small intestinal organoids through immunofluo-
rescence microscopy (Fig. 1A). IL-6 caused a significant increase
in the incorporation of BrdU at 10 and 100 ng/ml IL-6, but
exhibited a dome-shaped response curve at higher concentrations
(1000 ng/ml) (Fig. 1B). Using the specific STAT3 inhibitor
STATTIC, we demonstrated that the increased BrdU incorporation
induced by IL-6 was significantly reduced compared with IL-6
alone (Fig. 1C). There was no effect of STATTIC on basal pro-
liferation, which was in contrast with the effects of chronic
treatment with STATTIC, where a significant decrease in BrdU
incorporation compared with control was observed (Supplemental
Fig. 1A). Organoid survival following STATTIC treatment in the
presence or absence of IL-6 was comparable to control (DMSO
control 74.9 6 3.9; STATTIC 73.7 6 4.5; IL-6 63.1 6 4.9;
STATTIC + IL-6 69.5 6 4.7). However, there was a small but
significant (n = 3, **p , 0.01) effect of STATTIC on the per-
centage of caspase 3–positive cells per crypt compared with
control (DMSO control 3.6 6 0.4; **STATTIC 6.0 6 0.7; IL-6 2.
2 6 0.4; STATTIC + IL-6 4.8 6 0.7). A significant increase in
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BrdU incorporation was observed following chronic IL-6 stimu-
lation (Supplemental Fig. 1B).
IL-6 induces activation of nuclear pSTAT3 in Paneth cells of
the small intestine via differential expression of the IL-6
receptor
We next investigated the effect of IL-6 on pSTAT3 activation in the
small intestinal epithelium using immunolabeling and visualiza-
tion of pSTAT3 activation by confocal microscopy. Following 1 h
stimulation with IL-6 (100 ng/ml), we observed pSTAT3 (green) in
the nucleus (red) of UEA-1– (pink) and lysozyme-positive (blue)
cells, which was abrogated by a blocking peptide to pSTAT3
(Fig. 2A). No fluorescent labeling was observed in IgG controls
for the lysozyme Ab (Supplemental Fig. 1C). Following IL-6
stimulation, all UEA-1 lysozyme-positive cells in a crypt do-
main were positive for nuclear pSTAT3 (see projection Fig. 2A).
All lysozyme-positive cells were UEA-1 positive and character-
istic of Paneth cells (23). Although the majority of control orga-
noids expressed no pSTAT3 (Fig. 2B), nuclear pSTAT3 activation
in UEA-1–positive cells was observed in 9 out of 113 control
organoids counted. Time course studies showed that maximal
activation of nuclear (red) pSTAT3 (green) in UEA-1–positive
(pink) Paneth cells occurred at 30 min, and persisted at 1 and 3 h
poststimulation (Fig. 2B). Semiquantitative analysis showed the
level of nuclear pSTAT3 activation remained significantly higher
than control levels 1 and 3 h after IL-6 stimulation. Results also
showed that pSTAT3 phosphorylation levels at 1 h were the same
for 100 or 1000 ng/ml IL-6 (Fig. 2C).
The localization of the IL-6 receptor (red) in organoids was
restricted to the basal membrane of lysozyme-positive (green) cells
of the small intestine in vitro (Fig. 2D). Furthermore, in vivo la-
beling of the IL-6 receptor displayed the same distribution as in
the in vitro crypt organoid cultures (Fig. 2E), with basal epithelial
IL-6 receptor expression constrained to the lysozyme-positive
cells (green) and on the membrane of their intracellular granules
(Fig. 2F) with no fluorescence observed in the IgG control for
lysozyme (Supplemental Fig. 2D). No IL-6R was expressed on
Lgr5EGFP-positive stem cells (cyan). The small intestinal crypt
in vitro model was therefore considered a relevant in vitro model
to study IL-6 signaling in the small intestinal crypt epithelium.
Next, we demonstrated the ability to modulate the IL-6 STAT3
signaling axis in small intestinal organoids utilizing a receptor-
blocking Ab to IL-6 or neutralizing Ab to IL-6. Either of these
Abs in combination with IL-6 abrogated the IL-6–induced phos-
phorylation of STAT3 (Supplemental Fig. 1J–M).
Autocrine IL-6 signaling in the small intestinal epithelium
modulates crypt cell proliferation in vitro
The next step was to determine whether autocrine IL-6 signaling
played a role in crypt homeostasis. We first used conventional PCR
to demonstrate the expression of IL-6 mRNA in crypts in vivo using
freshly isolated (0 h) and in vitro cultured (48 h) small intestinal
crypts (Fig. 3A). Immunofluorescent studies showed that IL-6
protein (red) was localized inside epithelial cells toward the
basal pole as well as extracellularly in discrete pools around the
crypt basal membrane (white arrows, Fig. 3B). We next used a
blocking Ab to the IL-6 receptor or a neutralizing Ab to the IL-6
cytokine in crypt organoid cultures and assessed basal BrdU in-
corporation (Fig. 3C, 3D respectively), and observed a significant
decrease in the percentage of crypt nuclei incorporating BrdU
compared with the respective IgG controls with both Abs.
We also confirmed that the Abs could functionally block IL-6
signaling in organoids. Incubation of either an IL-6 receptor–
blocking or an IL-6 neutralizing–Ab with IL-6 significantly de-
creased BrdU incorporation of organoids compared with IL-6
stimulation alone (Supplemental Fig. 1D, 1E). Caspase 3 (used
as a measure of cell death), and organoid survival was unaffected
by either of these Ab treatments compared with IgG control
organoids (Supplemental Fig. 1F–I).
Lack of gut phenotype in IL-6 knockout mice
To understand the effects of perturbation of the IL-6 signaling
pathway in vivo, tissue was obtained from IL-6 knockout mice. No
difference was observed in the number of lysozyme-positive cells
per crypt, crypt length, and the number of nuclei per crypt in IL-6
knockout tissue compared with wild-type tissue (Supplemental
Fig. 2A–C). Furthermore, using immunolabeling, low levels of
pSTAT3 were detected in some UEA-1–positive cells at the base
of the crypts in both wild-type and IL-6 KO small intestine
(Supplemental Fig. 2J, 2K). We confirmed the specificity of the
pSTAT3 Ab labeling by using a blocking peptide to pSTAT3,
which abrogated the pSTAT3 signal in the UEA-1–positive cells
(Supplemental Fig. 2I).
IL-6 signaling axis modulates Lgr5EGFP stem cell numbers
in vitro and in vivo
As intestinal stem cells drive the renewal of the crypt epithelium,
we examined the effects of modifying the IL-6 signaling axis on
crypt stem cells both in vitro and in vivo. In addition to the observed
increase in the small intestinal organoid proliferation in vitro, we
FIGURE 1. IL-6 stimulates proliferation of small intestinal organoids
via a STAT3-mediated signaling pathway. (A) Representative confocal
images of BrdU incorporation (green) into the nuclei (DAPI; red) of small
intestinal organoids cultured in the absence or presence of IL-6 (100 ng/ml).
DAPI BrdU positive cells (yellow). Scale bar, 10 mm. (B) Histogram showing
the percentage of BrdU-positive nuclei in mouse small intestinal organoids
following 24 h IL-6 (10–1000 ng/ml) stimulation compared with control.
(C) Histogram showing percentage of BrdU-positive nuclei in mouse small
intestinal organoids following 24 h IL-6 stimulation (100 ng/ml) in
the presence or absence of STATTIC and compared with control. n = 3.
***p , 0.001.
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also demonstrated that the percentage of Lgr5EGFP-positive
nuclei per organoid (Fig. 4A) was significantly increased com-
pared with control. Furthermore, the average number of new buds
per small intestinal organoid, also a measure of stem cell numbers,
was significantly increased compared with control, an effect that
was abrogated by STAT3 inhibition with STATTIC (Fig. 4B). The
use of an IL-6R blocking Ab also caused a significant reduction in
the budding of small intestinal crypts (Fig. 4C). Complementary
in vivo studies using Lgr5EGFP mice treated with the IL-6 re-
ceptor–blocking Ab caused a significant reduction in the number
of Lgr5EGFP cells per crypt, the number of crypt nuclei, crypt
length, and villus height compared with IgG-treated mice
(Fig. 4D–G respectively). Similar findings were obtained after
mice were treated with an IL-6–neutralizing Ab with a significant
FIGURE 2. IL-6 induces activation of nuclear pSTAT3 in Paneth cells of the small intestine through differential expression of the IL-6 receptor. (A)
Representative confocal images showing the presence of pSTAT3 immunofluorescent labeling (green) in the nuclei (DAPI; red) of UEA-1– (pink) and
lysozyme-positive (blue) Paneth cells in organoids following 1 h IL-6 (100 ng/ml) stimulation in the presence or absence of a pSTAT3-blocking peptide. (B)
Representative confocal images of pSTAT3 (green) in the nuclei (DAPI; red) of UEA-1–positive (pink) cells in organoids stimulated with IL-6 (1000 ng/ml)
for 0–6 h. E-cadherin-white. (C) Histogram showing the time course of IL-6–induced pSTAT3 activation in UEA-1–positive cells from 0 to 6 h post-
stimulation using 1000 or 100 ng/ml. Data expressed as fluorescence intensity (arbitrary units) and normalized to control UEA-1–positive nuclei (n = 3,
***p , 0.001). (D) Representative confocal images showing immunofluorescent labeling of IL-6 receptor localization (red) in lysozyme-positive (green)
cells in small intestinal organoid culture. (E and F) Representative confocal images of small intestine taken from Lgr5EGFP mice showing IL-6 receptor
localization (red) on the basal membrane of lysozyme-positive cells (E) and intracellular granules (F); Lgr5EGFP- (cyan) and lysozyme-positive cells
(green). Confocal imaging data are representative of n = 3 independent experiments. Scale bar, 10 mm.
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reduction in the number of Lgr5EGFP cells per crypt, the number
of crypt nuclei, and villus height compared with IgG-treated mice
(Fig. 4H, 4I, 4K). No significant difference was observed in crypt
length between mice treated with a IL-6–neutralizing Ab or
control IgG (Fig. 4J). Furthermore, both the IL-6 receptor–
blocking Ab and the neutralizing IL-6 Ab caused a significant
reduction in the number of lysozyme- (Fig. 4L, 4N) and UEA-1–
positive (Fig. 4M, 4O) cells per crypt compared with the respec-
tive IgG-treated mice. Representative confocal images from
mouse in vivo Ab experiments including Lgr5EGFP, lysozyme,
UEA-1, Ki67, and caspase 3 labeling are included in Supplemental
Fig. 2E–H.
IL-6 induces crypt cell proliferation through a Wnt signaling
pathway
Paneth cells have been shown to be a major source of Wnts and the
Wnt signaling pathway is a master regulator of epithelial renewal.
We next determined whether IL-6 was affecting epithelial renewal
or proliferation and stem cell numbers in vitro through this pathway
by utilizing the Wnt inhibitor IWP2. We show that IWP2 abrogates
the IL-6–induced increase in both proliferation and the average
number of buds per organoid compared with control (Fig. 5). The
percentage of caspase 3–positive cells and organoid survival in
the presence of IWP2 and/or IL-6 was comparable to control
(Supplemental Fig. 4).
Discussion
This work highlights a previously unrecognized role for autocrine
IL-6 signaling during homeostasis in the small intestine. IL-6
stimulation was shown to increase in vitro crypt cell prolifera-
tion and stem cell numbers through the STAT3 signaling pathway.
IL-6 activated pSTAT3 specifically in the nucleus of the Paneth cell
through differential expression of the IL-6 receptor located on the
Paneth cell basal membrane. IL-6 was also expressed in the crypt
epithelium. Neutralizing IL-6 or blocking the IL-6 receptor with
Abs lowered basal organoid proliferation and crypt budding in vitro
and reduced crypt stem and Paneth cell numbers in vivo. Use of the
Wnt inhibitor IWP2 abrogated the IL-6–induced increase in
organoid proliferation and crypt budding. These data suggest a
role of autocrine IL-6 signaling and the Wnt signaling pathway in
the regulation of crypt homeostasis.
Previous work using IL-6 receptors or IL-6 knockout mice
demonstrated a role for IL-6 signaling in mouse models of in-
flammation and crypt epithelial cell survival and regeneration
rather than homeostasis (11, 12, 14, 16, 24, 25). In agreement with
other studies, we also showed that gut tissue from healthy IL-6
knockout mice was similar to tissue from wild type mice
(Supplemental Fig. 2A–C). However, using a blocking Ab
approach we demonstrated a previously unrecognized role for
autocrine IL-6 signaling in the maintenance of crypt stem cell
numbers (and Paneth cell numbers; see below) in vivo. These
differences may be explained by redundancy effects known to
occur in knockout mouse models, and highlights the importance of
interrogating this pathway using a variety of methods as has been
shown in other studies (26).
Other groups have also implicated a role for IL-6 in maintaining
homeostasis (27–29) as well as ageing (30–32). Our findings
suggest that classic signaling is involved in crypt homeostasis; we
show that addition of IL-6 to the basal side of crypts in vitro
causes pSTAT3 activation in Paneth cells only, which correlates
with the expression of the IL-6 receptor on the Paneth cell basal
membrane. It has been suggested that anti-inflammatory and re-
generative properties of IL-6 most likely depend on IL-6 classic
rather than trans signaling (20, 33). Our studies concur with this;
if binding of soluble IL-6 receptor to the ubiquitously expressed
gp130 was occurring in our system then this would permit all cells
of the crypt epithelium to express nuclear pSTAT3 in response to
IL-6, an effect that we did not observe. The relative contribution
of classic IL-6 signaling versus trans signaling in crypt homeo-
stasis versus inflammation remains the focus of future work.
Our findings demonstrated that IL-6 mediated its in vitro effects
on crypt cell proliferation and stem cells through the pSTAT3
pathway. Crypt cell proliferation in response to IL-6 exhibited a
bell-shaped concentration response curve, which has previously
been described (34). The epithelial STAT3 signaling pathway has
shown to be key for small intestinal stem cell survival (35) and
regeneration during intestinal mucosal wound healing (9, 13).
Using full growth factor media and chronic STAT3 inhibition, we
also showed that epithelial STAT3 was important for in vitro crypt
regeneration even in the absence of exogenous IL-6 (Supplemental
Fig. 1A). Interestingly, we showed in vivo that low levels of nu-
clear pSTAT3 activation (Supplemental Fig. 2J) were present in
most UEA-1–positive Paneth cells at the base of small intestinal
crypts; there was also evidence of a small number of crypts
expressing high pSTAT3 activation in Paneth cells (Supplemental
Fig. 2K). These findings support the hypothesis that pSTAT3
signaling is dynamic and transient during homeostasis. In the
future the development of fluorescent reporter systems would be
required to study dynamic pSTAT3 signaling in real time.
The STAT3 signaling pathway can be activated by a number of
cytokines including IL-6 and IL-22 (36, 37). Interestingly, acti-
vation of IL-22 rather than IL-6 was shown to be key in regulating
epithelial STAT3 wound healing following dextran sodium
sulfate–induced experimental colitis in mice (13) and in ameliorat-
ing gut inflammation (38). This highlights the complexity of STAT3
signaling and it is likely that finetuning of this pathway through
different cytokines exerts different functional responses depend-
ing on the context. Indeed, we showed that IL-22 stimulation of
FIGURE 3. Autocrine IL-6 signaling regulates small intestinal organoid
proliferation. (A) PCR gel showing IL-6 transcript expression in in vivo
and freshly isolated (0 h) and cultured (48 h) small intestinal crypts (B)
Representative confocal image showing immunofluorescent labeling of IL-
6 (red), nuclei (DAPI blue) of small intestinal organoids with the differ-
ential interference contrast image overlaid and associated projection image
in vitro. White arrows indicate extracellular pools of IL-6. Scale bar, 10
mm. (C) Histogram showing percentage of BrdU-positive nuclei in mouse
small intestinal organoids in the presence of an IL-6 receptor–blocking Ab
and (D) an IL-6 neutralizing–Ab compared with respective IgG control.
Data are represented as mean 6 SEM. n = 3. **p , 0.01, ***p , 0.001.
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organoids resulted in global epithelial pSTAT3 activation
(Supplemental Fig. 3A), which was in contrast to the restricted
activation in Paneth cells following IL-6 exposure. We also concur
with previous findings (39) that IL-22 induces proliferation of
both large and small intestinal organoids and affects organoid
budding (Supplemental Fig. 3), and we show that IL-6 can cause
proliferation of colonic organoids. Whether the same mechanisms
exist in the human gut epithelium remains to be elucidated. The
relative contribution of different cytokines in regulating the
STAT3 pathway in gut homeostasis versus inflammation and in
the small intestine versus the colon is the subject of future
investigation.
Although Paneth cells are not an absolute requirement for
survival, proliferation, and stem cell activity (40, 41), previous
work has shown that they provide important regenerative signals
for modulation of the crypt stem cell niche (2, 42). Future work
will elucidate the identity of the Wnt pathway(s) involved in IL-6
and STAT3 signaling in small intestinal crypt homeostasis. This
FIGURE 4. IL-6 receptor signaling modulates Lgr5EGFP+ crypt stem cell numbers in vitro and in vivo. (A) Histogram showing the effect of IL-6 (100
ng/ml) treatment on the percentage of Lgr5EGFP-positive cells per crypt organoid compared with control. (B) Histogram showing the average number of
buds per crypt organoid following IL-6 (100 ng/ml) treatment, or treatment with STATTIC (20 mM). (C) Histogram showing the average number of buds per
organoid in vitro when cultured in the presence of an IL-6 receptor–blocking Ab compared with IgG control. (D) Histogram showing the average number of
Lgr5EGFP-positive stem cells per crypt, (E) the average number of nuclei per crypt, (F) the crypt length, and (G) the villus height in the small intestine of
mice treated with a IL-6 receptor–blocking Ab compared with respective IgG controls. (H) Histogram showing the average number of Lgr5EGFP-positive
stem cells per crypt, (I) the average number of nuclei per crypt, (J) the average crypt length, and (K) the average villus height in the small intestine of mice
treated with a IL-6–neutralizing Ab. Histograms showing the in vivo effect of an IL-6 receptor–blocking Ab on the number of (L) lysozyme- or (M) UEA-1–
positive cells per crypt compared with IgG controls. Histograms showing the effect of an IL-6–neutralizing Ab on the number of (N) lysozyme- or (O)
UEA-1–positive cells per small intestinal crypt compared with IgG controls. Data are represented as mean 6 SEM. n = 3. ***p , 0.001, **p , 0.01, *p ,
0.05.
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study has also identified a novel role for the IL-6 signaling axis in
regulating Paneth cell numbers in vivo. Paneth cell metaplasia in
the colon is a feature of inflammatory bowel disease (43, 44),
in addition to elevated levels of IL-6 in the serum and tissues (45,
46). We speculate that alterations in the IL-6 signaling axis may be
a contributing factor to this phenotype. Furthermore, in the clinic,
some rheumatoid arthritis patients treated with the IL-6 Ab toci-
lizumab display adverse side effects (47, 48); the mechanism by
which this occurs is unknown.
IL-6 can also activate other signaling pathways not studied in this
paper (17). This highlights the importance of understanding the
complex biology of IL-6 during health and disease. In this study,
we show a previously unrecognized role for IL-6 signaling in
health. Understanding the mechanisms of IL-6 regulation of crypt
cell renewal has wider implications for the prevention or devel-
opment of future treatments for inflammatory bowel disease. More
targeted treatments for inflammatory disorders that retain classic
IL-6 signaling and homeostatic levels of epithelial crypt renewal
but inhibit trans IL-6 signaling (49) through specific cell types
appears to be the ideal scenario for the future (50, 51).
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Supplemental Figure 1. Modulation of the STAT3-IL-6 signalling-axis in small intestinal organoids.
(A) Histogram showing a significant reduction in the percentage of BrdU positive nuclei in small intestinal organoids
following 48 hour culture with STATTIC (20mM) in full growth factor media compared to control organoids (n=3,
***P<0.001). (B) Histogram showing a significant increase in BrdU incorporation following exposure to IL-6 (100ng /
ml) for 5 days, media was changed every 2 days. BrdU was added for the last 18 hours of culture (n=3, **P<0.01) (C)
Representative confocal images showing labelling of lysozyme (green) with a primary mouse anti-lysozyme antibody
followed by a secondary donkey anti-mouse Alexafluor 568 antibody and absence of labelling with the mouse IgG
antibody control. E-cadherin white. (D-E) Histograms showing a significant reduction in the percentage of BrdU positive
nuclei in small intestinal organoids treated for 18 hours with IL-6 (100 ng / ml) in the presence of (D) an IL-6 receptor
blocking (n=4, **P<0.01) or (E) an IL-6 neutralising antibody compared to respective IgG + IL-6 treated crypts (n=3,
**P<0.01). (F) Histogram showing the percentage of caspase 3 positive cells in organoids following culture with an IL-6
receptor antibody or a (G) IL-6 neutralising antibody compared to respective IgG controls (n=3). Histograms showing
the organoid survival after treatment with (H) an IL-6 receptor antibody or (I) IL-6 neutralising antibody compared to
respective IgG controls (n=3) (J) Representative confocal images showing abrogation of IL-6-induced pSTAT3 labelling
(green) in the nucleus (DAPI-red) of UEA-1 positive cells (pink) in organoids treated with an IL-6 receptor blocking
antibody compared to IL-6 + IgG treated crypts. E-cadherin white. (n=3). (K) Histogram showing a significant reduction
in IL-6-induced pSTAT3 fluorescence intensity (a.u.) in organoids treated with an IL-6 receptor blocking antibody
compared to IL-6 + IgG treated crypts. Fluorescence intensity was normalised to control (n=3, ***p<0.001). (L)
Representative confocal images showing abrogation of IL-6-induced pSTAT3 labelling (green) in the nucleus (DAPI-red)
of UEA-1 positive cells (pink) in organoids treated with an IL-6 neutralising antibody compared to IL-6 + IgG treated
crypts. E-cadherin white. (n=3). (M) Histogram showing a significant reduction in IL-6-induced pSTAT3 fluorescence
intensity (a.u.) in organoids treated with an IL-6 neutralising antibody compared to IgG + IL-6 treated crypts.
Fluorescence intensity was normalised to control (n=3, ***p<0.001). Data are represented as mean +/- SEM. Scale bar
10mm.
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Supplemental Figure 2. Crypt morphology and pSTAT3 labelling of IL6KO tissue is the same as WT. IL-6 receptor
blocking or neutralising antibodies alter crypt stem cell and Paneth cell status.
Histogram showing (A) the average crypt length (B) the average number of crypt nuclei and (C) the average number of
lysozyme positive cells per crypt in the small intestine of IL-6 knockout mice and WT (n=3). Data are represented as
mean +/- SEM. (D) Representative confocal images demonstrating in vivo labelling of lysozyme (red) and absence of
labelling with a corresponding IgG to the mouse lysozyme antibody followed by a secondary anti-mouse IgG Alexafluor
568 antibody (red). Lysozyme positive cells (red) were also UEA-1 positive (green). E-cadherin; white and DAPI / nuclei
blue. (E-H) Sections from IL-6 neutralising antibody, IL-6 receptor antibody and IgG treated mice. Representative
confocal images showing a decrease in (E) Lgr5EGFP (green) , lysozyme (red) and (F) UEA-1 (green) positive cells in
antibody treated mice compared to IgG controls. (G) Representative confocal images of Ki67 labelling (green). DAPI /
nuclei-red, E-cadherin-blue. (H) Caspase 3 (red) labelling (+ve; caspase 3 positive control tissue) DAPI / nuclei-blue. (I-
K) Representative confocal images of in vivo WT and IL-6KO small intestine. (I) A blocking peptide (BP) to pSTAT3
pre-incubated with the pSTAT3 antibody abrogated the pSTAT3 labelling in the nucleus of UEA-1 positive cells (pink)
compared to tissue treated with pSTAT3 antibody (green) alone. No nuclear labelling was observed utilizing the
secondary antibody (20Ab) alone. (J) Representative confocal images demonstrating low level pSTAT3 (green) labelling
in UEA-1 (pink) positive cells of both WT and IL-6 KO mice. Images are projections of several focal planes formed
using image analysis software. (K) Representative confocal image of high pSTAT3 fluorescent labelling observed in the
mouse small intestine. Experiments were repeated on three different mice. Scale bar 10mm.
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Supplemental Figure 3. IL-22 induces global nuclear pSTAT3 activation, BrdU incorporation and crypt
budding in small intestinal organoids. IL-6 and IL-22 induces BrdU incorporation in colonic organoids.
(A) Representative confocal images showing the presence of pSTAT3 immunofluorescent labelling (green) in the
nuclei (red) of crypt organoids following 1 hour IL-22 (100 ng / ml) stimulation. Scale bar 50 mm. (B) Histogram
showing the percentage of BrdU positive nuclei in small intestinal organoids following 24 hours stimulation with IL-
22 (0.1- 1000 ng / ml) compared to control (n=3,***P<0.001). (C) Histogram showing the average number buds per
small intestinal organoid following IL-22 (10 ng / ml) treatment (n=3, *P<0.05) compared to control. (D) Histogram
showing the percentage of BrdU positive nuclei in colonic organoids following 24 hours stimulation with IL-6 (100 ng
/ ml) or IL-22 (100 ng / ml) compared to control (n=3,**P<0.01; ***P<0.001).
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Supplemental Figure 4. IWP2 has no effect on cell death and survival of small intestinal organoids.
Histogram showing no change in (A) the percentage of caspase 3 positive cells per crypt or (B) the percentage
survival of organoids, following 17h culture with IWP2 (5mM) +/- IL-6 (100 ng / ml) compared to control (DMSO).
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